AAV capsids and compositions containing same

JP2023550581A5Inactive Publication Date: 2024-11-07THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526506
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-06-24
Filing Date
2021-10-29
Publication Date
2024-11-07
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current AAV vectors in gene therapy face challenges due to pre-existing immunity and limited tissue tropism, necessitating the development of new AAV vectors with improved targeting capabilities.

Method used

The development of recombinant adeno-associated virus (rAAV) vectors with novel capsid proteins, such as AAVhu72, AAVhu75, AAVhu79, and others, which are at least 95% identical to specific sequences, and optionally deamidated at certain positions, to enhance tissue targeting and overcome immune responses.

Benefits of technology

These novel rAAV vectors demonstrate enhanced transduction efficiency and tissue specificity, reducing immune response and improving gene delivery efficacy across various tissues.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Novel AAV capsids and recombinant AAV vectors containing the same are provided.
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] Adeno-associated virus (AAV) vectors hold great promise in human gene therapy and have been widely used in various studies to target liver, muscle, heart, brain, eye, kidney, and other tissues due to their ability to provide long-term gene expression and lack of pathogenicity. AAV belongs to the Parvoviridae family and contains a single-stranded DNA genome flanked by two inverted terminal repeats. Dozens of naturally occurring AAV capsids have been reported, and their unique capsid structures enable them to recognize and transduce different cell types and organs.

[0002] Since the first trial began in 1981, no vector-related toxicity has been reported in clinical trials of AAV vector-based gene therapy. The accumulated safety record of AAV vectors in clinical trials, combined with their proven efficacy, makes AAV an attractive platform. In particular, AAV is easily manipulated because it is a single-stranded DNA virus with a relatively small genome (approximately 4.7 kb) and simple genetic components: inverted terminal repeats (ITRs), Rep genes, and Cap genes. AAV vectors require only the ITRs and AAV capsid proteins. The ITRs function as replication and packaging signals for vector production, while the capsid proteins play a central role by forming the capsid to accommodate the vector genomic DNA and determining tissue tropism.

[0003] AAV is one of the most effective vector candidates for gene therapy due to its low immunogenicity and non-pathogenic nature.However, despite enabling efficient gene transfer, the AAV vector currently used in clinics can be hindered by pre-existing immunity to the virus and limited tissue tropism.Therefore, additional AAV vectors are needed. Summary of the Invention

[0004] In one aspect, provided herein is a recombinant adeno-associated virus (rAAV) comprising a capsid and a vector genome comprising an AAV 5' inverted terminal repeat (ITR), an expression cassette comprising a nucleic acid sequence encoding a gene product operably linked to an expression control sequence, and an AAV 3' ITR, wherein the capsid is selected from the group consisting of: (a) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:40, or a sequence at least 99% identical thereto having an Asn (N) amino acid residue at position 24 based on the numbering of SEQ ID NO:40; (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:39, or a sequence at least 95% identical thereto encoding SEQ ID NO:40; or (iii) an AAVrh75 capsid that is 95% to 100% deamidated at at least positions N57, N262, N384, and / or N512 of SEQ ID NO:40, and optionally deamidated at other positions. an AAVrh75 capsid, consisting of a capsid that is a heterogeneous mixture of vp1, vp2, and vp3 proteins; (b) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:4, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO:3 or a sequence that is at least 95% identical thereto that encodes SEQ ID NO:4, or (iii) an AAVrh71 / 74 capsid that is 95% to 100% deamidated at at least four positions of SEQ ID NO:4 and optionally deamidated at other positions. AAVhu71 / 74 capsids, consisting of a capsid that is a heterogeneous mixture of vp1, vp2, and vp3 proteins; (c) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:6, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:5, or a sequence that is at least 95% identical thereto that encodes SEQ ID NO:6, or (iii) an AAVhu79 capsid that is 95% to 100% deamidated at at least four positions of SEQ ID NO:6, and optionally deamidated at other positions. AAV consists of a capsid that is a heterogeneous mixture of vp1, vp2, and vp3 proteins hu79 capsids; (d) AAVhu80 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:8, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO:7 or a sequence at least 95% identical thereto that encodes SEQ ID NO:8, or (iii) a capsid that is a heterogeneous mixture of AAVhu80 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:8 and optionally deamidated at other positions; (e) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:10, (i) a capsid produced from the nucleic acid sequence of SEQ ID NO:9 or a sequence at least 95% identical thereto that encodes SEQ ID NO:10, or (iii) an AAVhu83 capsid that is 95% to 100% deamidated at at least four positions of SEQ ID NO:10 and optionally deamidated at other positions. (f) AAVhu83 capsids, which consist of capsids that are a heterogeneous mixture of vp1, vp2, and vp3 proteins; (i) capsids produced from a nucleic acid sequence encoding SEQ ID NO:12, (ii) capsids produced from the nucleic acid sequence of SEQ ID NO:11 or a sequence that is at least 95% identical thereto that encodes SEQ ID NO:12, or (iii) AAVhu74 / 71 capsids that are 95% to 100% deamidated at at least four positions of SEQ ID NO:12 and optionally deamidated at other positions. (g) AAVhu74 / 71 capsids, consisting of a capsid that is a heterogeneous mixture of vp1, vp2, and vp3 proteins; (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:14, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO:13, or a sequence that is at least 95% identical thereto that encodes SEQ ID NO:14, or (iii) an AAVhu77 capsid, consisting of a capsid that is a heterogeneous mixture of AAVhu77 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:14 and optionally deamidated at other positions;(h) AAVhu78 / 88 capsids, consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 16, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO: 15, or a sequence at least 95% identical thereto that encodes SEQ ID NO: 16, or (iii) a capsid that is a heterogeneous mixture of AAVhu78 / 88 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 16 and optionally deamidated at other positions; (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 18, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO: 17, or a sequence at least 95% identical thereto that encodes SEQ ID NO: 18, or (iii) an AAVhu78 / 88 capsid that is 95% to 100% deamidated at at least four positions of SEQ ID NO: 18 and optionally deamidated at other positions. (j) an AAVhu70 capsid, consisting of a capsid that is a heterogeneous mixture of vp1, vp2, and vp3 proteins; (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:20, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO:19, or a sequence that is at least 95% identical thereto that encodes SEQ ID NO:20, or (iii) an AAVhu72 capsid that is 95% to 100% deamidated at at least four positions of SEQ ID NO:20, and optionally deamidated at other positions. (k) AAVhu72 capsids, consisting of capsids that are a heterogeneous mixture of vp1, vp2, and vp3 proteins; (i) capsids produced from a nucleic acid sequence encoding SEQ ID NO:22, (ii) capsids produced from the nucleic acid sequence of SEQ ID NO:21 or a sequence at least 95% identical thereto that encodes SEQ ID NO:22, or (iii) AAVhu75 capsids, consisting of capsids that are a heterogeneous mixture of AAVhu75 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:22 and optionally deamidated at other positions;(l) AAVhu76 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:24, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO:23, or a sequence at least 95% identical thereto that encodes SEQ ID NO:24, or (iii) a capsid that is a heterogeneous mixture of AAVhu76 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:24 and optionally deamidated at other positions; (m) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:26, (ii) a nucleic acid sequence of SEQ ID NO:25, or a sequence that encodes SEQ ID NO:26; or (iii) a capsid that is a heterogeneous mixture of AAVhu81 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:26, and optionally deamidated at other positions; (n) an AAVhu81 capsid, comprising (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:28, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO:27, or a sequence that is at least 95% identical to that encoding SEQ ID NO:28, or (iii) an AAVhu82 capsid that is 95% to 100% deamidated at at least four positions of SEQ ID NO:28, and optionally deamidated at other positions. an AAVhu82 capsid, consisting of a capsid that is a heterogeneous mixture of vp1, vp2, and vp3 proteins; (o) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:30, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO:29, or a sequence that is at least 95% identical thereto that encodes SEQ ID NO:30, or (iii) an AAVhu84 capsid that is 95% to 100% deamidated at at least four positions of SEQ ID NO:30, and optionally deamidated at other positions. an AAVhu84 capsid, consisting of a capsid that is a heterogeneous mixture of vp1, vp2, and vp3 proteins; (p) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 32, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO: 31, or a sequence that is at least 95% identical thereto that encodes SEQ ID NO: 32, or (iii) an AAVhu86 that is 95% to 100% deamidated at at least four positions of SEQ ID NO: 32, and optionally deamidated at other positions. (q) AAVhu86 capsids, consisting of capsids that are a heterogeneous mixture of vp1, vp2, and vp3 proteins; (q) AAVhu87 capsids, consisting of (i) capsids produced from a nucleic acid sequence encoding SEQ ID NO:34, (ii) capsids produced from the nucleic acid sequence of SEQ ID NO:33 or a sequence at least 95% identical thereto that encodes SEQ ID NO:34, or (iii) capsids that are a heterogeneous mixture of AAVhu87 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:34 and optionally deamidated at other positions;(r) AAVhu88 / 78 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:36, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO:35, or a sequence at least 95% identical thereto that encodes SEQ ID NO:36, or (iii) a capsid that is a heterogeneous mixture of AAVhu88 / 78 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:36 and optionally deamidated at other positions; (s) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:38, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO:37, or a sequence at least 95% identical thereto that encodes SEQ ID NO:38, or (iii) an AAVhu69 capsid that is 95% to 100% deamidated at at least four positions of SEQ ID NO:38 and optionally deamidated at other positions. an AAVhu69 capsid, consisting of a capsid that is a heterogeneous mixture of vp1, vp2, and vp3 proteins; (t) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:42, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO:41, or a sequence that is at least 95% identical thereto that encodes SEQ ID NO:42, or (iii) an AAVhu69 that is 95% to 100% deamidated at at least four positions of SEQ ID NO:42, and optionally deamidated at other positions. AAVrh76 capsids, consisting of capsids that are a heterogeneous mixture of vp1, vp2, and vp3 proteins; (u) AAVrh77 capsids, consisting of (i) capsids produced from a nucleic acid sequence encoding SEQ ID NO:44, (ii) capsids produced from the nucleic acid sequence of SEQ ID NO:43 or a sequence at least 95% identical thereto that encodes SEQ ID NO:44, or (iii) capsids that are a heterogeneous mixture of AAVrh71 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:44 and optionally deamidated at other positions;(v) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 46, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO: 45, or a sequence at least 95% identical thereto that encodes SEQ ID NO: 46, or (iii) a capsid that is 95% to 100% deamidated at at least four positions of SEQ ID NO: 46, and optionally; an AAVrh78 capsid consisting of a capsid that is a heterogeneous mixture of AAVrh78 vp1, vp2, and vp3 proteins that are deamidated at other positions; (w) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 50, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO: 49, or a sequence that is at least 95% identical thereto that encodes SEQ ID NO: 50, or (iii) an AAVrh81 capsid that is 95% to 100% deamidated at at least four positions of SEQ ID NO: 50, and optionally deamidated at other positions. an AAVrh81 capsid, consisting of a capsid that is a heterogeneous mixture of vp1, vp2, and vp3 proteins; (x) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 52, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO: 51 or a sequence that is at least 95% identical thereto that encodes SEQ ID NO: 52, or (iii) an AAVrh89 that is 95% to 100% deamidated at at least four positions of SEQ ID NO: 52 and optionally deamidated at other positions. an AAVrh89 capsid, consisting of a capsid that is a heterogeneous mixture of vp1, vp2, and vp3 proteins; (y) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 54, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO: 53, or a sequence that is at least 95% identical thereto that encodes SEQ ID NO: 54, or (iii) an AAVrh82 capsid that is 95% to 100% deamidated at at least four positions of SEQ ID NO: 54, and optionally deamidated at other positions. (z) AAVrh82 capsids, consisting of capsids that are a heterogeneous mixture of vp1, vp2, and vp3 proteins; (i) capsids produced from a nucleic acid sequence encoding SEQ ID NO: 56, (ii) capsids produced from the nucleic acid sequence of SEQ ID NO: 55, or a sequence at least 95% identical thereto that encodes SEQ ID NO: 56, or (iii) AAVrh83 capsids, consisting of capsids that are a heterogeneous mixture of AAVrh83 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 56 and optionally deamidated at other positions;(aa) AAVrh84 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 58, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO: 57, or a sequence at least 95% identical thereto that encodes SEQ ID NO: 58, or (iii) a capsid that is a heterogeneous mixture of AAVrh84 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 58 and optionally deamidated at other positions; (bb) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 60, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO: 59, or a sequence at least 95% identical thereto that encodes SEQ ID NO: 60, or (iii) an AAVrh85 capsid that is 95% to 100% deamidated at at least four positions of SEQ ID NO: 60 and optionally deamidated at other positions. an AAVrh85 capsid, consisting of a capsid that is a heterogeneous mixture of vp1, vp2, and vp3 proteins; (cc) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 62, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO: 61, or a sequence that is at least 95% identical thereto that encodes SEQ ID NO: 62, or (iii) an AAVrh87 capsid that is 95% to 100% deamidated at at least four positions of SEQ ID NO: 62, and optionally deamidated at other positions. (dd) AAVrh87 capsids, consisting of a capsid that is a heterogeneous mixture of vp1, vp2, and vp3 proteins; (dd) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 74, (ii) a capsid produced from the nucleic acid sequence of SEQ ID NO: 73, or a sequence at least 95% identical thereto that encodes SEQ ID NO: 74, or (iii) an AAVhu73 capsid, consisting of a capsid that is a heterogeneous mixture of AAVrh73 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 74 and optionally deamidated at other positions;

[0005] In one aspect, provided herein is a pharmaceutical composition comprising an rAAV and a physiologically compatible carrier, buffer, adjuvant, and / or diluent.

[0006] In one aspect, there is provided a method for delivering a transgene to a cell, the method comprising: Provided herein are methods comprising contacting a mammalian cell line with the rAAV of any one of claims 1 to 4, wherein the rAAV comprises a transgene.

[0007]

[0013] In one aspect, a method of generating a recombinant adeno-associated virus (rAAV) comprising an AAV capsid includes: (a) injecting the rAAV into a recombinant adeno-associated virus (rAAV) comprising an AAV capsid, the rAAV comprising: AAVrh75 (SEQ ID NO: 40), AAVhu71 / 74 (SEQ ID NO: 4), AAVhu79 (SEQ ID NO: 6), AAVhu80 (SEQ ID NO: 8), AAVhu83 (SEQ ID NO: 10), AAVhu74 / 71 (SEQ ID NO: 12), AAVhu77 (SEQ ID NO: 14), AAVhu78 / 88 (SEQ ID NO: 16), AAVhu70 (SEQ ID NO: 18), AAVhu72 (SEQ ID NO: 20), AAVhu75 (SEQ ID NO: 22), AAVhu76 (SEQ ID NO: 24), AAVhu81 (SEQ ID NO: 26), AAVhu82 (SEQ ID NO: 27), AAVhu83 (SEQ ID NO: 28), AAVhu84 (SEQ ID NO: 29), AAVhu85 (SEQ ID NO: 30), AAVhu86 (SEQ ID NO: 31), AAVhu87 (SEQ ID NO: 32), AAVhu88 (SEQ ID NO: 33), AAVhu89 (SEQ ID NO: 34), AAVhu90 (SEQ ID NO: 35), AAVhu91 (SEQ ID NO: 36), AAVhu92 (SEQ ID NO: 37), AAVhu93 (SEQ ID NO: 38), AAVhu94 (SEQ ID NO: 39), AAVhu95 (SEQ ID NO: 40), AAVhu96 (SEQ ID NO: 41), AAVhu97 (S AAVs of sequence number 28), AAVhu84 (SEQ ID NO: 30), AAVhu86 (SEQ ID NO: 32), AAVhu87 (SEQ ID NO: 34), AAVhu88 / 78 (SEQ ID NO: 36), AAVhu69 (SEQ ID NO: 38), AAVrh76 (SEQ ID NO: 42), AAVrh77 (SEQ ID NO: 44), AAVrh78 (SEQ ID NO: 46), AAVrh81 (SEQ ID NO: 50), AAVrh89 (SEQ ID NO: 52), AAVrh82 (SEQ ID NO: 54), AAVrh83 (SEQ ID NO: 56), AAVrh84 (SEQ ID NO: 58), AAVrh85 (SEQ ID NO: 60), AAVrh87 (SEQ ID NO: 62), or AAVhu73 (SEQ ID NO: 74). Provided herein are methods that include culturing a host cell containing: (a) a molecule encoding AAV vp1, vp2, and / or vp3 capsid proteins, or a molecule encoding AAV vp1, vp2, and / or vp3 capsid proteins that share at least 99% identity to any of SEQ ID NOs: 40, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 42, 44, 46, 50, 52, 54, 56, 58, 60, 62, or 74; (b) functional genes; (c) a vector genome comprising AAV inverted terminal repeats (ITRs) and a transgene; and (d) sufficient helper functions to allow packaging of the vector genome into AAV capsid proteins.

[0008] In one aspect, the vectors selected from the group consisting of AAVrh75 (SEQ ID NO: 39), AAVhu71 / 74 (SEQ ID NO: 3), AAVhu79 (SEQ ID NO: 5), AAVhu80 (SEQ ID NO: 7), AAVhu83 (SEQ ID NO: 9), AAVhu74 / 71 (SEQ ID NO: 11), AAVhu77 (SEQ ID NO: 13), AAVhu78 / 88 (SEQ ID NO: 15), AAVhu70 (SEQ ID NO: 17), AAVhu72 (SEQ ID NO: 19), AAVhu75 (SEQ ID NO: 21), AAVhu76 (SEQ ID NO: 23), AAVhu81 (SEQ ID NO: 25), AAVhu82 (SEQ ID NO: 27), AAVhu84 (SEQ ID NO: 29), AAVhu86 (SEQ ID NO: 31), AAVhu87 (SEQ ID NO: 33), AAVhu88 / 78 (SEQ ID NO: 35), AAVhu69 (SEQ ID NO: 37), AAVrh76 (SEQ ID NO: 41), AAVrh7 vp1, vp2, and / or vp3 of AAVrh7 (SEQ ID NO: 43), AAVrh78 (SEQ ID NO: 45), AAVrh81 (SEQ ID NO: 49), AAVrh89 (SEQ ID NO: 51), AAVrh82 (SEQ ID NO: 53), AAVrh83 (SEQ ID NO: 55), AAVrh84 (SEQ ID NO: 57), AAVrh85 (SEQ ID NO: 59), AAVrh87 (SEQ ID NO: 61), or AAVhu73 (SEQ ID NO: 73). Provided herein are plasmids comprising a vp1, vp2, and / or vp3 sequence, or a vp1, vp2, and / or vp3 sequence that shares at least 95% identity with any of SEQ ID NOs: 39, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 41, 43, 45, 49, 51, 53, 55, 57, 59, 61, or 73. In a further embodiment, a cultured host cell containing such a plasmid is provided.

[0009] Other aspects and advantages of these compositions and methods are further described in the detailed description that follows. [Brief explanation of the drawings]

[0010] [Figure 1]A diagram of AAV single genome amplification (AAV-SGA) is shown. Bulk mammalian genomic DNA samples were screened by PCR using AAV-specific primers that amplify a 3.1 kb region of the AAV genome encompassing the terminal one-third of the Rep gene and the complete Cap gene sequence. Samples that yield positive results in the AAV detection PCR were end-point diluted in a 96-well plate format and used as templates for a 3.1 kb amplicon AAV-specific PCR. Dilutions of gDNA that result in a positive PCR rate of less than 30% contain one amplifiable AAV genome in each reaction. Each positive amplicon is size-selected and sequenced using the Illumina MiSeq platform. Reads derived from the single genomes are de novo assembled to recover full-length AAV contigs containing the VP1 capsid gene. [Figures 2A-2D]Shows the analysis of variable fidelity of DNA polymerase and biological activity of PCR variants. (Figure 2A) Comparison of PCR errors induced by HiFi and Q5 DNA polymerases on circular and linearized plasmid templates. PCR products were cloned and sequenced. Each dot represents an individual plasmid clone. HiFi circular, n = 19, HiFi linear, n = 20, Q5 circular, n = 24, Q5 linear, n = 20 plasmid clones. (Figure 2B) Vector production titers of AAV9 variant PCR isolates generated by HiFi PCR. Variant capsids packaged the CB7.ffluciferase.rBG transgene. Genomic copy titers were measured by qPCR of total HEK293 triple transfection cell lysates. (Figure 2C) Huh7 infectivity titers of PCR variants measured by luciferase luminescence. "n / a": "not available" because luminescence values were below the detection limit. For B and C, the AAV9 control was set to 100%, and values are shown as mean and standard deviation (SD). Statistical significance was evaluated using the Wilcoxon rank sum test (Figure 2A) and Student's t-test (Figures 2B and 2C), not significant (NS): p >= 0.05, *p < 0.05, **p < 0.01 and ***p < 0.001. (Figure 2D) Schematic diagram of aligned PCR variant AAV cap DNA sequences. Each nucleotide mismatch with AAV9 is shown as a black line. Sequence information of mismatches in these experiments is detailed in Table 1. [Figure 3A-3C] Shows the phylogenetic analysis of positive selection of the AAV VP1 gene from the phylogenetic tree of neighbor-joining of AAV VP1 DNA sequences from human isolates (Figure 3A), rhesus monkey isolates (Figure 3B), and previously reported human AAV HSC (Figure 3C). Branches where BUSTED detected evidence of positive selection are colored red. Circular branch nodes represent bootstrap support values > 70. [Figure 4] Shows the phylogenetic analysis of the HiFi PCR variant AAV VP1 gene. Neighbor-joining phylogenetic tree of the AAV VP1 DNA sequences of HiFi PCR variants. [Figures 5A-5C]1 shows an alignment of the amino acid sequences of AAVhu72 (SEQ ID NO: 20), AAVhu75 (SEQ ID NO: 22), AAVhu79 (SEQ ID NO: 6), AAVhu80 (SEQ ID NO: 81), AAVhu81 (SEQ ID NO: 26), AAVhu82 (SEQ ID NO: 28), AAVhu83 (SEQ ID NO: 10), and AAVhu86 (SEQ ID NO: 32). [Figures 6A-6G] An alignment of the nucleotide sequences of AAVhu72 (SEQ ID NO: 19), AAVhu75 (SEQ ID NO: 21), AAVhu79 (SEQ ID NO: 5), AAVhu80 (SEQ ID NO: 7), AAVhu81 (SEQ ID NO: 25), AAVhu82 (SEQ ID NO: 27), AAVhu83 (SEQ ID NO: 9), and AAVhu86 (SEQ ID NO: 31) is shown. [Figures 7A-7D] 1 shows an alignment of the amino acid sequences of AAVhu69 (SEQ ID NO: 38), AAVhu70 (SEQ ID NO: 18), AAVhu71.74 (SEQ ID NO: 4), AAVhu73 (SEQ ID NO: 74), AAVhu74.71 (SEQ ID NO: 12), AAVhu76 (SEQ ID NO: 24), AAVhu77 (SEQ ID NO: 14), AAVhu78.88 (SEQ ID NO: 16), AAVhu84 (SEQ ID NO: 30), AAVhu87 (SEQ ID NO: 34), AAVhu88.78 (SEQ ID NO: 36), and AAVhu81 (SEQ ID NO: 50). [Figures 8A-8J] An alignment of the nucleotide sequences of AAVhu69 (SEQ ID NO: 37), AAVhu70 (SEQ ID NO: 17), AAVhu71.74 (SEQ ID NO: 3), AAVhu73 (SEQ ID NO: 73), AAVhu74.71 (SEQ ID NO: 11), AAVhu76 (SEQ ID NO: 23), AAVhu77 (SEQ ID NO: 13), AAVhu78.88 (SEQ ID NO: 15), AAVhu84 (SEQ ID NO: 29), AAVhu87 (SEQ ID NO: 33), AAVhu88.78 (SEQ ID NO: 25), and AAVhu81 (SEQ ID NO: 49) is shown. [Figure 9A-9B] 1 shows an alignment of the amino acid sequences of AAVrh76 (SEQ ID NO: 42), AAVrh85 (SEQ ID NO: 60), AAVrh87 (SEQ ID NO: 62), AAVrh89 (SEQ ID NO: 52), and AAV7 (SEQ ID NO: 85). [Figures 10A-10E]An alignment of the nucleotide sequences of AAVrh75 (SEQ ID NO: 39), AAVrh76 (SEQ ID NO: 41), AAVrh85 (SEQ ID NO: 59), AAVrh87 (SEQ ID NO: 61), AAVrh89 (SEQ ID NO: 51), and AAV7 (SEQ ID NO: 84) is shown. [Figures 11A-11B] 1 shows an alignment of the amino acid sequences of AAVrh75 (SEQ ID NO: 40), AAVrh79 (SEQ ID NO: 48), AAVrh83 (SEQ ID NO: 56), AAVrh84 (SEQ ID NO: 58), and AAV8 (SEQ ID NO: 83). [Figures 12A-12E] An alignment of the nucleotide sequences of AAVrh79 (SEQ ID NO: 47), AAVrh83 (SEQ ID NO: 55), AAVrh84 (SEQ ID NO: 57), and AAV8 (SEQ ID NO: 82) is shown. [Figure 13] 1 shows an alignment of the amino acid sequences of AAVrh77 (SEQ ID NO: 44), AAVrh78 (SEQ ID NO: 46), and AAVrh82 (SEQ ID NO: 54). [Figures 14A-14C] An alignment of the nucleotide sequences of AAVrh77 (SEQ ID NO: 43), AAVrh78 (SEQ ID NO: 45), and AAVrh82 (SEQ ID NO: 53) is shown. [Figure 15] AAV vector yields are shown. A vector genome containing the TBG promoter and eGFP transgene was packaged using a cis-plasmid containing the capsid gene of the indicated isolate. Vectors were produced by triple transfection (one CellStack each), purified on an iodixanol gradient, and titrated using qPCR. "E+#" refers to the index following E+ in numerical terms; for example, E+13 refers to "x1013." "GC" refers to vector genome copies. [Figure 16] The infectious titers of AAVrh75 and AAVrh81 vector preparations are shown. AAVrh75 and AAVrh81 capsid-containing vectors (carrying a reporter transgene cassette) were prepared at plate scale, with AAV8 as a control. Crude lysates were then used to transduce human and mouse cell lines. The infectious titers of AAVrh75 and AAVrh81 are presented as transduction relative to the AAV8 control. [Figure 17]Liver transduction of AAVrh81 vectors. C57BL / 6J mice were intravenously administered AAVrh91.LSP.hF9 or AAV8.LSP.hF9 at 1 x 10 gc / animal, and plasma was collected 28 days post-dose for human F9 (hF9) measurements. [Figure 18] Liver transduction of AAVrh83 and AAVrh84 vectors is shown. C57BL / 6J mice were intravenously administered AAVrh83.TBG.eGFP or AAVrh84.TBG.eGFP at a dose of 1 x 10 gc / animal. Livers were harvested 14 days later for GFP imaging. Representative images from each animal are shown. [Figure 19] Liver transduction of novel AAV isolates is shown. C57BL / 6J mice were intravenously administered AAVrh78.TBG.eGFP, AAVrh78.TBG.eGFP, AAVrh78.TBG.eGFP, or AAVrh78.TBG.eGFP at a dose of 1 × 10 gc / animal (AAVrh87 was 6.4 × 10 gc / animal due to a low preparation titer). Livers were harvested 14 days later, and genomic DNA was extracted for vector genome copy measurement by qPCR. Liver transduction levels for AAVrh78, AAVrh85, AAVrh87, and AAVrh89 were approximately 49%, 72%, 16%, and 22% of those of AAV8, respectively. P values ​​(t-test compared with the AAV8 group) are indicated. DETAILED DESCRIPTION OF THE INVENTION

[0011] Genetic variation of AAV in its natural mammalian host was explored by using AAV single genome amplification, a technique used to precisely isolate individual AAV genomes from within a viral population (Figure 1). Described herein are the isolation of novel AAV sequences from rhesus macaque and human tissues that can be classified into various clades. Twelve novel AAV isolates from rhesus macaque tissue can be classified into clades D, E, and a primate clade outgroup, including AAVrh32.33. Additionally, 20 novel AAV isolates from human tissue can be classified into clades B and C, respectively, or those resembling AAV2 and AAV2-AAV3 hybrids.

[0012] Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs and by reference to published documents which provide such artisans with general guidance to many of the terms used herein. The following definitions are provided for clarity only and are not intended to limit the invention as claimed.

[0013] The terms "substantial homology" or "substantial similarity," when referring to a nucleic acid, or a fragment thereof, indicate that when optimally aligned with another nucleic acid (or its complementary strand) by appropriate nucleotide insertions or deletions, the nucleic acid or fragment has at least about 95-99% nucleotide sequence identity with the aligned sequence. Preferably, the homology is over the full-length sequence, or its open reading frame, or another suitable fragment at least 15 nucleotides in length. Examples of suitable fragments are described herein.

[0014] The terms "sequence identity," "percent sequence identity," or "percent identical" in the context of nucleic acid sequences refer to the residues in two sequences that are the same when aligned for maximum correspondence. The length of sequence identity comparison can be, and preferably is, over the entire length of a genome, the entire length of a gene coding sequence, or a fragment of at least about 500-5000 nucleotides. However, identity between smaller fragments, e.g., at least about 9 nucleotides, usually at least about 20-24 nucleotides, at least about 28-32 nucleotides, or at least about 36 or more nucleotides, may also be desired. Similarly, "percent sequence identity" can be readily determined for the amino acid sequence of a protein or fragment thereof over its entire length. Preferably, the fragment is at least about 8 amino acids in length and can be up to about 700 amino acids in length. Examples of suitable fragments are described herein.

[0015] The terms "substantial homology" or "substantial similarity," when referring to an amino acid, or a fragment thereof, indicate that when optimally aligned with another amino acid (or its complementary strand) by appropriate amino acid insertion or deletion, the amino acid has at least about 95-99% amino acid sequence identity with the aligned sequence. Preferably, the homology is over the full-length sequence, or a protein thereof, e.g., cap protein, rep protein, or a fragment thereof that is at least 8 amino acids in length, or more preferably, at least 15 amino acids in length. Examples of suitable fragments are described herein.

[0016] The term "highly conserved" means at least 80% identity, preferably at least 90% identity, and more preferably greater than 97% identity. Identity is readily determined by those skilled in the art by relying on algorithms and computer programs known to those skilled in the art.

[0017] Generally, when referring to "identity," "homology," or "similarity" between two different adeno-associated viruses, the "identity," "homology," or "similarity" is determined with reference to "aligned" sequences. "Clustal" refers to multiple nucleic acid or protein (amino acid) sequences, often including corrections for missing or additional bases or amino acids compared to a reference sequence. In an example, an AAV alignment is performed using the published AAV9 sequence as a reference point. Alignments are performed using any of a variety of publicly or commercially available multiple sequence alignment programs. Examples of such programs include "Clustal Omega," "Clustal W," "CAP Sequence Assembly," "MAP," and "MEME," accessible through web servers on the Internet. Other sources of such programs are known to those skilled in the art. Alternatively, the Vector NTI utility can also be used. There are also several algorithms known in the art that can be used to measure nucleotide sequence identity, including those included in the programs described above. As another example, polynucleotide sequences can be compared using Fasta™, a program in GCG version 6.1. Fasta™ provides an alignment and percent sequence identity of the best overlap regions between the query and search sequences. For example, percent sequence identity between nucleic acid sequences can be determined using Fasta™ with its default parameters (word size 6 and NOPAM factor for the scoring matrix) as provided in GCG Version 6.1, incorporated herein by reference. Multiple sequence alignment programs, such as "Clustal Omega," "Clustal X," "MAP," "PIMA," "MSA," "BLOCKMAKER," "MEME," and "Match-Box" programs, are also available for amino acid sequences. Generally, one of these programs is used with default settings, although one of skill in the art can modify these settings as needed. Alternatively, one of skill in the art can utilize another algorithm or computer program that provides at least the same level of identity or alignment as that provided by the referenced algorithm and program.See, for example, JD Thomson et al., Nucl. Acids. Res., "A comprehensive comparison of multiple sequence alignments," 27(13):2682-2690 (1999).

[0018] The term "AAV intermediate" or "AAV vector intermediate" refers to an assembled rAAV capsid that lacks the desired genomic sequence packaged therein. These may also be referred to as "empty" capsids. Such capsids may contain no detectable genomic sequence of the expression cassette, or may contain only partially packaged genomic sequence that is insufficient to achieve expression of the gene product.

[0019] "Genetic element" includes any nucleic acid molecule, such as naked DNA, plasmids, phages, transposons, cosmids, episomes, viruses, etc., which transcribe the sequences carried thereon. Optionally, such genetic elements may utilize lipid-based carriers. Unless otherwise specified, genetic elements may be delivered by any suitable method, including transfection, electroporation, liposome delivery, membrane fusion techniques, high-speed DNA-coated pellets, viral infection, and protoplast fusion.

[0020] A "stable host cell" for rAAV production is a host cell, and its progeny, that has been engineered to contain one or more of the necessary rAAV production components (e.g., a minigene, a rep sequence, an AAVhu68 engineered cap sequence as defined herein, and / or helper functions). A stable host cell can contain the necessary components under the control of an inducible promoter. Alternatively, the necessary components can be under the control of a constitutive promoter. Examples of suitable inducible and constitutive promoters are provided herein in the discussion of regulatory elements suitable for use with transgenes. As yet another alternative, a selected stable host cell can contain selected components under the control of a constitutive promoter and other selected components under the control of one or more inducible promoters. For example, HEK293 cells (constitutive Stable host cells can be generated derived from E1 helper functions under the control of a promoter, Huh7 cells, Vero cells, and engineered to contain helper functions under the control of a suitable promoter, and optionally further containing rep and / or cap proteins under the control of an inducible promoter. Still other stable host cells can be generated by one of skill in the art.

[0021] As used herein, "expression cassette" refers to a nucleic acid molecule that includes a biologically useful nucleic acid sequence and operably linked regulatory sequences that direct or regulate the transcription, translation, and / or expression of the nucleic acid sequence (e.g., a gene cDNA encoding a protein, enzyme, or other useful gene product, mRNA, etc.) and the gene product.

[0022] The abbreviation "sc" refers to self-complementary. "Self-complementary AAV" refers to a construct in which the coding region carried by the recombinant AAV nucleic acid sequence is designed to form an intramolecular double-stranded DNA template. During infection, rather than waiting for cell-mediated synthesis of the second strand, the two complementary halves of the scAAV will associate to form a single double-stranded DNA (dsDNA) unit ready for immediate replication and transcription. See, for example, D. M. McCarty et al., "Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis," Gene Therapy, (August 2001), Vol. 8, Number 16, Pages 1248-1254. Self-complementary AAVs are described, for example, in U.S. Patent Nos. 6,596,535, 7,125,717, and 7,456,683, each of which is incorporated by reference herein in its entirety.

[0023] As used herein, the term "operably linked" refers both to expression control sequences that are contiguous with a gene of interest, and to expression control sequences that act in trans or at a distance to regulate a gene of interest.

[0024] The term "heterologous," when used with reference to a protein or nucleic acid, indicates that the protein or nucleic acid comprises two or more sequences or subsequences that are not found in the same relationship to each other in nature. For example, nucleic acids are typically produced recombinantly, having two or more sequences from unrelated genes arranged to create a new functional nucleic acid. For example, in one embodiment, a nucleic acid has a promoter from one gene arranged to direct expression of a coding sequence from a different gene. Thus, the promoter is heterologous with respect to the coding sequences.

[0025] A "replication-defective virus" or "viral vector" refers to a synthetic or artificial viral particle in which an expression cassette containing a gene of interest is packaged within a viral capsid or envelope, and any viral genomic sequences also packaged within the viral capsid or envelope are replication-defective, i.e., they are unable to produce progeny virions but retain the ability to infect target cells. In one embodiment, the genome of the viral vector does not contain genes encoding enzymes required for replication (the genome can be engineered to be "gutless," containing only the gene of interest flanked by signals required for amplification and packaging of the artificial genome), although these genes can be supplied during production. It is therefore considered safe for use in gene therapy because replication and infection by progeny virions cannot occur except in the presence of viral enzymes required for replication.

[0026] rAAV particles are often referred to as DNase resistant. In addition to nucleases (DNases), other endonucleases and exonucleases can be used in the purification steps described herein to remove contaminating nucleic acids. Such nucleases can be selected to degrade single-stranded and / or double-stranded DNA, and RNA. Such steps can involve a single nuclease or a mixture of nucleases directed against different targets, which can be endonucleases or exonucleases.

[0027] The term "nuclease-resistant" indicates that the AAV capsid is constructed entirely around an expression cassette designed to deliver genes into host cells, protecting these packaged genomic sequences from degradation (digestion) during a nuclease incubation step designed to remove contaminating nucleic acids that may be present from the production process.

[0028] As used herein, "effective amount" refers to the amount of rAAV composition that delivers and expresses the amount of gene product from the vector genome in a target cell. Effective amounts may be determined based on animal models rather than human patients. An example of a suitable mouse model is described herein.

[0029] The term "translation" in the context of the present invention relates to the process at the ribosome, whereby an mRNA chain controls the assembly of an amino acid sequence to produce a protein or peptide.

[0030] It should be noted that as used herein, the terms "a" or "an" refer to one or more, e.g., "an expression cassette" refers to one or more expression cassettes. Thus, the terms "a" (or "an"), "one or more," and "at least one" are used interchangeably herein.

[0031] As used herein, the term "about" means a 10% variability from a given reference, unless otherwise specified.

[0032] Although various embodiments in the specification are presented using the language "comprising," it is intended that, under other circumstances, the relevant embodiments be construed and described using the language "consisting of" or "consisting essentially of."

[0033] With respect to the description that follows, each of the compositions described herein is contemplated, in another embodiment, to be useful in the methods of the present invention. Additionally, each of the compositions useful in the methods is also contemplated, in another embodiment, to be an embodiment of the present invention itself.

[0034] A. AAV capsid The nucleic acid encoding the AAV capsid contains three overlapping coding sequences, which vary in length due to alternative start codon usage. The translated proteins are referred to as VP1, VP2, and VP3, with VP1 being the longest and VP3 being the shortest. AAV particles consist of all three capsid proteins in a ratio of approximately 1:1:10 (VP1:VP2:VP3). VP1 at the N-terminus and VP3, contained within VP2, are the major structural components that assemble the particle. Capsid proteins can be referenced using several different numbering systems. For convenience, AAV sequences are referenced using VP1 numbering, beginning with the first residue, aa1, of VP1. However, the capsid proteins described herein include VP1, VP2, and VP3 (used interchangeably herein as vp1, vp2, and vp3).

[0035] Clade B Novel AAV capsid proteins having the vp1 sequences shown in the Sequence Listing are provided herein: AAVhu72 (SEQ ID NO: 20), AAVhu75 (SEQ ID NO: 22), AA Vhu79 (SEQ ID NO:6), AAVhu80 (SEQ ID NO:8), AAVhu81 (SEQ ID NO:26), AAVhu82 (SEQ ID NO:28), AAVhu83 (SEQ ID NO:10), or AAVhu86 (SEQ ID NO:32). Nucleotide and amino acid numbering corresponding to vp1, vp2, and vp3 is as follows: nucleotide (nt) AAVhu72: vp1-nt 1 to 2205, vp2-nt 412 to 2205, vp3-nt 607 to 2205 of SEQ ID NO: 19; AAVhu75: vp1-nt 1 to 2205, vp2-nt 412 to 2205, vp3-nt 607 to 2205 of SEQ ID NO: 21; AAVhu79: vp1-nt 1 to 2205, vp2-nt 412 to 2205, vp3-nt 607 to 2205 of SEQ ID NO:5; AAVhu80: vp1-nt 1 to 2205, vp2-nt 412 to 2205, vp3-nt 607 to 2205 of SEQ ID NO: 7; AAVhu81: vp1-nt 1 to 2205, vp2-nt 412 to 2205, vp3-nt 607 to 2205 of SEQ ID NO: 25; AAVhu82: vp1-nt 1 to 2205, vp2-nt 412 to 2205, vp3-nt 607 to 2205 of SEQ ID NO: 27; AAVhu83: vp1-nt 1 to 2205, vp2-nt 412 to 2205, vp3-nt 607 to 2205 of SEQ ID NO: 9; AAVhu86: vp1 - nt 1 to 2205, vp2 - nt 412 to 2205, vp3 - nt 607 to 2205 of SEQ ID NO: 31 amino acids (aa) AAVhu72: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO: 20; AAVhu75: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO: 22; AAVhu79: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO: 6; AAVhu80: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO:8; AAVhu81: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO: 26; AAVhu82: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO: 28; AAVhu83: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO: 10; AAVhu86: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO: 32

[0036] In certain embodiments, provided herein is an rAAV comprising at least one of vp1, vp2, and vp3 of any of AAVhu72 (SEQ ID NO: 20), AAVhu75 (SEQ ID NO: 22), AAVhu79 (SEQ ID NO: 6), AAVhu80 (SEQ ID NO: 8), AAVhu81 (SEQ ID NO: 26), AAVhu82 (SEQ ID NO: 28), AAVhu83 (SEQ ID NO: 10), or AAVhu86 (SEQ ID NO: 32). In certain embodiments, rAAVs are provided having capsid proteins comprising vp1, vp2, and / or vp3 sequences that are at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to AAVhu72 (SEQ ID NO:20), AAVhu75 (SEQ ID NO:22), AAVhu79 (SEQ ID NO:6), AAVhu80 (SEQ ID NO:8), AAVhu81 (SEQ ID NO:26), AAVhu82 (SEQ ID NO:28), AAVhu83 (SEQ ID NO:10), or AAVhu86 (SEQ ID NO:32). p1, vp2, and / or vp3 have at most 1, at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, or at most 10 amino acid differences compared to vp1, vp2, and / or vp3 of AAVhu72 (SEQ ID NO:20), AAVhu75 (SEQ ID NO:22), AAVhu79 (SEQ ID NO:6), AAVhu80 (SEQ ID NO:8), AAVhu81 (SEQ ID NO:26), AAVhu82 (SEQ ID NO:28), AAVhu83 (SEQ ID NO:10), or AAVhu86 (SEQ ID NO:32). Also provided is an rAAV comprising an AAV capsid encoded by at least one of the vp1, vp2, and / or vp3 sequences of AAVhu72 (SEQ ID NO: 19), AAVhu75 (SEQ ID NO: 21), AAVhu79 (SEQ ID NO: 5), AAVhu80 (SEQ ID NO: 7), AAVhu81 (SEQ ID NO: 25), AAVhu82 (SEQ ID NO: 27), AAVhu83 (SEQ ID NO: 9), or AAVhu86 (SEQ ID NO: 31), or a sequence at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 19, 21, 5, 7, 25, 27, 9, or 31. In certain embodiments, the sequences encode full-length vp1, vp2, and / or vp3 of AAVhu72 (SEQ ID NO:20), AAVhu75 (SEQ ID NO:22), AAVhu79 (SEQ ID NO:6), AAVhu80 (SEQ ID NO:8), AAVhu81 (SEQ ID NO:26), AAVhu82 (SEQ ID NO:28), AAVhu83 (SEQ ID NO:10), or AAVhu86 (SEQ ID NO:32). In other embodiments, vp1, vp2, and / or vp3 have N-terminal and / or C-terminal truncations (e.g., truncations of about 1 to about 10 amino acids).

[0037] Clade C Provided herein are novel AAV capsid proteins having the vp1 sequence shown in the Sequence Listing: AAVrh81 (SEQ ID NO:50), AAVhu71.74 (SEQ ID NO:4), AAVhu73 (SEQ ID NO:74), AAVhu74.71 (SEQ ID NO:12), AAVhu77 (SEQ ID NO:14), AAVhu78.88 (SEQ ID NO:16), AAVhu70 (SEQ ID NO:18), AAVhu76 (SEQ ID NO:24), AAVhu84 (SEQ ID NO:30), hu87 (SEQ ID NO:34), AAVhu88.78 (SEQ ID NO:36), or AAVhu69 (SEQ ID NO:38). Nucleotide and amino acid numbering corresponding to vp1, vp2, and vp3 is as follows: nucleotide (nt) AAVrh81: vp1-nt 1 to 2217, vp2-nt 412 to 2217, vp3-nt 619 to 2217 of SEQ ID NO: 49; AAVhu71.74: vp1-nt 1 to 2205, vp2-nt 412 to 2205, vp3-nt 607 to 2205 of SEQ ID NO: 3; AAVhu73: vp1-nt 1 to 2205, vp2-nt 412 to 2205, vp3-nt 607 to 2205 of SEQ ID NO: 73; AAVhu74.71: vp1-nt 1 to 2205, vp2-nt 412 to 2205, vp3-nt 607 to 2205 of SEQ ID NO: 11; AAVhu77: vp1-nt 1 to 2205, vp2-nt 412 to 2205, vp3-nt 607 to 2205 of SEQ ID NO: 13; AAVhu78.88: vp1-nt 1 to 2205, vp2-nt 412 to 2205, vp3-nt 607 to 2205 of SEQ ID NO: 15; AAVhu70: vp1-nt 1 to 2205, vp2-nt 412 to 2205, vp3-nt 607 to 2205 of SEQ ID NO: 17; AAVhu76: vp1-nt 1 to 2202, vp2-nt 412 to 2202, vp3-nt 607 to 2202 of SEQ ID NO: 23; AAVhu84: vp1-nt 1 to 2205, vp2-nt 412 to 2205, vp3-nt 607 to 2205 of SEQ ID NO: 29; AAVhu87: vp1-nt 1 to 2202, vp2-nt 412 to 2202, vp3-nt 607 to 2202 of SEQ ID NO: 33; AAVhu88.78: vp1-nt 1 to 2205, vp2-nt 412 to 2205, vp3-nt 607 to 2205 of SEQ ID NO: 35; AAVhu69: vp1 - nt 1 to 2205, vp2 - nt 412 to 2205, vp3 - nt 607 to 2205 of SEQ ID NO: 37 amino acids (aa) AAVrh81: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 207 to 739 of SEQ ID NO: 50; AAVhu71.74: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO: 4; AAVhu73: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO: 74; AAVhu74.71: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO: 12; AAVhu77: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO: 14; AAVhu78.88: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO: 16; AAVhu70: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO: 18; AAVhu76: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 734 of SEQ ID NO: 24; AAVhu84: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO: 30; AAVhu87: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 734 of SEQ ID NO: 34; AAVhu88.78: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO: 36; AAVrh69: aa vp1-1 to 735, vp2-aa 138 to 735, vp3-aa 203 to 735 of SEQ ID NO: 38

[0038] In certain embodiments, provided herein is an rAAV comprising at least one of vp1, vp2, and vp3 of any of AAVrh81 (SEQ ID NO:50), AAVhu71.74 (SEQ ID NO:4), AAVhu73 (SEQ ID NO:74), AAVhu74.71 (SEQ ID NO:12), AAVhu77 (SEQ ID NO:14), AAVhu78.88 (SEQ ID NO:16), AAVhu70 (SEQ ID NO:18), AAVhu76 (SEQ ID NO:24), AAVhu84 (SEQ ID NO:30), hu87 (SEQ ID NO:34), AAVhu88.78 (SEQ ID NO:36), or AAVhu69 (SEQ ID NO:38). In certain embodiments, rAAVs are provided that have capsid proteins comprising vp1, vp2, and / or vp3 sequences that are at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to AAVrh81 (SEQ ID NO:50), AAVhu71.74 (SEQ ID NO:4), AAVhu73 (SEQ ID NO:74), AAVhu74.71 (SEQ ID NO:12), AAVhu77 (SEQ ID NO:14), AAVhu78.88 (SEQ ID NO:16), AAVhu70 (SEQ ID NO:18), AAVhu76 (SEQ ID NO:24), AAVhu84 (SEQ ID NO:30), hu87 (SEQ ID NO:34), AAVhu88.78 (SEQ ID NO:36), or AAVhu69 (SEQ ID NO:38). In certain embodiments, vp1, vp2, and / or vp3 are selected from the group consisting of AAVrh81 (SEQ ID NO:50), AAVhu71.74 (SEQ ID NO:4), AAVhu73 (SEQ ID NO:74), AAVhu74.71 (SEQ ID NO:12), AAVhu77 (SEQ ID NO:14), AAVhu78.88 (SEQ ID NO:16), AAVhu70 (SEQ ID NO:18), AAVhu76 (SEQ ID NO:24), AAVhu84 (SEQ ID NO:30), hu87 (SEQ ID NO:34), AAVhu88.78 (SEQ ID NO:36), or AAVhu69 (SEQ ID NO:37). It has at most 1, at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, or at most 10 amino acid differences compared to vp1, vp2, and / or vp3 of column number 38). Also provided herein is an rAAV comprising an AAV capsid encoded by at least one of the vp1, vp2, and vp3 sequences of AAVrh81 (SEQ ID NO:49), AAVhu71.74 (SEQ ID NO:3), AAVhu73 (SEQ ID NO:73), AAVhu74.71 (SEQ ID NO:11), AAVhu77 (SEQ ID NO:13), AAVhu78.88 (SEQ ID NO:15), AAVhu70 (SEQ ID NO:17), AAVhu76 (SEQ ID NO:23), AAVhu84 (SEQ ID NO:29), hu87 (SEQ ID NO:33), AAVhu88.78 (SEQ ID NO:35), or AAVhu69 (SEQ ID NO:37), or a sequence at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:49, 3, 73, 11, 13, 15, 17, 23, 29, 33, 35, or 37. In certain embodiments, the sequences encode full-length vp1, vp2, and / or vp3 of AAVrh81 (SEQ ID NO:50), AAVhu71.74 (SEQ ID NO:4), AAVhu73 (SEQ ID NO:74), AAVhu74.71 (SEQ ID NO:12), AAVhu77 (SEQ ID NO:14), AAVhu78.88 (SEQ ID NO:16), AAVhu70 (SEQ ID NO:18), AAVhu76 (SEQ ID NO:24), AAVhu84 (SEQ ID NO:30), hu87 (SEQ ID NO:34), AAVhu88.78 (SEQ ID NO:36), or AAVhu69 (SEQ ID NO:38). In other embodiments, vp1, vp2, and / or vp3 have N-terminal and / or C-terminal truncations (e.g., truncations of about 1 to about 10 amino acids).

[0039] Clade D Provided herein are novel AAV capsid proteins having the vp1 sequence shown in the Sequence Listing: AAVrh76 (SEQ ID NO:42), AAVrh89 (SEQ ID NO:52), AAVrh85 (SEQ ID NO:60), or AAVrh87 (SEQ ID NO:62). The nucleotide and amino acid numbering corresponding to vp1, vp2, and vp3 is as follows: nucleotide (nt) AAVrh76: vp1-nt 1 to 2211, vp2-nt 412 to 2211, vp3-nt 610 to 2211 of SEQ ID NO: 41; AAVrh89: vp1-nt 1 to 2184, vp2-nt 412 to 2184, vp3-nt 595 to 2184 of SEQ ID NO: 51; AAVrh85: vp1-nt 1 to 2211, vp2-nt 412 to 2211, vp3-nt 610 to 2211 of SEQ ID NO: 59; AAVrh87: vp1 - nt 1 to 2211, vp2 - nt 412 to 2211, vp3 - nt 610 to 2211 of SEQ ID NO: 61 amino acids (aa) AAVrh76: aa vp1-1 to 737, vp2-aa 138 to 737, vp3-aa 204 to 737 of SEQ ID NO: 42; AAVrh89: aa vp1-1 to 728, vp2-aa 138 to 728, vp3-aa 199 to 728 of SEQ ID NO: 52; AAVrh85: aa vp1-1 to 737, vp2-aa 138 to 737, vp3-aa 204 to 737 of SEQ ID NO: 60; AAVrh87: aa vp1-1 to 737, vp2-aa 138 to 737, vp3-aa 204 to 737 of SEQ ID NO: 62

[0040] In certain embodiments, provided herein is an rAAV comprising at least one of vp1, vp2, and vp3 of any of AAVrh76 (SEQ ID NO: 42), AAVrh89 (SEQ ID NO: 52), AAVrh85 (SEQ ID NO: 60), or AAVrh87 (SEQ ID NO: 62). In certain embodiments, AAVrh75 (SEQ ID NO: 40), AAVrh76 (SEQ ID NO: 42), AAVrh89 (SEQ ID NO: 52), AAVrh85 (SEQ ID NO: 60), or AAVrh87 (SEQ ID NO: 62) is provided. Provided are rAAVs having capsid proteins comprising vp1, vp2, and / or vp3 sequences that are at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to AAVrh76 (SEQ ID NO: 42), AAVrh89 (SEQ ID NO: 52), AAVrh85 (SEQ ID NO: 60), or AAVrh87 (SEQ ID NO: 62). In certain embodiments, vp1, vp2, and / or vp3 have at most 1, at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, or at most 10 amino acid differences compared to vp1, vp2, and / or vp3 of AAVrh76 (SEQ ID NO: 42), AAVrh89 (SEQ ID NO: 52), AAVrh85 (SEQ ID NO: 60), or AAVrh87 (SEQ ID NO: 62). Also provided herein is an rAAV comprising an AAV capsid encoded by at least one of the vp1, vp2, and vp3 sequences of AAVrh75 (SEQ ID NO: 39), AAVrh76 (SEQ ID NO: 41), AAVrh89 (SEQ ID NO: 51), AAVrh85 (SEQ ID NO: 59), or AAVrh87 (SEQ ID NO: 61), or a sequence at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 39, 41, 51, 59, or 61. In certain embodiments, the sequence encodes the full-length vp1, vp2, and / or vp3 of AAVrh76 (SEQ ID NO: 42), AAVrh89 (SEQ ID NO: 52), AAVrh85 (SEQ ID NO: 60), or AAVrh87 (SEQ ID NO: 62). In other embodiments, vp1, vp2, and / or vp3 have an N-terminal and / or C-terminal truncation (eg, a truncation of about 1 to about 10 amino acids).

[0041] Clade E Provided herein are novel AAV capsid proteins having the vp1 sequence shown in the Sequence Listing: AAVrh75 (SEQ ID NO:40), AAVrh79 (SEQ ID NO:48), AAVrh83 (SEQ ID NO:56), or AAVrh84 (SEQ ID NO:58). The nucleotide and amino acid numbering corresponding to vp1, vp2, and vp3 is as follows: nucleotide (nt) AAVrh75: vp1-nt 1 to 2208, vp2-nt 412 to 2208, vp3-nt 607 to 2208 of SEQ ID NO: 39; AAVrh79: vp1-nt 1 to 2214, vp2-nt 412 to 2214, vp3-nt 610 to 2214 of SEQ ID NO: 47; AAVrh83: vp1-nt 1 to 2211, vp2-nt 412 to 2211, vp3-nt 610 to 2211 of SEQ ID NO: 55; AAVrh84: vp1 - nt 1 to 2211, vp2 - nt 412 to 2211, vp3 - nt 610 to 2211 of SEQ ID NO: 57 amino acids (aa) AAVrh75: aa vp1-1 to 736, vp2-aa 138 to 736, vp3-aa 203 to 736 of SEQ ID NO: 40; AAVrh79: aa vp1-1 to 738, vp2-aa 138 to 738, vp3-aa 204 to 738 of SEQ ID NO: 48; AAVrh83: aa vp1-1 to 737, vp2-aa 138 to 737, vp3-aa 204 to 737 of SEQ ID NO: 56; AAVrh84: aa vp1-1 to 737, vp2-aa 138 to 737, vp3-aa 204 to 737 of SEQ ID NO: 58

[0042] In certain embodiments, provided herein is an rAAV comprising at least one of vp1, vp2, and vp3 of any of AAVrh75 (SEQ ID NO:40), AAVrh79 (SEQ ID NO:48), AAVrh83 (SEQ ID NO:56), or AAVrh84 (SEQ ID NO:58). In certain embodiments, an rAAV comprising vp1, vp2, and / or vp3 sequences at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to AAVrh75 (SEQ ID NO:40), AAVrh79 (SEQ ID NO:48), AAVrh83 (SEQ ID NO:56), or AAVrh84 (SEQ ID NO:58). In certain embodiments, vp1, vp2, and / or vp3 have at most 1, at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, or at most 10 amino acid differences compared to vp1, vp2, and / or vp3 of AAVrh79 (SEQ ID NO:48), AAVrh83 (SEQ ID NO:56), or AAVrh84 (SEQ ID NO:58). Also provided herein are rAAVs comprising an AAV capsid encoded by at least one of vp1, vp2, and vp3 of AAVrh75 (SEQ ID NO:40), AAVrh79 (SEQ ID NO:47), AAVrh83 (SEQ ID NO:55), or AAVrh84 (SEQ ID NO:57), or a sequence at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:47, 55, or 57. In certain embodiments, the sequences encode full-length vp1, vp2, and / or vp3 of AAVrh79 (SEQ ID NO: 48), AAVrh83 (SEQ ID NO: 56), or AAVrh84 (SEQ ID NO: 58). In other embodiments, vp1, vp2, and / or vp3 have N-terminal and / or C-terminal truncations (e.g., truncations of about 1 to about 10 amino acids).

[0043] "Fringe clade" outgroups Provided herein are novel AAV capsid proteins having the vp1 sequence shown in the Sequence Listing: AAVrh77 (SEQ ID NO: 44), AAVrh78 (SEQ ID NO: 46), or AAVrh82 (SEQ ID NO: 54). The nucleotide and amino acid numbering corresponding to vp1, vp2, and vp3 is as follows: nucleotide (nt) AAVrh77: vp1-nt 1 to 2199, vp2-nt 412 to 2199, vp3-nt 589 to 2199 of SEQ ID NO: 43; AAVrh78: vp1-nt 1 to 2199, vp2-nt 412 to 2199, vp3-nt 589 to 2199 of SEQ ID NO: 45; AAVrh82: vp1 - nt 1 to 2199, vp2 - nt 412 to 2199, vp3 - nt 589 to 2199 of SEQ ID NO: 53 amino acids (aa) AAVrh77: aa vp1-1 to 733, vp2-aa 138 to 733, vp3-aa 197 to 733 of SEQ ID NO: 44; AAVrh78: aa vp1-1 to 733, vp2-aa 138 to 733, vp3-aa 197 to 733 of SEQ ID NO: 46; AAVrh82: aa vp1-1 to 733, vp2-aa 138 to 733, vp3-aa 197 to 733 of SEQ ID NO: 82

[0044] In certain embodiments, provided herein is an rAAV comprising at least one of vp1, vp2, and vp3 of any of AAVrh77 (SEQ ID NO:44), AAVrh78 (SEQ ID NO:46), or AAVrh82 (SEQ ID NO:54). In certain embodiments, provided is an rAAV having a capsid protein comprising vp1, vp2, and / or vp3 sequences that are at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to AAVrh77 (SEQ ID NO:44), AAVrh78 (SEQ ID NO:46), or AAVrh82 (SEQ ID NO:54). In certain embodiments, vp1, vp2, and / or vp3 have at most 1, at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, or at most 10 amino acid differences compared to vp1, vp2, and / or vp3 of AAVrh77 (SEQ ID NO: 44), AAVrh78 (SEQ ID NO: 46), or AAVrh82 (SEQ ID NO: 54). Also included are rAAVs comprising an AAV capsid encoded by at least one of vp1, vp2, and vp3 of AAVrh77 (SEQ ID NO: 43), AAVrh78 (SEQ ID NO: 45), or AAVrh82 (SEQ ID NO: 53), or a sequence at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NOs: 43, 45, 53. Provided herein are vp1, vp2, and / or vp3, which are full-length capsid proteins of AAVrh77 (SEQ ID NO: 44), AAVrh78 (SEQ ID NO: 46), or AAVrh82 (SEQ ID NO: 54). In other embodiments, vp1, vp2, and / or vp3 have N-terminal and / or C-terminal truncations (e.g., truncations of about 1 to about 10 amino acids).

[0045] "Recombinant AAV" or "rAAV" is a DNAse-resistant viral particle containing two elements: an AAV capsid and a vector genome containing at least a non-AAV coding sequence packaged within the AAV capsid. Unless otherwise specified, this term may be used interchangeably with the phrase "rAAV vector." rAAV lacks any functional AAV rep gene or cap gene and is unable to generate progeny, making it a "replication-deficient virus" or "viral vector." In certain embodiments, the only AAV sequences are AAV inverted terminal repeats (ITRs), typically located at the extreme 5' and 3' ends of the vector genome to allow genes and regulatory sequences located between the ITRs to be packaged within the AAV capsid.

[0046] As used herein, "vector genome" refers to a nucleic acid sequence packaged inside the rAAV capsid that forms the viral particle. Such a nucleic acid sequence contains AAV inverted terminal repeats (ITRs). In the example herein, the vector genome contains at least, from 5' to 3', the AAV 5' ITR, a coding sequence, and the AAV 3' ITR. ITRs from AAV2, a source AAV different from the capsid, or other than full-length ITRs may be selected. In certain embodiments, the ITRs are from the same AAV source as the AAV that provides the rep function or trans-complementing AAV during production. Additionally, other ITRs may be used. Additionally, the vector genome includes regulatory sequences that direct the expression of gene products. Suitable components of a vector genome are discussed in more detail herein. A vector genome may also be referred to herein as a "minigene."

[0047] rAAV consists of an AAV capsid and a vector genome. The AAV capsid is an assembly of a heterogeneous population of vp1, a heterogeneous population of vp2, and a heterogeneous population of vp3 proteins. As used herein, when used in reference to vp capsid proteins, the term "heterogeneous," or any grammatical variant thereof, refers to a population of non-identical members, for example, having vp1, vp2, or vp3 monomers (proteins) with different modified amino acid sequences.

[0048] As used herein, the term "heterogeneous population" in reference to vp1, vp2, and vp3 proteins (alternatively referred to as isoforms) refers to differences in the amino acid sequences of the vp1, vp2, and vp3 proteins within the capsid. AAV capsids contain subpopulations within the vp1, vp2, and vp3 proteins that have predicted amino acid residue modifications. These subpopulations contain, at a minimum, specific deamidated asparagine (N or Asn) residues. For example, a specific subpopulation contains at least one, two, three, or four highly deamidated asparagine (N) positions in asparagine-glycine pairs, and optionally further contains other deamidated amino acids, where deamidation results in amino acid changes and other optional modifications.

[0049] As used herein, a "subpopulation" of vp proteins, unless otherwise specified, refers to a group of vp proteins that share at least one defined common characteristic and consist of at least one group member and fewer than all members of the reference group. For example, a "subpopulation" of vp1 proteins, unless otherwise specified, is at least one (1) vp1 protein in an assembled AAV capsid, and can be less than all vp1 proteins. A "subpopulation" of vp3, unless otherwise specified, is at least one (1) vp1 protein in an assembled AAV capsid. In a capsid, there may be one or fewer than all vp3 proteins. For example, in an assembled AAV capsid, vp1 proteins may be a subpopulation of vp proteins, vp2 proteins may be another subpopulation of vp proteins, and vp3 may be yet a further subpopulation of vp proteins. In another example, the vp1, vp2, and vp3 proteins may comprise subpopulations with, for example, at least one, two, three, or four highly deamidated asparagines, e.g., different modifications at asparagine-glycine pairs.

[0050] Unless otherwise specified, highly deamidated refers to at least 45% deamidation, at least 50% deamidation, at least 60% deamidation, at least 65% deamidation, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or up to about 100% deamidation at a reference amino acid position compared to the predicted amino acid sequence at the reference amino acid position. Such percentages may be determined using 2D gels, mass spectrometry techniques, or other suitable techniques.

[0051] Without intending to be bound by theory, deamidation of at least the highly deamidated residues in the vp protein in AAV capsids is thought to be nonenzymatic in nature and is caused by functional groups within the capsid protein that deamidate selected asparagine and, to a lesser extent, glutamine residues. The efficient capsid assembly of the largely deamidated vp1 protein suggests that these events occur after capsid assembly or that deamidation in individual monomers (vp1, vp2, or vp3) is structurally well tolerated and largely does not affect assembly kinetics. Extensive deamidation in the VP1-unique (VP1-u) region (approximately aa 1-137), which is generally believed to be internally located prior to cell entry, suggests that VP deamidation may occur prior to capsid assembly.

[0052] Without intending to be bound by theory, deamidation of N may occur through nucleophilic attack on the Asn side chain amide group carbon atom via the backbone nitrogen atom of its C-terminal residue. An intermediate ring-closed succinimide residue is believed to be formed. The succinimide residue then undergoes rapid hydrolysis to yield the final product, aspartic acid (Asp) or isoaspartic acid (IsoAsp). Thus, in certain embodiments, deamidation of asparagine (N or Asn) leads to Asp or IsoAsp, which can be interconverted, for example, via a succinimide intermediate, as illustrated below. [ka]

[0053] As provided herein, each deamidated N in VP1, VP2, or VP3 can independently be aspartic acid (Asp), isoaspartic acid (isoAsp), aspartate, and / or an interconverting blend of Asp and isoAsp, or a combination thereof. Any suitable ratio of α- and isoaspartic acid can be present. For example, in certain embodiments, the ratio can be 10:1 to 1:10 asparagine to isoasparagine, about 50:50 asparagine:isoasparagine, or about 1:3 asparagine:isoasparagine, or another selected ratio.

[0054] In certain embodiments, one or more glutamines (Q) can be deamidated to glutamic acid (Glu), i.e., α-glutamic acid, γ-glutamic acid (Glu), or a blend of α- and γ-glutamic acid, which can be interconverted via a common glutarimide intermediate. Any suitable ratio of α-glutamic acid and γ-glutamic acid can be present. For example, in certain embodiments, the ratio can be 10:1 to 1:10 α:γ, about 50:50 α:γ, or about 1:3 α:γ, or another selected ratio. [ka]

[0055] Thus, the rAAV contains subpopulations of vp1, vp2, and / or vp3 proteins in the rAAV capsid that have deamidated amino acids, including at least one subpopulation that contains at least one highly deamidated asparagine. Additionally, other modifications may include isomerization, particularly at selected aspartic acid (D or Asp) residue positions. In yet other embodiments, modifications may include amidation at Asp positions.

[0056] In certain embodiments, AAV capsids comprise subpopulations of vp1, vp2, and vp3 having at least one, at least two, at least three, at least four, at least five, or at least about 25 deamidated amino acid residue positions, of which at least 1-10%, at least 10-25%, at least 25-50%, at least 50-70%, at least 70-100%, at least 75-100%, at least 80-100%, or at least 90-100% are deamidated relative to the encoded amino acid sequence of the vp proteins. The majority of these may be N residues. However, Q residues may also be deamidated.

[0057] As used herein, "encoded amino acid sequence" refers to predicted amino acids based on translation of known DNA codons of a reference nucleic acid sequence that are translated into amino acids. The table below illustrates DNA codons and the 20 common amino acids, showing both the one-letter code (SLC) and the three-letter code (3LC). [Table 1]

[0058] In certain embodiments, the rAAV has an AAV capsid having vp1, vp2, and vp3 proteins and has subpopulations that include combinations of 2, 3, 4, 5, or more deamidated residues at the positions shown in the tables provided herein (which are incorporated herein by reference).

[0059] Deamidation of rAAV can be determined using 2D gel electrophoresis, and / or mass spectrometry, and / or protein modeling techniques. Online chromatography was performed using an Acclaim PepMap column and a NanoFlex source (Thermo Fisher Scientific). The sequence analysis can be performed on a Thermo UltiMate 3000 RSLC system (Thermo Fisher Scientific) coupled to a Q Exactive HF with a Thermo Fisher Scientific MS data are acquired using the data-dependent top-20 method of the Q Exactive HF, which dynamically selects the most abundant and as yet unsequenced precursor ions from the survey scan (200–2000 m / z). Higher-energy collisional dissociation fragmentation was performed with a target value of 1e5 ions determined by predictive automatic gain control, and precursor isolation was performed in a 4 m / z window. Survey scans were acquired at m / z 200 with a resolution of 120,000. The resolution of the HCD spectrum may be set to 30,000 at m / z 200, with a maximum ion injection time of 50 ms and a normalized collision energy of 30. The S-lens RF level may be set to 50 to provide optimal transmission of the m / z region occupied by peptides from the digest. Precursor ions with a single unassigned charge state or six or more charge states from the fragmentation selection may be excluded. BioPharma Finder 1.0 software (Thermo Fischer Scientific) may be used to analyze the acquired data. For peptide mapping, searches are performed using a single-entry protein FASTA database with carbamidomethylation as the fixed modification, oxidation, deamidation, and phosphorylation as variable modifications, 10 ppm mass accuracy, high protease specificity, and a confidence level of 0.8 in MS / MS spectra. Examples of suitable proteases include trypsin or chymotrypsin. Because deamidation adds 0.984 Da (the mass difference between the -OH and -NH groups) to the mass of the intact molecule, mass spectrometric identification of deamidated peptides is relatively straightforward. The percentage of deamidation for a particular peptide is determined by dividing the mass area of ​​the deamidated peptide by the sum of the areas of the deamidated and native peptides. Considering the number of potential deamidation sites, isobaric species deamidated at different sites may comigrate in a single peak. As a result, fragment ions derived from peptides with multiple potential deamidation sites can be used to locate or distinguish multiple sites of deamidation. In these cases, the relative intensities within the observed isotope patterns can be used to specifically determine the relative abundances of different deamidated peptide isomers. This method assumes that the fragmentation efficiency for all isomeric species is the same and is independent of the deamidation site. It will be understood by those skilled in the art that several variations of these exemplary methods can be used.For example, suitable mass spectrometers include, for example, Waters Xevo or Agilent. These instruments may include a quadruple time of flight (QTOF) mass spectrometer such as the 6530, or an Orbitrap instrument such as the Orbitrap Fusion or Orbitrap Velos (Thermo Fisher). Suitable liquid chromatography systems include, for example, the Waters Acquity UPLC system or Agilent systems (1100 or 1200 series). Suitable data analysis software may include, for example, MassLynx (Waters), Pinpoint and Pepfinder (Thermo Fisher Scientific), Mascot (Matrix Science), and Peaks DB (Bioinformatics Solutions). Further techniques may be described, for example, in X. Jin et al., Hu Gene Therapy Methods, Vol. 28, No. 5, pp. 255-267, published online June 16, 2017.

[0060] In addition to deamidation, other modifications may occur that do not convert one amino acid to a different amino acid residue, and such modifications may include acetylated residues, isomerization, phosphorylation, or oxidation.

[0061] Modulation of deamidation: In certain embodiments, AAV is modified to change the glycine in an asparagine-glycine pair to reduce deamidation. In other embodiments, the asparagine is changed to a different amino acid, for example, glutamine, which deamidates at a slower rate, or to an amino acid lacking an amide group (e.g., glutamine and asparagine contain amide groups) and / or an amino acid lacking an amine group (e.g., lysine, arginine, and histidine contain amine groups). As used herein, an amino acid lacking an amide or amine side group is, for example, glycine, alanine, valine, leucine, isoleucine, serine, threonine, cystine, phenylalanine, tyrosine, or tryptophan. The term "asparagine-glycine pair" refers to an asparagine, an amino acid, and / or a proline. The modifications as described may be in one, two, or three of the asparagine-glycine pairs found in the encoded AAV amino acid sequence. In certain embodiments, such modifications are not made to all four of the asparagine-glycine pairs. Thus, methods for reducing deamidation of AAV and / or engineered AAV variants have a lower deamidation rate. Additionally, or alternatively, one or more other amide amino acids may be changed to non-amide amino acids to reduce deamidation of AAV. In certain embodiments, the mutant AAV capsids described herein contain mutations in asparagine-glycine pairs such that glycine is changed to alanine or serine. The mutant AAV capsid may contain one, two, or three mutations at positions where the reference AAV naturally contains four NG pairs. In certain embodiments, the AAV capsid may contain one, two, three, or four such mutations at positions where the reference AAV naturally contains five NG pairs. In certain embodiments, the mutant AAV capsid contains only a single mutation in the NG pair. In certain embodiments, the mutant AAV capsid contains mutations in two different NG pairs. In certain embodiments, the mutant AAV capsid contains mutations in two different NG pairs that are structurally separated in the AAV capsid. In certain embodiments, the mutations are not in the VP1 unique region. In certain embodiments, one of the mutations is in the VP1 unique region. Optionally, the mutant AAV capsid does not contain a modification in the NG pair, but contains a mutation to minimize or eliminate deamidation in one or more asparagines or glutamines located away from the NG pair.

[0062] In certain embodiments, a method for increasing the potency of an rAAV vector is provided, comprising engineering an AAV capsid to eliminate one or more NGs in a wild-type AAV capsid. In certain embodiments, the coding sequence for the "G" of "NG" is engineered to encode another amino acid. In the specific example below, an "S" or an "A" is substituted. However, other suitable amino acid coding sequences may be selected.

[0063] Amino acid modifications can be made by conventional genetic engineering techniques. For example, a nucleic acid sequence containing a modified AAV vp codon can be generated, in which one to three of the codons encoding glycine in an asparagine-glycine pair are modified to encode an amino acid other than glycine. In certain embodiments, a nucleic acid sequence containing a modified asparagine codon can have one to three of the asparagine-glycine pairs engineered so that the modified codon encodes an amino acid other than asparagine. Each modified codon can encode a different amino acid. Alternatively, one or more of the altered codons can encode the same amino acid. In certain embodiments, these modified nucleic acid sequences can be used to generate mutant rAAVs having capsids with less deamidation than native AAV3B variant capsids. Such mutant rAAVs can have reduced immunogenicity and / or increased stability during storage, particularly storage in suspension form.

[0064] Also provided herein are nucleic acid sequences encoding AAV capsids with reduced deamidation. It is within the skill of the art to design nucleic acid sequences encoding this AAV capsid, including DNA (genomic or cDNA) or RNA (e.g., mRNA). Such nucleic acid sequences can be codon-optimized for expression in a selected system (i.e., cell type) and can be designed by a variety of methods. This optimization can be performed using methods available online (e.g., GeneArt), published methods, or companies that provide codon optimization services, such as DNA2.0 (Menlo Park, CA). One codon optimization method is described, for example, in International Patent Publication No. 2015 / 012924, which is incorporated herein by reference in its entirety. See also, for example, U.S. Patent Publication Nos. 2014 / 0032186 and 2006 / 0136184. Preferably, the entire length of the product open reading frame (ORF) is modified. However, in some embodiments, only a fragment of the ORF may be altered. These people Using one of these methods, frequencies can be applied to any given polypeptide sequence to produce a nucleic acid fragment of a codon-optimized coding region that encodes the polypeptide. Several options are available for making the actual codon changes or for synthesizing a codon-optimized coding region designed as described herein. Such modification or synthesis can be performed using standard and routine molecular biology procedures well known to those skilled in the art. In one approach, a series of complementary oligonucleotide pairs, each 80-90 nucleotides in length and spanning the desired sequence length, are synthesized by standard methods. These oligonucleotide pairs are synthesized such that, upon annealing, they form 80-90 base pair double-stranded fragments containing cohesive ends; for example, each oligonucleotide in a pair is synthesized to extend 3, 4, 5, 6, 7, 8, 9, 10, or more bases beyond the region complementary to the other oligonucleotide in the pair. The single-stranded end of each pair of oligonucleotides is designed to anneal to the single-stranded end of another pair of oligonucleotides. The oligonucleotide pairs are annealed, and then approximately five to six of these double-stranded fragments are annealed together via the cohesive single-stranded ends. They are then ligated together and cloned into a standard bacterial cloning vector, such as the TOPO® vector available from Invitrogen Corporation, Carlsbad, Calif. The construct is then sequenced by standard methods. Some of these constructs consist of five to six 80-90 base pair fragments ligated together, i.e., approximately 500 base pair fragments are prepared, so that the entire desired sequence is represented in a series of plasmid constructs. The inserts of these plasmids are then cut with appropriate restriction enzymes and ligated together to form the final construct. The final construct is then cloned into a standard bacterial cloning vector and sequenced. Additional methods will be readily apparent to those skilled in the art. In addition, gene synthesis is readily available commercially.

[0065] In certain embodiments, AAV capsids are provided that have a heterogeneous population of AAV capsid isoforms (i.e., VP1, VP2, VP3) that contain multiple highly deamidated "NG" positions. In certain embodiments, the highly deamidated positions are at the positions shown below, with reference to the predicted full-length VP1 amino acid sequence. In other embodiments, the capsid gene is modified to remove the referenced "NG" and a mutant "NG" is engineered into another position.

[0066] B. rAAV Vectors and Compositions In one aspect, provided herein are molecules that utilize the AAV capsid sequences described herein (including fragments thereof) to produce viral vectors useful for delivering heterologous genes or other nucleic acid sequences to target cells. In certain embodiments, the provided rAAVs have a capsid described herein, and a vector genome comprising a non-AAV nucleic acid sequence is packaged within the capsid. In certain embodiments, vectors useful in the compositions and methods described herein contain at least a selected AAV capsid described herein, e.g., AAVhu71 / 74 (SEQ ID NO: 4), AAVhu79 (SEQ ID NO: 6), AAVhu80 (SEQ ID NO: 8), AAVhu83 (SEQ ID NO: 10), AAVhu74 / 71 (SEQ ID NO: 12), AAVhu77 (SEQ ID NO: 14), AAVhu78 / 88 (SEQ ID NO: 16), AAVhu70 (SEQ ID NO: 18), AAVhu72 (SEQ ID NO: 20), AAVhu75 (SEQ ID NO: 22), AAVhu76 (SEQ ID NO: 24), AAVhu77 / 88 (SEQ ID NO: 17), AAVhu78 (SEQ ID NO: 18), AAVhu72 (SEQ ID NO: 20), AAVhu75 (SEQ ID NO: 22), AAVhu76 (SEQ ID NO: 24), AAVhu79 / 88 (SEQ ID NO: 17), AAVhu79 / 88 (SEQ ID NO: 18), AAVhu72 / 88 (SEQ ID NO: 18), AAVhu79 ... hu81 (SEQ ID NO: 26), AAVhu82 (SEQ ID NO: 28), AAVhu84 (SEQ ID NO: 30), AAVhu86 (SEQ ID NO: 32), AAVhu87 (SEQ ID NO: 34), AAVhu88 / 78 (SEQ ID NO: 36), AAVhu69 (SEQ ID NO: 38), AAVrh75 (SEQ ID NO: 40), AAVrh76 (SEQ ID NO: 42), AAVrh77 (SEQ ID NO: 44), AAVrh78 (SEQ ID NO: 46), AAVrh79 (SEQ ID NO: 48), AAVrh81 (SEQ ID NO: 50), AAVrh89 (SEQ ID NO: 52), AAVrh82 (SEQ ID NO: 54), AAVrh83 (SEQ ID NO: 56) ), AAVrh84 (SEQ ID NO:58), AAVrh85 (SEQ ID NO:60), AAVrh87 (SEQ ID NO:62), or AAVhu73 (SEQ ID NO:74), or a fragment thereof comprising the vp1, vp2, or vp3 capsid protein. In certain embodiments, useful vectors include sequences encoding at least an AAV serotype rep protein, or a fragment thereof. Optionally, such vectors may include both the AAV cap and rep proteins. In vectors in which both AAV rep and cap are provided, the AAV rep and AAV cap sequences can both be of one serotype origin (e.g., all of the AAVhu71 / 74, AAVhu79, AAVhu80, AAVhu83, AAVhu74 / 71, AAVhu77, AAVhu78 / 88, AAVhu70, AAVhu72, AAVhu75, AAVhu76, AAVhu81, AAVhu82, AAVhu84, AAVhu86, AAVhu87, AAVhu88 / 78, AAVhu69, AAVrh75, AAVrh76, AAVrh77, AAVrh78, AAVrh79, AAVrh81, AAVrh89, AAVrh82, AAVrh83, AAVrh84, AAVrh85, AAVrh87, or AAVhu73 origin). Alternatively, a vector may be used in which the rep sequence is derived from a different AAV than the wild-type AAV that provides the cap sequence, for example the same AAV that provides the ITRs and rep.

[0067] In one embodiment, the rep and cap sequences are expressed from separate sources (e.g., separate vectors, or a host cell and a vector). In another embodiment, the rep sequences are fused in-frame to the cap sequence of a different AAV serotype to form a chimeric AAV vector, such as AAV2 / 8, as described in U.S. Patent No. 7,282,199, incorporated herein by reference. Optionally, the vector further comprises a minigene containing a selected transgene flanked by the AAV 5' ITR and AAV 3' ITR. In another embodiment, the AAV is a self-complementary AAV (sc-AAV). See US 2012 / 0141422 (incorporated herein by reference). Self-complementary vectors package an inverted repeat genome that can fold into dsDNA without the need for DNA synthesis or base pairing between multiple vector genomes. Because scAAVs do not require conversion of the single-stranded DNA (ssDNA) genome to double-stranded DNA (dsDNA) before expression, they are more efficient vectors. However, the trade-off for this efficiency is a loss of half the coding capacity of the vector, making ScAAV useful for small protein-coding genes (up to approximately 55 kd) currently available for RNA-based therapies.

[0068] Pseudotype vectors in which one AAV capsid is replaced with a heterologous capsid protein are useful in the present invention. For example, AAV vectors utilizing AAVhu71 / 74, AAVhu79, AAVhu80, AAVhu83, AAVhu74 / 71, AAVhu77, AAVhu78 / 88, AAVhu70, AAVhu72, AAVhu75, AAVhu76, AAVhu81, AAVhu82, AAVhu84, AAVhu86, AAVhu87, AAVhu88 / 78, AAVhu69, AAVrh75, AAVrh76, AAVrh77, AAVrh78, AAVrh79, AAVrh81, AAVrh89, AAVrh82, AAVrh83, AAVrh84, AAVrh85, AAVrh87, or AAVhu73 capsids described herein contain AAV2 ITRs. See Mussolini et al. Unless otherwise specified, AAV ITRs and other selected AAV components described herein can be individually selected from any AAV serotype, including, but not limited to, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or other known or unknown AAV serotypes. In one preferred embodiment, ITRs from AAV serotype 2 are used. However, ITRs from other suitable serotypes may also be selected. These ITRs or other AAV components can be readily isolated from AAV serotypes using techniques available to those skilled in the art. Such AAVs may be obtained from academic, commercial, or public sources (e.g., American Type AAV sequences can be isolated or obtained from the American AAV Culture Collection, Manassas, VA. Alternatively, AAV sequences can be obtained synthetically or through other suitable means by reference to published sequences such as those available in the literature or databases, e.g., GenBank, PubMed, etc.

[0069] The rAAVs provided herein comprise a vector genome, which is composed of at least a non-AAV or heterologous nucleic acid sequence (e.g., a transgene), regulatory sequences, and 5' and 3' AAV inverted terminal repeats (ITRs), as described below. It is this minigene that is packaged into capsid proteins and delivered to a selected target cell or tissue.

[0070] A transgene is a nucleic acid sequence heterologous to the vector sequences flanking the transgene that encodes a polypeptide, protein, or other product of interest. The nucleic acid coding sequence is operably linked to regulatory components in a manner that allows transcription, translation, and / or expression of the transgene in target cells. The heterologous nucleic acid sequence (transgene) can be derived from any organism. An AAV can contain one or more transgenes.

[0071] As used herein, the terms "target cell" and "target tissue" can refer to any cell or tissue intended to be transduced by the subject AAV vector. The terms can refer to any one or more of muscle, liver, lung, airway epithelium, central nervous system, neurons, eye (visual cells), or heart. In one embodiment, the target tissue is the liver. In another embodiment, the target tissue is the heart. In another embodiment, the target tissue is the brain. In another embodiment, the target tissue is muscle.

[0072] As used herein, the term "mammalian subject" or "subject" includes any mammal in need of the treatment or prevention methods described herein, and particularly includes humans. Other mammals in need of such treatment or prevention include dogs, cats, or other domesticated animals, horses, farm animals, laboratory animals, and the like, including non-human primates. The subject may be male or female.

[0073] As used herein, the term "host cell" can refer to a packaging cell line in which an rAAV is produced from a plasmid. Alternatively, the term "host cell" can refer to a target cell in which expression of a transgene is desired.

[0074] Therapeutic transgenes Useful products encoded by transgenes include various gene products that replace missing or defective genes, inactivate or "knock out," or "knock down" or reduce expression of genes that are expressed at undesirably high levels, or deliver gene products with a desired therapeutic effect. In most embodiments, the treatment is "somatic cell gene therapy," i.e., the introduction of genes into cells of the body that do not produce sperm or eggs. In certain embodiments, the transgene-expressed protein has the sequence of a native human sequence. However, in other embodiments, synthetic proteins are expressed. Such proteins may be intended for human treatment, or in other embodiments, may be designed for the treatment of animals, including companion animals such as dog or cat populations, or for the treatment of livestock or other animals that come into contact with the human population.

[0075] Examples of suitable gene products may include those associated with familial hypercholesterolemia, muscular dystrophy, cystic fibrosis, and rare or orphan diseases. Examples of such rare diseases include spinal muscular atrophy (SMA), Huntington's disease, Rett syndrome (e.g., methyl-CpG binding protein 2 (MeCP2), UniProtKB-P51608), myocardial infarction (MYC), and myocardial ischemia (MIA). Examples of transgenes that may be included include amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy, Friedreich's ataxia (e.g., frataxin), ATXN2 associated with spinocerebellar ataxia type 2 (SCA2) / ALS, TDP-43 associated with ALS, and progranulin (PRGN) (associated with non-Alzheimer's brain degeneration, including frontal dementia (FTD), progressive non-fluent aphasia (PNFA), and semantic dementia). See, for example, orpha.net / consor / cgi-bin / Disease_Search_List.php;rarediseases.info.nih.gov / diseases. In one embodiment, the transgene is not a human low-density lipoprotein receptor (hLDLR). In another embodiment, the transgene is not an engineered human low-density lipoprotein receptor (hLDLR) variant, such as that described in WO2015 / 164778.

[0076] Examples of suitable genes include, for example, insulin, glucagon, glucagon-like peptide-1 (GLP1), growth hormone (GH), parathyroid hormone (PTH), growth hormone-releasing factor (GRF), follicle-stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (hCG), vascular endothelial growth factor (VEGF), angiopoietin, angiostatin, granulocyte colony-stimulating factor (GCSF), erythropoietin (EPO) (e.g., any one of the transforming growth factor alpha superfamily, including human, canine, or feline epo), connective tissue growth factor (CTGF), neutrophil factors, such as basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin growth factor I and II (IGF-I and IGF-II), TGFα, activin, inhibin, or bone morphogenetic protein (BMP) 1-15, hormones and growth and differentiation factors including, but not limited to, any one of the following families: the heregluin / neuregulin / ARIA / neu differentiation factor (NDF) family of growth factors, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophins NT-3 and NT-4 / 5, ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor (GDNF), neurturin, agrin, semaphorin / collapsin, netrin 1 and netrin 2, hepatocyte growth factor (HGF), ephrin, noggin, sonic hedgehog, tyrosine hydroxylase.

[0077] Other useful transgene products include proteins that regulate the immune system, including, but not limited to, cytokines and lymphokines such as thrombopoietin (TPO), interleukins (IL), IL-1 through IL-36 (e.g., human interleukins IL-1, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-6, IL-8, IL-12, IL-11, IL-12, IL-13, IL-18, IL-31, and IL-35), monocyte chemotactic protein, leukemia inhibitory factor, granulocyte-macrophage colony-stimulating factor, Fas ligand, tumor necrosis factors α and β, interferons α, β, and γ, stem cell factor, and flk-2 / flt3 ligand. Gene products produced by the immune system are also useful in the present invention. These include, but are not limited to, immunoglobulins IgG, IgM, IgA, IgD, and IgE, chimeric immunoglobulins, humanized antibodies, single-chain antibodies, T cell receptors, chimeric T cell receptors, single-chain T cell receptors, class I and class II MHC molecules, and engineered immunoglobulins and MHC molecules. For example, in certain embodiments, rAAV antibodies can be designed to deliver canine or feline antibodies, such as anti-IgE, anti-IL31, anti-IL33, anti-CD20, anti-NGF, and anti-GnRH. Useful gene products also include complement regulatory proteins, such as complement regulatory proteins, membrane cofactor protein (MCP), decay-accelerating factor (DAF), CR1, CF2, CD59, and C1 esterase inhibitor (C1-INH).

[0078] Still other useful gene products include any one of the receptors for hormones, growth factors, cytokines, lymphokines, regulatory proteins, and immune system proteins. The present invention encompasses receptors for cholesterol control and / or lipid regulation, including low-density lipoprotein (LDL) receptors, high-density lipoprotein (HDL) receptors, very-low-density lipoprotein (VLDL) receptors, and scavenger receptors. The present invention also encompasses gene products such as members of the steroid hormone receptor superfamily, including glucocorticoid and estrogen receptors, vitamin D receptors, and other nuclear receptors. Additionally, useful gene products include transcription factors such as jun, fos, max, mad, serum response factor (SRF), AP-1, AP2, myb, MyoD, and myogenin, ETS box containing proteins, TFE3, E2F, ATF1, ATF2, ATF3, ATF4, ZF5, NFAT, CREB, HNF-4, C / EBP, SP1, CCAAT box binding proteins, interferon regulatory factor (IRF-1), Wilms tumor protein, ETS binding proteins, STATs, GATA box binding proteins, e.g., GATA-3, and the forkhead family of winged helix proteins.

[0079] Other useful gene products include hydroxymethylbilane synthase (HMBS), carbamoyl synthetase I, ornithine transcarbamylase (OTC), argininosuccinate synthetase, argininosuccinate lyase (ASL) for the treatment of argininosuccinate lyase deficiency, arginase, fumarate hydrolase, phenylalanine hydroxylase, alpha-1 antitrypsin, rhesus alpha-fetoprotein (AFP), chorionic gonadotropin (CG), glucose-6-phosphatase, porphobilinogen deaminase, and cis- Examples of useful gene products include thione beta-synthase, branched-chain keto acid decarboxylase, albumin, isovaleryl-CoA dehydrogenase, propionyl-CoA carboxylase, methylmalonyl-CoA mutase, glutaryl-CoA dehydrogenase, insulin, beta-glucosidase, pyruvate carboxylate, hepatic phosphorylase, phosphorylase kinase, glycine decarboxylase, H-protein, T-protein, cystic fibrosis transmembrane conductance regulator (CFTR) sequence, and dystrophin gene products (e.g., mini- or micro-dystrophin). Still other useful gene products include enzymes that may be useful in enzyme replacement therapy, which is useful in various conditions caused by insufficient enzyme activity. For example, enzymes containing mannose-6-phosphate may be used in therapy for lysosomal storage diseases (e.g., suitable genes include those encoding β-glucuronidase (GUSB)). In another example, the gene product is ubiquitin protein ligase E3A (UBE3A). Further useful gene products include UDP glucuronosyltransferase family 1 member A1 (UGT1A1).

[0080] In certain embodiments, rAAV may be used in gene editing systems, which may involve the co-administration of one rAAV or multiple rAAV strains. For example, rAAV may be engineered to deliver SpCas9, SaCas9, ARCUS, Cpfl (also known as Cas12a), CjCas9, and other suitable gene editing constructs.

[0081] Still other useful gene products include those used to treat hemophilia, including hemophilia B (including factor IX) and hemophilia A (including factor VIII and its variants, e.g., heterodimers and B-deleted domain light and heavy chains; U.S. Patent Nos. 6,200,560 and 6,221,349). In some embodiments, the minigene contains the first 57 base pairs of the factor VIII heavy chain encoding a 10-amino acid signal sequence and the human growth hormone (hGH) polyadenylation sequence. In alternative embodiments, the minigene further contains the A1 and A2 domains, and 5 amino acids from the N-terminus of the B domain and / or 85 amino acids from the C-terminus of the B domain, as well as the A3, C1, and C2 domains. In yet other embodiments, nucleic acids encoding the factor VIII heavy and light chains are provided in a single minigene separated by 42 nucleic acids encoding the 14 amino acids of the B domain [U.S. Patent No. 6,200,560].

[0082] Other useful gene products include non-naturally occurring polypeptides, such as chimeric or hybrid polypeptides with non-naturally occurring amino acid sequences containing insertions, deletions, or amino acid substitutions. For example, single-chain engineered immunoglobulins may be useful in certain immunodeficient patients. Other types of non-naturally occurring gene sequences include antisense molecules and catalytic nucleic acids, such as ribozymes, which can be used to reduce overexpression of targets.

[0083] Reducing and / or modulating gene expression is particularly desirable for treating hyperproliferative conditions characterized by hyperproliferative cells, such as cancer and psoriasis. Target polypeptides include polypeptides produced exclusively or at higher levels in hyperproliferative cells compared to normal cells. Target antigens include polypeptides encoded by oncogenes such as myb, myc, and fyn, as well as translocation genes bcr / abl, ras, src, p53, neu, trk, and EGRF. In addition to oncogene products as target antigens, target polypeptides for anti-cancer therapeutic and protective regimens include variable regions of antibodies produced by B-cell lymphomas and variable regions of T-cell receptors in T-cell lymphomas, and in some embodiments are also used as target antigens for autoimmune diseases. Other tumor-associated polypeptides can be used as target polypeptides, such as polypeptides found at higher levels in tumor cells, including polypeptides recognized by monoclonal antibody 17-1A and folate-binding polypeptides.

[0084] Other suitable therapeutic polypeptides and proteins include those that may be useful for treating individuals suffering from autoimmune diseases and disorders by conferring a broad protective immune response against targets associated with autoimmunity, including cellular receptors and cells that produce "self"-directed antibodies. T cell-mediated autoimmune diseases include rheumatoid arthritis (RA), multiple sclerosis (MS), Sjögren's syndrome, sarcoidosis, insulin-dependent diabetes mellitus (IDDM), autoimmune thyroiditis, reactive arthritis, ankylosing spondylitis, scleroderma, polymyositis, dermatomyositis, psoriasis, vasculitis, Wegener's granulomatosis, Crohn's disease, and ulcerative colitis. Each of these diseases is characterized by a T cell receptor (TCR) that binds to an endogenous antigen and initiates the inflammatory cascade associated with the autoimmune disease.

[0085] For example, additional exemplary genes that can be delivered via the rAAV provided herein for the treatment of liver indications include, but are not limited to, glucose-6-phosphatase (associated with glycogen storage disease or type 1A deficiency (GSD1)), phosphoenolpyruvate carboxykinase (PEPCK, associated with PEPCK deficiency), cyclin-dependent kinase-like 5 (CDKL5), also known as serine / threonine kinase 9 (STK9), associated with seizures and severe neurodevelopmental disorders, galactose-1-phosphate uridyltransferase (associated with galactosemia), phenylalanine hydroxylase (PAH) (associated with phenylketonuria (PKU)), gene products associated with primary hyperoxaluria type 1, including hydroxyacid oxidase 1 (GO / HAO1) ​​and AGXT, branched-chain alpha-ketoacid dehydrogenases, including BCKDH, BCKDH-E2, BAKDH-E1a, and BAKDH-E1b. Protein (associated with maple syrup urine disease), fumarylacetoacetate hydrolase (associated with tyrosinemia type 1), methylmalonyl-CoA mutase (associated with methylmalonic acidemia), medium-chain acyl-CoA dehydrogenase (associated with medium-chain acyl-CoA dehydrogenase deficiency), ornithine transcarbamylase (OTC, associated with ornithine transcarbamylase deficiency), argininosuccinate synthetase (ASS1, associated with citrullinemia), lecithin-cholesterol acyltransferase (LCAT, deficiency), methylmalonic acidemia (MMA), NPC1 (associated with Niemann-Pick disease type C1), propionic acidemia (PA), TTR (associated with transthyretin (TTR)-related hereditary amyloidosis), low-density lipoprotein receptor (LDLR) protein (associated with familial hypercholesterolemia (FH)), LDLR variants (e.g., WO2015 / 16 4778), PCSK9, ApoE and ApoC proteins (associated with dementia), UDP-glucuronosyltransferase (associated with Crigler-Najjar disease), adenosine deaminase (associated with severe combined immunodeficiency), hypoxanthine guanine phosphoribosyltransferase (associated with gout and Lesch-Nyhan syndrome), biotin (associated with biotin deficiency), alpha-galactosidase A (a-GalA, associated with Fabry disease), beta-galactosidase (GLB1) (GM1 gangliosides), sphingomyelinase (associated with Wilson's disease), ATP7B (associated with Wilson's disease), β-glucocerebrosidase (associated with Gaucher's disease types 2 and 3), peroxisomal membrane protein 70 kDa (associated with Zellweger's syndrome), arylsulfatase A (ARSA, associated with metachromatic leukodystrophy), galactocerebrosidase (GALC, an enzyme associated with Krabbe's disease), α-glucosidase (GAA, associated with Pompe's disease), sphingomyelinase (SMPD1, a gene associated with Niemann-Pick disease type A), arginine Citric acid synthase (associated with adult-onset type II citrullinemia (CTLN2)), carbamoyl phosphate synthase 1 (CPS1, associated with urea cycle disorders), survival motor neuron (SMN) protein (associated with spinal muscular atrophy), ceramidase (associated with Farber lipogranulomatosis), β-hexosaminidase (associated with GM2 gangliosidosis, Tay-Sachs disease, and Sandhoff disease), aspartylglucosaminidase (associated with aspartylglucosaminuria), α-fucosidase (associated with fucosidosis) ), alpha-mannosidase (associated with alpha-mannosidosis), porphobilinogen deaminase (associated with acute intermittent porphyria (AIP)), alpha-1 antitrypsin (for the treatment of alpha-1 antitrypsin deficiency (emphysema)), erythropoietin (for the treatment of anemia due to thalassemia or renal failure), vascular endothelial growth factor, angiopoietin-1, and fibroblast growth factor (for the treatment of ischemic disease), thrombomodulin and tissue factor pathway inhibitor (for the treatment of blocked blood vessels seen, for example, in atherosclerosis, thrombosis, or embolism),These include aromatic amino acid decarboxylase (AADC) and tyrosine hydroxylase (TH) (for the treatment of Parkinson's disease), PRKN for the treatment of Parkinson's disease, beta-adrenergic receptors, antisense to phospholamban or its mutants, sarco(endoplasmic reticulum) adenosine triphosphatase-2 (SERCA2), and cardiac adenylate cyclase (for the treatment of congestive heart failure), tumor suppressor genes (such as p53, for the treatment of various cancers), cytokines (such as various interleukins for the treatment of inflammatory and immune disorders and cancer), dystrophin or mini-dystrophin and utrophin or mini-utrophin (for the treatment of muscular dystrophy), and insulin or GLP-1 (for the treatment of diabetes).

[0086] Additional genes and diseases of interest include SCN9A-related diseases, such as dystonin gene-associated diseases, such as hereditary sensory and autonomic dyspraxia type VI (the DST gene encodes dystonin, and dual AAV vectors may be required due to the size of the protein (approximately 7570 aa)), loss of function mutations resulting in an inability to sense pain, and gain of function mutations causing pain conditions such as erythromelalgia. Another condition is Charcot-Marie-Tooth (CMT) types 1F and 2E, which are caused by mutations in the NEFL gene (neurofilament light chain). It is characterized by progressive peripheral motor and sensory neuropathy with variable clinical and electrophysiological manifestations. Other gene products associated with CMT include mitofusin 2 (MFN2).

[0087] In certain embodiments, the rAAVs described herein can be used in the treatment of mucopolysaccharidosis (MPS) disorders. Such rAAVs can contain nucleic acid sequences encoding α-L-iduronidase (IDUA) for treating MPS I (Hurler, Hurler-Scheie, and Scheie syndromes), iduronate-2-sulfatase (IDS) for treating MPS II (Hunter syndrome), and sulfamidase (SGSH) for treating MPS III A, B, C, and D (Sanfilippo syndrome). sequences, a nucleic acid sequence encoding N-acetylgalactosamine-6-sulfate sulfatase (GALNS) for treating MPS IV A and B (Morquio syndrome), a nucleic acid sequence encoding arylsulfatase B (ARSB) for treating MPS VI (Maroteaux-Lamy syndrome), a nucleic acid sequence encoding hyaluronidase for treating MPS I IX (hyaluronidase deficiency), and a nucleic acid sequence encoding beta-glucuronidase for treating MPS VII (Sly syndrome).

[0088] In some embodiments, an rAAV vector containing a nucleic acid encoding a gene product associated with cancer (e.g., a tumor suppressor) can be used to treat cancer by administering the rAAV harboring the rAAV vector to a subject with cancer. In some embodiments, an rAAV vector containing a nucleic acid encoding a small interfering nucleic acid (e.g., shRNA, miRNA) that inhibits the expression of a gene product associated with cancer (e.g., an oncogene) can be used to treat cancer by administering the rAAV harboring the rAAV vector to a subject with cancer. In some embodiments, an rAAV vector containing a nucleic acid encoding a gene product associated with cancer (or a functional RNA that inhibits the expression of a gene associated with cancer) can be used for research purposes, for example, to study cancer or to identify therapeutic agents to treat cancer. The following is a non-limiting list of exemplary genes (e.g., oncogenes and tumor suppressors) known to be associated with the development of cancer: AARS, ABCB1, ABCC4, ABI2, ABL1, ABL2, ACK1, ACP2, ACY1, ADSL, AK1, AKR1C2, AKT1, ALB, ANPEP, ANXA5, ANXA7, AP2M1, APC, ARHGAP5, ARHGEF5, ARID4A, ASNS, ATF4, ATM, ATP5B, ATP5O, AXL, BARD1, BAX, BCL2, BHLHB2, BLMH, BRAF, BRCA1, BRCA2, BTK, CANX, CAP1, CAPN1, CAPNS1, CAV1, CBFB, CBLB, CCL2, CCND1, CCND2, CCND3, CCNE1, CCT5, CCYR61, CD24, CD44, CD59, CDC20, CDC25, CDC25A, CDC25B, CDC2L5, CDK10, CDK4, CDK5, CDK9, CDKL1, CDKN1A, CDKN1B, CDKN1C, CDKN2A, CDKN2B, CDKN2D, CEBPG, CEN PC1, CGRRF1, CHAF1A, CIB1, CKMT1, CLK1, CLK2, CLK3, CLNS1A, CLTC, COL1A1, COL6A3, COX6C, COX7A2, CRAT, CRHR1, CSF1R, CSK, CSNK1G2, CTNNA1, CTNNB1, CTPS, CTSC, CTSD, CUL1, CYR61, DCC,DCN、DDX10、DEK、DHCR7、DHRS2、DHX8、DLG3、DVL1、DVL3、E2F1、E2F3、E2F5、EGFR、EGR1、EIF5、EPHA2、ERBB2、ER BB3、ERBB4、ERCC3、ETV1、ETV3、ETV6、F2R、FASTK、FBN1、FBN2、FES、FGFR1、FGR、FKBP8、FN1、FOS、FOSL1、FOSL2 FOXG1A, FOXO1A, FRAP1, FRZB, FTL, FZD2, FZD5, FZD9, G22P1, GAS6, GCN5L2, GDF15, GNA13, GNAS, GNB2, GNB2L1, GPR39, GBRB2, GSK3A, GSPT1, GTF2I, HDAC1, HDGF, HMMR, HPRT1, HRB, HSPA4, HSPA5, HSPA8, HSPB1, HSPH1, HYA L1, HYOU1, ICAM1, ID1, ID2, IDUA, IER3, IFITM1, IGF1R, IGF2R, IGFBP3, IGFBP4, IGFBP5, IL1B, ILK, ING1, IRF3, ITGA3, ITGA6, ITGB4, JAK1, JARID1A, JUN, JUNB, JUND, K-ALPHA-1, KIT, KITLG, KLK10, KPNA2, KRAS2, KRT18 、KRT2A、KRT9、LAMB1、LAMP2、LCK、LCN2、LEP、LITAF、LRPAP1、LTF、LYN、LZTR1、MADH1、MAP2K2、MAP3K8、MAPK12 、MAPK13、MAPKAPK3、MAPRE1、MARS、MAS1、MCC、MCM2、MCM4、MDM2、MDM4、MET、MGST1、MICB、MLLT3、MME、MMP1、MM、 P14、MMP17、MMP2、MNDA、MSH2、MSH6、MT3、MYB、MYBL1、MYBL2、MYC、MYCL1、MYCN、MYD88、MY L9、MYLK、NEO1、NF1、NF2、NFKB1、NFKB2、NFSF7、NID、NINE、NMBR、NME1、NME2、NME3、NOTCH 1、NOTCH2、NOTCH4、NPM1、NQO1、NR1D1、NR2F1、NR2F6、NRAS、NRG1、NSEP1、OSM、PA2G4、PAB PC1、PCNA、PCTK1、PCTK2、PCTK3、PDGFA、PDGFB、PDGFRA、PDPK1、PEA15、PFDN4、PFDN5、PGAM 1、PHB、PIK3CA、PIK3CB、PIK3CG、PIM1、PKM2、PKMYT1、PLK2、PPARD、PPARG、PPIH、PPP1CA、 PPP2R5A、PRDX2、PRDX4、PRKAR1A、PRKCBP1、PRNP、PRSS15、PSMA1、PTCH、PTEN、PTGS1、PTMA 、PTN、PTPRN、RAB5A、RAC1、RAD50、RAF1、RALBP1、RAP1A、RARA、RARB、RASGRF1、RB1、RBBP4 、RBL2、REA、REL、RELA、RELB、RET、RFC2、RGS19、RHOA、RHOB、RHOC、RHOD、RIPK1、RPN2、RPS6 KB1、RRM1、SARS、SELENBP1、SEMA3C、SEMA4D、SEPP1、SERPINH1、SFN、SFPQ、SFRS7、SHB、SHH、SIAH2、SIVA、SIVATP53, SKI, SKIL, SLC16A1, SLC1A4, SLC20A1, SMO 1) SNAI2, SND1, SNRPB2, SOCS1, SOCS3, SOD1, SORT1, SPINT2, SPRY2, SRC, SRPX, S TAT1, STAT2, STAT3, STAT5B, STC1, TAF1, TBL3, TBRG4, TCF1, TCF7L2, TFAP2C, TFD P1, TFDP2, TGFA, TGFB1, TGFBI, TGFBR2, TGFBR3, THBS1, TIE, TIMP1, TIMP3, TJP1 TK1, TLE1, TNF, TNFRSF10A, TNFRSF10B, TNFRSF1A, TNFRSF1B, TNFRSF6, TNFSF7 TNK1, TOB1, TP53, TP53BP2, TP5313, TP73, TPBG, TPT1, TRADD, TRAM1, TRRAP, TSG1 01 TUFM TXNRD1 TYRO3 UBC UBE2L6 UCHL1 USP7 VDAC1 VEGF VHL VIL2 WEE1 WNT1, WNT2, WNT2B, WNT3, WNT5A, WT1, XRCC1, YES1, YWHAB, YWHAZ, ZAP70, and ZNF9.

[0089] The rAAV vector may include as a transgene a nucleic acid encoding a protein or functional RNA that regulates apoptosis. The following is a non-limiting list of nucleic acids encoding genes associated with apoptosis and the products of these genes and their homologs, as well as small interfering nucleic acids (e.g., shRNA, miRNA) that inhibit the expression of these genes and their homologs and are useful as transgenes in certain embodiments of the invention: RPS27A, ABL1, AKT1, APAF1, BAD, BAG1, BAG3, BAG4, BAK1, BAX, BCL10, BCL2, BCL2A1, BCL2L1, BCL2L10, BCL2L11, BCL2L12, BCL2L13, BCL2L2, BCLAF1, BFAR, BID, BIK, NAIP, BIRC2, BIRC3, XIAP, BIRC5, BIRC6, BIRC7, BIRC8, BNIP1, B NIP2, BNIP3, BNIP3L, BOK, BRAF, CARD10, CARD11, NLRC4, CARD14, NOD2, NOD1, CARD6, CARDS, CARDS, CASP1, CASP10, CASP14, CASP2, CASP3, CASP4, CASP5, CASP6, CASP7, CASP8, CASP9, CFLAR, CIDEA, CID EB, CRADD, DAPK1, DAPK2, DFFA, DFFB, FADD, GADD45A, GDNF, HRK, IGF1R, LTA, LTBR, ​​MCL1, NOL3, PYCARD, RIPK1, RIPK2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11B, TNFRSF12A, TNFRS F14, TNFRSF19, TNFRSF1A, TNFRSF1B, TNFRSF21, TNFRSF25, CD40, FAS, TNFRSF6B, CD27, TNFRSF9, TNFSF10, TNFSF14, TN FSF18, CD40LG, FASLG, CD70, TNFSF8, TNFSF9, TP53, TP53BP2, TP73, TP63, TRADD, TRAF1, TRAF2, TRAF3, TRAF4, and TRAF5.

[0090] Useful transgene products also include miRNAs. miRNAs and other small interfering nucleic acids regulate gene expression through cleavage / degradation of target RNA transcripts or translational repression of target messenger RNAs (mRNAs). miRNAs are typically naturally expressed as final 19-25 untranslated RNA products. miRNAs exert their activity through sequence-specific interactions with the 3' untranslated region (UTR) of target mRNAs. These endogenously expressed miRNAs form hairpin precursors, which are then processed into miRNA duplexes and further into "mature" single-stranded miRNA molecules. This mature miRNA guides the multiprotein complex miRISC, which identifies target sites (e.g., in the 3'UTR region) of target mRNAs based on complementarity to the mature miRNA.

[0091] The following non-limiting list of miRNA genes, and their homologs, are useful in certain embodiments of the method as transgenes or as targets for small interfering nucleic acids (e.g., miRNA sponges, antisense oligonucleotides, TuD RNAs) encoded by the transgenes: hsa-let-7a, hsa-let-7a * , hsa-let-7b, hsa-let-7b * , hsa-let-7c, hsa-let-7c * , hsa-let-7d, hsa-let-7d * , hsa-let-7e, hsa-let-7e * , hsa-let-7f, hsa-let-7f-1 * , hsa-let-7f-2 * , hsa-let-7g, hsa-let-7g * , hsa-let-71, hsa-let-71 * , hsa-miR-1, hsa-miR-100, hsa-miR-100 * , hsa-miR-101, hsa-miR-101 * , hsa-miR-103, hsa-miR-105, hsa-miR-105 * , hsa-miR-106a, hsa-miR-106a* hsa-miR-106b hsa-miR-106b * hsa-miR-107 hsa-miR-10a hsa-miR-10a * hsa-miR-10b hsa-miR-10b * hsa-miR-1178 hsa-miR-1179 hsa-miR-1180 hsa-miR-1181 hsa-miR-1182 hsa-miR-1183 hsa-miR-1184 hsa-miR-1185 hsa-miR-1197 hsa-miR-1200 hsa-miR -1201, hsa-miR-1202, hsa-miR-1203, hsa-miR-1204, hsa-miR-1205, hsa-miR-1206, hsa-miR-1207-3p, hsa-miR-1207-5p, hsa-miR-1208, hsa-miR-122, hsa-miR-122 * hsa-miR-1224-3p hsa-miR-1224-5p hsa-miR-1225-3p hsa-miR-1225-5p hsa-miR-1226 hsa-miR-1226 * hsa-miR-1227 hsa-miR-1228 hsa-miR-1228 * hsa-miR-1229 hsa-miR-1231 hsa-miR-1233 hsa-miR-1234 hsa-miR-1236 hsa-miR-1237 hsa-miR-1238 hsa-miR-124 hsa-miR-124 * hsa-miR-1243 hsa-miR-1244 hsa-miR-1245 hsa-miR-1246 hsa-miR-1247 hsa-miR-1248 hsa-miR-1249 hsa-miR-1250 hsa-miR-1251 hsa-miR-1252 hsa-miR-1253 hsa-miR-1254、hsa-miR-1255a、hsa-miR-1255b、hsa-miR-1256、hsa-miR-1257、hsa-m iR-1258、hsa-miR-1259、hsa-miR-125a-3p、hsa-miR-125a-5p、hsa-miR-125b、hsa-miR -125b-1 * hsa-miR-125b-2 * hsa-miR-126 hsa-miR-126 * hsa-miR-1260 hsa-miR-1261 hsa-miR-1262 hsa-miR-1263 hsa-miR-1264 hsa-miR-1265 hsa-miR-1266 hsa-miR-1267 hsa-miR-1268 hsa-miR-1269 hsa-miR-1270 hsa-miR-1271 hsa-miR-1272 hsa-miR-1273 hsa-miR-127-3p hsa-miR-1274a hsa-miR-1274b hsa -miR-1275, hsa-miR-127-5p, hsa-miR-1276, hsa-miR-1277, hsa-miR-1278, hsa-miR-1279, hsa-miR-128, hsa-miR-1280, hsa-miR-1281, hsa-miR-1282, hsa-miR-1283, hsa-miR-1284, hsa-miR-1285, hsa-miR-1286, hsa-miR-1287, hsa-miR-1288, hsa-miR-1289, hsa-miR-129 * hsa-miR-1290 hsa-miR-1291 hsa-miR-1292 hsa-miR-1293 hsa-miR-129-3p hsa-miR-1294 hsa-miR-1295 hsa-miR-129-5p hsa-miR-1296 hsa-miR-1297 hsa-miR-1298 hsa -miR-1299, hsa-miR-1300, hsa-miR-1301, hsa-miR-1302, hsa-miR-1303, hsa-miR-1304, hsa-miR-1305, hsa-miR-1306, hsa-miR-1307, hsa-miR-1308, hsa-miR-130a, hsa-miR-130a * 、hsa-miR-130b、hsa-miR-130b * hsa-miR-132 hsa-miR-132 *hsa-miR-1321 hsa-miR-1322 hsa-miR-1323 hsa-miR-1324 hsa-miR-133a hsa-miR-133b hsa-miR-134 hsa-miR-135a hsa-miR-135a * hsa-miR-135b hsa-miR-135b * hsa-miR-136 hsa-miR-136 * hsa-miR-137 hsa-miR-138 hsa-miR-138-1 * hsa-miR-138-2 * hsa-miR-139-3p hsa-miR-139-5p hsa-miR-140-3p hsa-miR-140-5p hsa-miR-141 hsa-miR-141 * hsa-miR-142-3p hsa-miR-142-5p hsa-miR-143 hsa-miR-143 * hsa-miR-144 hsa-miR-144 * hsa-miR-145 hsa-miR-145 * hsa-miR-146a hsa-miR-146a * hsa-miR-146b-3p hsa-miR-146b-5p hsa-miR-147 hsa-miR-147b hsa-miR-148a hsa-miR-148a * hsa-miR-148b hsa-miR-148b * hsa-miR-149 hsa-miR-149 * hsa-miR-150 hsa-miR-150 * hsa-miR-151-3p hsa-miR-151-5p hsa-miR-152 hsa-miR-153 hsa-miR-154 hsa-miR-154 * hsa-miR-155 hsa-miR-155 * hsa-miR-15a hsa-miR-15a * hsa-miR-15b hsa-miR-15b * hsa-miR-16 hsa-miR-16-1* hsa-miR-16-2 * hsa-miR-17 hsa-miR-17 * 、hsa-miR-181a、hsa-miR-181a * hsa-miR-181a-2 * hsa-miR-181b hsa-miR-181c hsa-miR-181c * hsa-miR-181d hsa-miR-182 hsa-miR-182 * hsa-miR-1825 hsa-miR-1826 hsa-miR-1827 hsa-miR-183 hsa-miR-183 * hsa-miR-184 hsa-miR-185 hsa-miR-185 * hsa-miR-186 hsa-miR-186 * hsa-miR-187 hsa-miR-187 * 、hsa-miR-188-3p、hsa-miR-188-5p、hsa-miR-18a、hsa -miR-18a * hsa-miR-18b hsa-miR-18b * hsa-miR-190 hsa-miR-190b hsa-miR-191 hsa-miR-191 * hsa-miR-192 hsa-miR-192 * 、hsa-miR-193a-3p、hsa-miR-193a-5p、hsa-miR-193b、hsa-miR-193b * hsa-miR-194 hsa-miR-194 * hsa-miR-195 hsa-miR-195 * 、hsa-miR-196a、hsa-miR-196a * hsa-miR-196b hsa-miR-197 hsa-miR-198 hsa-miR-199a-3p hsa-miR-199a-5p hsa-miR-199b-5p hsa-miR-19a hsa-miR-19a * hsa-miR-19b hsa-miR-19b-1 *hsa-miR-19b-2 * hsa-miR-200a hsa-miR-200a * hsa-miR-200b hsa-miR-200b * 、hsa-miR-200c、hsa-miR-200c * hsa-miR-202 hsa-miR-202 * hsa-miR-203 hsa-miR-204 hsa-miR-205 hsa-miR-206 hsa-miR-208a hsa-miR-208b hsa-miR-20a hsa-miR-20a * hsa-miR-20b hsa-miR-20b * hsa-miR-21 hsa-miR-21 * hsa-miR-210 hsa-miR-211 hsa-miR-212 hsa-miR-214 hsa-miR-214 * hsa-miR-215 hsa-miR-216a hsa-miR-216b hsa-miR-217 hsa-miR-218 hsa-miR-218-1 * hsa-miR-218-2 * hsa-miR-219-1-3p hsa-miR-219-2-3p hsa-miR-219-5p hsa-miR-22 hsa-miR-22 * hsa-miR-220a hsa-miR-220b hsa-miR-220c hsa-miR-221 hsa-miR-221 * hsa-miR-222 hsa-miR-222 * hsa-miR-223 hsa-miR-223 * 、hsa-miR-224、hsa-miR-23a、hsa-miR-23a * hsa-miR-23b hsa-miR-23b * hsa-miR-24 hsa-miR-24-1 * hsa-miR-24-2 * hsa-miR-25 hsa-miR-25 * hsa-miR-26a hsa-miR-26a-1* hsa-miR-26a-2 * hsa-miR-26b hsa-miR-26b * hsa-miR-27a hsa-miR-27a * hsa-miR-27b hsa-miR-27b * hsa-miR-28-3p hsa-miR-28-5p hsa-miR-296-3p hsa-miR-296-5p hsa-miR-297 hsa-miR-298 hsa-miR-299-3p hsa-miR-299-5p hsa-miR-29a hsa-miR-29a * hsa-miR-29b hsa-miR-296-1 * hsa-miR-296-2 * hsa-miR-29c hsa-miR-29c * 、hsa-miR-300、hsa-miR-301a、hsa-miR-301b、hsa-miR-302a、hsa-miR-302a * 、hsa-miR-302b、hsa-miR-302b * 、hsa-miR-302c、hsa-miR-302c * hsa-miR-302d hsa-miR-302d * hsa-miR-302e hsa-miR-302f hsa-miR-30a hsa-miR-30a * hsa-miR-30b hsa-miR-30b * hsa-miR-30c hsa-miR-30c-1 * hsa-miR-30c-2 * hsa-miR-30d hsa-miR-30d * hsa-miR-30e hsa-miR-30e * hsa-miR-31 hsa-miR-31 * hsa-miR-32 hsa-miR-32 *hsa-miR-320a hsa-miR-320b hsa-miR-320c hsa-miR-320d hsa-miR-323-3p hsa-miR-323-5p hsa-miR-324-3p hsa-miR-324-5p hsa-miR-325 hsa-miR-326 hsa-miR-328 hsa-miR-329 hsa-miR-330-3p hsa-miR-330-5p hsa-miR-331-3p hsa-miR-331-5p, hsa-miR-335, hsa-miR-335 * hsa-miR-337-3p hsa-miR-337-5p hsa-miR-338-3p hsa-miR-338-5p hsa-miR-339-3p hsa-miR-339-5p hsa-miR-33a hsa-miR-33a * hsa-miR-33b hsa-miR-33b * hsa-miR-340 hsa-miR-340 * hsa-miR-342-3p hsa-miR-342-5p hsa-miR-345 hsa-miR-346 hsa-miR-34a hsa-miR-34a * hsa-miR-34b hsa-miR-34b * hsa-miR-34c-3p hsa-miR-34c-5p hsa-miR-361-3p hsa-miR-361-5p hsa-miR-362-3p hsa-miR-362-5p hsa-miR-363 hsa-miR-363 * hsa-miR-365 hsa-miR-367 hsa-miR-367 * hsa-miR-369-3p hsa-miR-369-5p hsa-miR-370 hsa-miR-371-3p hsa-miR-371-5p hsa-miR-372 hsa-miR-373 hsa-miR-373 * 、hsa-miR-374a、hsa-miR-374a * 、hsa-miR-374b、hsa-miR-374b *hsa-miR-375 hsa-miR-376a hsa-miR-376a * hsa-miR-376b hsa-miR-376c hsa-miR-377 hsa-miR-377 * hsa-miR-378 hsa-miR-378 * hsa-miR-379 hsa-miR-379 * hsa-miR-380 hsa-miR-380 * hsa-miR-381 hsa-miR-382 hsa-miR-383 hsa-miR-384 hsa-miR-409-3p hsa-miR-409-5p hsa-miR-410 hsa-miR-411 hsa-miR-411 * hsa-miR-412 hsa-miR-421 hsa-miR-422a hsa-miR-423-3p hsa-miR-423-5p hsa-miR-424 hsa-miR-424 * hsa-miR-425 hsa-miR-425 * hsa-miR-429 hsa-miR-431 hsa-miR-431 * hsa-miR-432 hsa-miR-432 * hsa-miR-433 hsa-miR-448 hsa-miR-449a hsa-miR-449b hsa-miR-450a hsa-miR-450b-3p hsa-miR-450b-5p hsa-miR-451 hsa-miR-452 hsa-miR-452 * hsa-miR-453 hsa-miR-454 hsa-miR-454 * hsa-miR-455-3p hsa-miR-455-5p hsa-miR-483-3p hsa-miR-483-5p hsa-miR-484 hsa-miR-485-3p hsa-miR-485-5p hsa-miR-486-3p hsa-miR-486-5p hsa-miR-487a hsa-miR-487b hsa-miR-488 hsa-miR-488 *hsa-miR-489 hsa-miR-490-3p hsa-miR-490-5p hsa-miR-491-3p hsa-miR-491-5p hsa-miR-492 hsa-miR-493 hsa-miR-493 * hsa-miR-494 hsa-miR-495 hsa-miR-496 hsa-miR-497 hsa-miR-497 * hsa-miR-498 hsa-miR-499-3p hsa-miR-499-5p hsa-miR-500 hsa-miR-500 * hsa-miR-501-3p hsa-miR-501-5p hsa-miR-502-3p hsa-miR-502-5p hsa-miR-503 hsa-miR-504 hsa-miR-505 hsa-miR-505 * hsa-miR-506 hsa-miR-507 hsa-miR-508-3p hsa-miR-508-5p hsa-miR-509-3-5p hsa-miR-509-3p hsa-miR-509-5p hsa-miR-510 hsa-miR-511 hsa-miR-512-3p hsa-miR-512-5p hsa-miR-513a-3p hsa-miR-513a-5p hsa-miR-513b hsa-miR-513c hsa-mi R-514, hsa-miR-515-3p, hsa-miR-515-5p, hsa-miR-516a-3p, hsa-miR-516a-5p, hsa-miR-516b, hsa-miR-517 * 、hsa-miR-517a、hsa-miR-517b、hsa-miR-517c、hsa-miR-518a-3p、hsa-miR-518a-5p、hsa-miR-518b、hsa-miR-518c、hsa-miR-518c * 、hsa-miR-518d-3p、hsa-miR-518d-5p、hsa-miR-518e、hsa-miR-518e * 、hsa-miR-518f、hsa-miR-518f *hsa-miR-519a hsa-miR-519b-3p hsa-miR-519c-3p hsa-miR-519d hsa-miR-519e hsa-miR-519e * 、hsa-miR-520a-3p、hsa-miR-520a-5p、hsa-miR-520b、hsa-miR-520c-3p、hsa- miR-520d-3p、hsa-miR-520d-5p、hsa-miR-520e、hsa-miR-520f、hsa-miR-520g、 hsa-miR-520h, hsa-miR-521, hsa-miR-522, hsa-miR-523, hsa-miR-524-3p, hsa-miR-524-5p, hsa-miR-525-3p, hsa-miR-525-5p, hsa-miR-526b, hsa-miR-526b * hsa-miR-532-3p hsa-miR-532-5p hsa-miR-539 hsa-miR-541 hsa-miR-541 * hsa-miR-542-3p hsa-miR-542-5p hsa-miR-543 hsa-miR-544 hsa-miR-545 hsa-miR-545 * 、hsa-miR-548a-3p、hsa-miR-548a-5p、hsa-miR-548b-3p、hsa-miR-5486-5p、hsa-miR-548c-3p 、hsa-miR-548c-5p、hsa-miR-548d-3p、hsa-miR-548d-5p、hsa-miR-548e、hsa-miR-548f、hsa-m iR-548g, hsa-miR-548h, hsa-miR-548i, hsa-miR-548j, hsa-miR-548k, hsa-miR-5481, hsa-miR-548m, hsa-miR-548n, hsa-miR-548o, hsa-miR-548p, hsa-miR-549, hsa-miR-550, hsa-miR-550 * 、hsa-miR-551a、hsa-miR-551b、hsa-miR-551b *hsa-miR-552 hsa-miR-553 hsa-miR-554 hsa-miR-555 hsa-miR-556-3p hsa-miR-556-5p hsa-miR-557 hsa-miR-558 hsa-miR-559 hsa-miR-561 hs a-miR-562, hsa-miR-563, hsa-miR-564, hsa-miR-566, hsa-miR-567, hsa-miR-568, hsa-miR-569, hsa-miR-570, hsa-miR-571, hsa-miR-572, hsa-miR-573 hsa-miR-574-3p hsa-miR-574-5p hsa-miR-575 hsa-miR-576-3p hsa-miR-576-5p hsa-miR-577 hsa-miR-578 hsa-miR-579 hsa-miR-580 hsa-miR- 581, hsa-miR-582-3p, hsa-miR-582-5p, hsa-miR-583, hsa-miR-584, hsa-miR-585, hsa-miR-586, hsa-miR-587, hsa-miR-588, hsa-miR-589, hsa-miR-589 * hsa-miR-590-3p hsa-miR-590-5p hsa-miR-591 hsa-miR-592 hsa-miR-593 hsa-miR-593 * hsa-miR-595 hsa-miR-596 hsa-miR-597 hsa-miR-598 hsa-miR-599 hsa-miR-600 hsa-miR-601 hsa-miR-602 hsa-miR-603 hsa-miR-604 hsa-miR-605 hsa-miR-606 hs a-miR-607, hsa-miR-608, hsa-miR-609, hsa-miR-610, hsa-miR-611, hsa-miR-612, hsa-miR-613, hsa-miR-614, hsa-miR-615-3p, hsa-miR-615-5p, hsa-miR-616, hsa-miR-616 *hsa-miR-617 hsa-miR-618 hsa-miR-619 hsa-miR-620 hsa-miR-621 hsa-miR-622 hsa-miR-623 hsa-miR-624 hsa-miR-624 * hsa-miR-625 hsa-miR-625 * hsa-miR-626 hsa-miR-627 hsa-miR-628-3p hsa-miR-628-5p hsa-miR-629 hsa-miR-629 * hsa-miR-630 hsa-miR-631 hsa-miR-632 hsa-miR-633 hsa-miR-634 hsa-miR-635 hsa-miR-636 hsa-miR-637 hsa-miR-638 hsa-miR-639 hsa-miR-640 hsa-miR-641 hsa-miR-642 hsa-miR-643 hsa-miR-644 hsa-miR-645 hsa-miR-646 hsa-miR-647 hsa-miR-648 hs a-miR-649, hsa-miR-650, hsa-miR-651, hsa-miR-652, hsa-miR-653, hsa-miR-654-3p, hsa-miR-654-5p, hsa-miR-655, hsa-miR-656, hsa-miR-657, hsa-miR-658, hsa-miR-659, hsa-miR-660, hsa-miR-661, hsa-miR-662, hsa-miR-663, hsa-miR-663b, hsa-miR-664, hsa-miR-664 * hsa-miR-665 hsa-miR-668 hsa-miR-671-3p hsa-miR-671-5p hsa-miR-675 hsa-miR-7 hsa-miR-708 hsa-miR-708 * hsa-miR-7-1 * hsa-miR-7-2 * hsa-miR-720 hsa-miR-744 hsa-miR-744 *、hsa-miR-758, hsa-miR-760, hsa-miR-765, hsa-miR-766, hsa-miR-767-3p, hsa-miR-767-5p, hsa-miR-768-3p, hsa-miR-768-5p, hsa-miR-769-3p, hsa-miR-769-5p, hsa-miR-770-5p, hsa-miR-802, hsa-miR-873, hsa-miR-874, hsa-miR-875-3p, hsa-miR-875-5p, hsa-miR-876-3p, hsa-miR-876-5p, hsa-miR-877, hsa-miR-877 * 、hsa-miR-885-3p, hsa-miR-885-5p, hsa-miR-886-3p, hsa-miR-886-5p, hsa-miR-887, hsa-miR-888, hsa-miR-888 * 、hsa-miR-889, hsa-miR-890, hsa-miR-891a, hsa-miR-891b, hsa-miR-892a, hsa-miR-892b, hsa-miR-9, hsa-miR-9 * 、hsa-miR-920, hsa-miR-921, hsa-miR-922, hsa-miR-923, hsa-miR-924, hsa-miR-92a, hsa-miR-92a-1 * 、hsa-miR-92a-2 * 、hsa-miR-92b, hsa-miR-92b * 、hsa-miR-93, hsa-miR-93 * 、hsa-miR-933, hsa-miR-934, hsa-miR-935, hsa-miR-936, hsa-miR-937, hsa-miR-938, hsa-miR-939, hsa-miR-940, hsa-miR-941, hsa-miR-942, hsa-miR-943, hsa-miR-944, hsa-miR-95, hsa-miR-96, hsa-miR-96 * 、hsa-miR-98, hsa-miR-99a, hsa-miR-99a * 、hsa-miR-99b, and hsa-miR-99b *For example, miRNAs targeting chromosome 8 open reading frame 72 (C9orf72), which expresses superoxide dismutase (SOD1), which is associated with amyotrophic lateral sclerosis (ALS), are of interest.

[0092] miRNAs inhibit the function of targeted mRNAs, resulting in the inhibition of expression of the polypeptides encoded by the mRNAs. Therefore, blocking (partially or completely) the activity of miRNAs (e.g., silencing miRNAs) results in the inhibition of expression. This can effectively induce or restore expression of the polypeptide encoded by the miRNA (derepressing the polypeptide). In one embodiment, derepression of a polypeptide encoded by an mRNA target of the miRNA is achieved by inhibiting miRNA activity in a cell through any one of a variety of methods. For example, blocking the activity of the miRNA can be achieved by hybridization with a small interfering nucleic acid (e.g., an antisense oligonucleotide, miRNA sponge, TuD RNA) that is complementary or substantially complementary to the miRNA, thereby blocking the interaction of the miRNA with its target mRNA. As used herein, a small interfering nucleic acid that is substantially complementary to a miRNA is a nucleic acid that can hybridize to the miRNA and block the activity of the miRNA. In some embodiments, a small interfering nucleic acid that is substantially complementary to a miRNA is a small interfering nucleic acid that is complementary to the miRNA at all but 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 bases. "miRNA inhibitors" are agents that block the function, expression, and / or processing of miRNAs. For example, these molecules include, but are not limited to, microRNA-specific antisense molecules, microRNA sponges, tough decoy RNAs (TuD RNAs), and microRNA oligonucleotides (double-stranded, hairpin, short oligonucleotides) that inhibit miRNA interaction with the Drosha complex.

[0093] Still other useful transgenes may include those encoding immunoglobulins that confer passive immunity to pathogens. An "immunoglobulin molecule" is a protein comprising the immunologically active portions of an immunoglobulin heavy chain and an immunoglobulin light chain, covalently linked to each other and capable of specifically combining with an antigen. Immunoglobulin molecules may be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass. The terms "antibody" and "immunoglobulin" may be used interchangeably herein.

[0094] An "immunoglobulin heavy chain" is a polypeptide that comprises at least a portion of the antigen-binding domain of an immunoglobulin and at least a portion of the variable region of an immunoglobulin heavy chain or at least a portion of the constant region of an immunoglobulin heavy chain. Thus, an immunoglobulin-derived heavy chain has significant regions of amino acid sequence homology with members of the immunoglobulin gene superfamily. For example, the heavy chain in a Fab fragment is an immunoglobulin-derived heavy chain.

[0095] An "immunoglobulin light chain" is a polypeptide that comprises at least a portion of the antigen-binding domain of an immunoglobulin and at least a portion of the variable region or at least a portion of the constant region of an immunoglobulin light chain. Thus, immunoglobulin-derived light chains have significant regions of amino acid homology with members of the immunoglobulin gene superfamily.

[0096] "Immunoadhesins" are chimeric antibody-like molecules that combine the functional domain of a binding protein, usually a receptor, ligand, or cell adhesion molecule, with immunoglobulin constant domains, usually including the hinge and Fc regions.

[0097] A "fragment antigen-binding" (Fab) fragment is the region of an antibody that binds to an antigen. It consists of the constant and variable domains of each of the heavy and light chains.

[0098] Anti-pathogen constructs are selected based on the causative agent (pathogen) of the disease against which protection is sought. These pathogens may be of viral, bacterial, or fungal origin and may be used to prevent infection in humans for human diseases or in non-human mammals or other animals for veterinary diseases.

[0099] rAAV may contain genes encoding antibodies, particularly neutralizing antibodies against viral pathogens. Such anti-viral antibodies can include anti-influenza antibodies directed against one or more of influenza A, influenza B, and influenza C. Type A viruses are the most virulent human pathogens. Influenza A serotypes that have been associated with pandemics include H1N1, which caused the Spanish flu in 1918, H2N2, which caused the swine flu in 2009, H2N2, which caused the Asian flu in 1957, H3N2, which caused the Hong Kong flu in 1968, and H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, and H10N7, which caused the avian flu in 2004. Other target pathogenic viruses include arenaviruses (including Funin, Machupo, and Lassa), filoviruses (including Marburg and Ebola), hantaviruses, picornaviridae (including rhinoviruses and echoviruses), coronaviruses, paramyxoviruses, morbilliviruses, respiratory syncytial viruses, togaviruses, coxsackieviruses, JC virus, parvovirus B19, parainfluenza, adenoviruses, reoviruses, varicella virus (variola major (smallpox)), and members of the poxvirus family, vaccinia virus (cowpox) and varicella-zoster (pseudorabies). Viral hemorrhagic fevers are caused by members of the arenavirus family (Lassa fever) (a family also related to lymphocytic choriomeningitis (LCM)), filoviruses (Ebola virus), and hantaviruses (Premara). Members of the picornavirus family (rhinoviridae subfamily) are associated with the common cold in humans. The coronavirus family includes several non-human viruses, such as infectious bronchitis virus (poultry), transmissible porcine gastrointestinal virus (pigs), porcine hemagglutinin encephalomyelitis virus (pigs), feline infectious peritonitis virus (cats), feline enteric coronavirus (cats), and canine coronavirus (dogs). Human respiratory coronaviruses are presumed to be related to the common cold, non-A, B, or C hepatitis, and sudden acute respiratory syndrome (SARS).The paramyxovirus family includes parainfluenza virus type 1, parainfluenza virus type 3, bovine parainfluenza virus type 3, rubulavirus (mumps virus), parainfluenza virus type 2, parainfluenza virus type 4, Newcastle disease virus (chicken), rinderpest, morbilliviruses including measles and canine distemper, and pneumonia viruses including respiratory syncytial virus (RSV). The parvovirus family includes feline parvovirus (feline enteritis), feline panleucopeniavirus, canine parvovirus, and porcine parvovirus. The adenovirus family includes viruses that cause respiratory diseases (e.g., AD7, ARD, OB). Thus, in certain embodiments, the rAAV vectors described herein can be engineered to express anti-Ebola antibodies, e.g., 2G4, 4G7, 13C6, anti-influenza antibodies, e.g., FI6, CR8033, and anti-RSV antibodies, e.g., palivizumab, motavizumab. Neutralizing antibodies against bacterial pathogens Constructs may also be selected for use in the present invention. In one embodiment, the neutralizing antibody construct is directed against the bacterium itself. In another embodiment, the neutralizing antibody construct is directed against a toxin produced by the bacterium. Examples of airborne bacterial pathogens include, for example, Neisseria meningitidis (meningitis), Klebsiella pneumoniae (pneumonia), Pseudomonas aeruginosa (pneumonia), Burkholderia mallei (pneumonia), Acinetobacter (pneumonia), Staphylococcus catarrhalis, Moraxella lactucata, Alcaligenes, Cardiobacterium, Haemophilus influenzae (influenza), These include Haemophilus parainfluenzae, Bordetella pertussis (whooping cough), Francisella tularensis (pneumonia, fever), Legionnaires' disease (Legionnaires' disease), Chlamydia psittacosis (pneumonia), Chlamydia pneumoniae (pneumonia), Mycobacterium tuberculosis (tuberculosis (TB)), Mycobacterium kansasii (TB), Mycobacterium avium (pneumonia), Nocardia asteroides (pneumonia), Bacillus anthracis (anthrax), Staphylococcus aureus (pneumonia), Streptococcus pyogenes (scarlet fever), Streptococcus pneumoniae (pneumonia), Corynebacterium diphtheriae (diphtheria), and Mycoplasma pneumoniae (pneumonia).

[0100] rAAVs can contain genes encoding antibodies, particularly neutralizing antibodies against bacterial pathogens such as the causative agent of anthrax, the toxin produced by Bacillus anthracis. Neutralizing antibodies against the protective agent (PA), one of three peptides that form the toxoid, have been described. The other two The polypeptides consist of lethal factor (LF) and edema factor (EF). Anti-PA neutralizing antibodies have been described as effective for passive immunization against anthrax. See, e.g., U.S. Patent No. 7,442,373; R. Sawada-Hirai et al., J Immune Based Ther Vaccines. 2004;2:5. (online May 12, 2004). Still other anti-anthrax toxin neutralizing antibodies have been described and / or can be generated. Similarly, neutralizing antibodies against other bacteria and / or bacterial toxins can be used to generate AAV-delivered anti-pathogen constructs as described herein.

[0101] Antibodies against infections may be raised by parasites or fungi, including, for example, Aspergillus, Absidiacolymbifera, Rhizopus, Mucor pulveus, Cryptococcus neoformans, Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides immitis, Penicillium species, Micropolyspora faenii, Thermoactinomyces vulgaris, Alternaria alternata, Cladosporium species, Helminthosporium, and Stachybotrys species.

[0102] rAAV may contain genes encoding antibodies, particularly neutralizing antibodies, against pathogenic factors of diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), GBA-associated Parkinson's disease (GBA-PD), rheumatoid arthritis (RA), irritable bowel syndrome (IBS), chronic obstructive pulmonary disease (COPD), cancer, tumors, systemic sclerosis, asthma, and other diseases. Such antibodies include, but are not limited to, α-synuclein, anti-vascular endothelial growth factor (VEGF) (anti-VEGF), anti-VEGFA, anti-PD-1, anti-PDL1, anti-CTLA-4, anti-TNF-α, anti-IL-17, anti-IL-23, anti-IL-21, anti-IL-6, anti-IL-6 receptor, anti-IL-5, anti-IL-7, anti-Factor XII, anti-IL-2, anti-HIV, anti-IgE, anti-tumor necrosis factor receptor 1 (TNFR1), anti-Notch 2 / 3, anti-Notch 1, anti-OX40, anti-erb-b2 receptor tyrosine kinase 3 (ErbB3), anti-ErbB2, anti-beta cell maturation antibodies, and anti-IL-17. Antibodies against CD4+, CD5+, CD6+, CD8+, CD9+, CD10+, CD11+, CD12+, CD13+, CD14+, CD15+, CD16+, CD17+, CD18+, CD20+, CD30+, CD4+, CD5+, CD19+, CD21+, CD32+, CD33+, CD4+, CD4+, CD5+, CD6+, CD19+, CD22+, CD35+, CD4+, CD19+, CD25+, CD36+, CD4+, CD19+, CD37+, CD4+, CD5+, CD18+, CD38+, CD4+, CD5+, CD19+, CD39+, CD4+, CD5+, CD6+, CD19+, CD39+, CD4+, CD5+, CD6+, CD19+, CD38+, CD39+, CD4+, CD5+, CD39+, CD4+, CD5+, CD39+, CD4+, CD5+, CD39+, CD4+, CD5+, CD5+, CD6+, CD39+, CD4+, CD5+, CD6+, CD39+, CD4+, CD5+, CD6+, CD39+, CD4+, CD5+, CD5+, CD6+, CD6+, CD7+, CD7+, CD7+, CD8+, CD9+, CD9+, CD10+, CD11+, CD3+, CD3+, CD4+, CD5+, CD5+, CD6+, CD7+, CD8+, CD9+, CD12+, CD13+, CD14+, CD15+, CD15+, CD16+, CD17+, CD3+, CD3+, CD4+, CD5+, CD5+, CD6+, CD7+, CD8+, CD14+ Other suitable antibodies can include, for example, antibodies useful for treating Alzheimer's disease, such as anti-beta-amyloid (e.g., crenezumab, solanezumab, adacunamab), anti-beta-amyloid fibrils, anti-beta-amyloid plaques, anti-tau, bapineuzamab, among others. Other suitable antibodies for treating various indications include, for example, those described in PCT / US2016 / 058968, filed October 27, 2016, published as WO 2017 / 075119A1.

[0103] Reducing and / or modulating gene expression is particularly desirable for treating hyperproliferative conditions characterized by hyperproliferative cells, such as cancer and psoriasis. Target polypeptides include polypeptides produced exclusively or at higher levels in hyperproliferative cells compared to normal cells. Target antigens include polypeptides encoded by oncogenes such as myb, myc, and fyn, as well as translocation genes bcr / abl, ras, src, p53, neu, trk, and EGRF. In addition to oncogene products as target antigens, target polypeptides for anticancer therapeutic and protective regimens include variable regions of antibodies produced by B-cell lymphomas and variable regions of T-cell receptors in T-cell lymphomas, and in some embodiments are also used as target antigens for autoimmune diseases. Other tumor-associated polypeptides can be used as target polypeptides, such as polypeptides found at higher levels in tumor cells, including polypeptides recognized by monoclonal antibody 17-1A and folate-binding polypeptide. It is possible.

[0104] Other suitable therapeutic polypeptides and proteins include those that may be useful for treating individuals suffering from autoimmune diseases and disorders by conferring a broad protective immune response against targets associated with autoimmunity, including cellular receptors and cells that produce self-directed antibodies. T cell-mediated autoimmune diseases include rheumatoid arthritis (RA), multiple sclerosis (MS), Sjögren's syndrome, sarcoidosis, insulin-dependent diabetes mellitus (IDDM), autoimmune thyroiditis, reactive arthritis, ankylosing spondylitis, scleroderma, polymyositis, dermatomyositis, psoriasis, vasculitis, Wegener's granulomatosis, Crohn's disease, and ulcerative colitis. Each of these diseases is characterized by a T cell receptor (TCR) that binds to an endogenous antigen and initiates the inflammatory cascade associated with the autoimmune disease.

[0105] Alternatively, or in addition, the vector can include a transgene encoding a peptide, polypeptide, or protein that induces an immune response against the AAV sequences of the invention and a selected immunogen. For example, the immunogen can be selected from various viral families. Examples of viral families to which an immune response is desired include the picornavirus family, including the rhinovirus genus, which is responsible for approximately 50% of cold cases; the enterovirus genus, which includes human enteroviruses such as polioviruses, coxsackieviruses, echoviruses, and hepatitis A virus; and the aptovirus genus, which is primarily responsible for foot-and-mouth disease in non-human animals. Within the picornavirus family of viruses, target antigens include VP1, VP2, VP3, VP4, and VPG. Another viral family is the calcivirus family, which includes the Norwalk virus group, an important causative agent of epidemic gastroenteritis. Yet another desirable viral family for use in targeting antigens to induce immune responses in humans and non-human animals is the Togavirus family, which includes the Alphavirus genus, which includes Sindbis virus, Ross River virus, and Venezuelan, Eastern, and Western equine encephalitis viruses, as well as Rubivirus, which includes rubella virus. The Flaviviridae family includes dengue fever, yellow fever, Japanese encephalitis, St. Louis encephalitis, and tick-borne encephalitis viruses. Other target antigens can be generated from the hepatitis C virus or coronavirus family, which includes several non-human viruses, such as infectious bronchitis virus (poultry), porcine transmissible gastroenteritis virus (pigs), porcine hemagglutinating encephalomyelitis virus (pigs), feline infectious peritonitis virus (cats), feline enteric coronavirus (cats), canine coronavirus (dogs), and human respiratory coronaviruses, which can cause the common cold and / or non-A, B, or C hepatitis. Within the coronavirus family, target antigens include E1 (also called M or matrix protein), E2 (also called S or spike protein), E3 (also called HE or hemagglutinin-eluterose) glycoproteins (not present in all coronaviruses), or N (nucleocapsid).Still other antigens may target the rhabdovirus family, which includes the vesiculovirus genus (e.g., vesicular stomatitis virus) and common lyssavirus (e.g., rabies virus).Within the rhabdovirus family, suitable antigens can be derived from G protein or N protein.The filovirus family includes hemorrhagic fever viruses such as Marburg virus and Ebola virus, and can be suitable sources of antigens. The Paramyxovirus family includes parainfluenza virus type 1, parainfluenza virus type 3, bovine parainfluenza virus type 3, rubulavirus (mumps virus), parainfluenza virus type 2, parainfluenza virus type 4, morbilliviruses, including Newcastle disease virus (chicken), rinderpest virus, measles virus, and canine distemper, and pneumoviruses, including respiratory syncytial virus. Influenza viruses are classified within the Orthomyxovirus family and are a suitable source of antigens (e.g., HA protein, N1 protein). The Bunyavirus family includes the genus Bunyavirus (California encephalitis, La Crosse), the genus Phlebovirus (Rift Valley fever), and the genus Hantavirus (Pyrenia and Hemahagin fever). The arenavirus family provides a source of antigens for LCM and Lassa fever viruses. The reovirus family includes the reovirus, rotavirus (causing acute gastroenteritis in children), orbiviruses, and calciviruses (Colorado tick fever, levombo (in humans), equine encephalopathy, and blue tongue).

[0106] The retrovirus family includes the Oncovirinae subfamily, which encompasses human and veterinary diseases such as feline leukemia virus, HTLV-1 and HTLV-2, lentiviruses (including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), equine infectious anemia virus, and spumaviruses). Many suitable antigens have been described for HIV and SIV, and can be readily selected. Examples of suitable HIV and SIV antigens include, but are not limited to, gag, pol, Vif, Vpx, VPR, Env, Tat, and Rev proteins, as well as various fragments thereof. Furthermore, various modifications of these antigens have been described. Suitable antigens for this purpose are known to those skilled in the art. For example, sequences encoding gag, pol, Vif and Vpr, Env, Tat, and Rev, among other proteins, may be selected. See, for example, the modified gag protein described in U.S. Pat. No. 5,972,596. See also the HIV and SIV proteins described in D.H. Barouch et al., J. Virol., 75(5):2462-2467 (March 2001), and R.R. Amara, et al., Science, 292:69-74 (April 6, 2001). These proteins or subunits thereof can be delivered alone or in combination via separate vectors or from a single vector.

[0107] The papovavirus family includes the Polyomavirinae subfamily (BKU and JCU viruses) and the Papillomavirinae subfamily (associated with the malignant progression of cancer or papillomas). The adenovirus family includes viruses that cause respiratory disease and / or enteritis (e.g., EX, AD7, ARD, OB). The parvovirus family includes feline parvovirus (feline enteritis), feline panleucopeniavirus, canine parvovirus, and porcine parvovirus. The herpesvirus family includes the Alphaherpesvirinae subfamily, including the genera Simplexvirus (HSVI, HSVII) and Varicellovirus (pseudorabies, varicella-zoster), and the Betaherpesvirinae subfamily, including the genus Cytomegalovirus (HCMV, Muromegalovirus), as well as the Gammaherpesvirinae subfamily, including the genera Lymphocryptovirus, EBV (Burkitt's lymphoma), infectious rhinotracheitis, Marek's disease virus, and Rhadinovirus. The poxvirus family includes the orthopoxvirus genera (variola (smallpox) and vaccinia (cowpox)), the chordopoxvirinae subfamily, which includes parapoxvirus, avipoxvirus, capripoxvirus, leporipoxvirus, and suipoxvirus, and the entomopoxvirinae subfamily. The hepadnavirus family includes hepatitis B virus. One unclassified virus that may be a suitable source of antigen is hepatitis delta virus. Still other viral sources include avian infectious bursal disease virus and porcine reproductive and respiratory syndrome virus. The alphavirus family includes equine arteritis virus and various encephalitis viruses.

[0108] rAAVs can also deliver sequences encoding immunogens useful for immunizing humans or non-human animals against other pathogens, including bacteria, fungi, parasitic microorganisms, or multicellular parasites that infect humans and non-human vertebrates, or from cancer or tumor cells. Examples of bacterial pathogens include pathogenic Gram-positive cocci, Streptococcus pneumoniae, Staphylococcus aureus, and Streptococcus. Pathogenic Gram-negative cocci include Neisseria meningitidis and Neisseria gonorrhoeae. Pathogenic enteric Gram-negative bacilli include Enterobacteriaceae, Pseudomonas, Acinetobacteria, and Eikenella, Mellioroides, and the like. sis, Salmonella, Shigella, Haemophilus, Moraxella, H. ducreyi (causing chalcoidosis), Brucella, Franisella tularensis (causing tularemia), Yersinia (Pasteurella), Streptobacillus moniliformis, and Spirillum. Gram-positive bacilli include Listeria monocytogenes, Erysipelothrix rhusiopathia, Corynebacterium diphtheriae (diphtheria), cholera, B. anthracis (anthrax), donovanosis (granuloma), and bartonellosis. Diseases caused by pathogenic anaerobic bacteria include tetanus, botulism, other clostridia, tuberculosis, leprosy, and other mycobacteria. Pathogenic spirochetal diseases include syphilis, treponematoses (strawberry disease, pinta, and endemic syphilis), and leptospirosis. Other infectious diseases caused by highly pathogenic bacteria and pathogenic fungi include actinomycosis, nocardiosis, cryptococcosis, blastomycosis, histoplasmosis, and coctidioidomycosis, candidiasis, aspergillosis, and mucormycosis, sporotrichosis, paracoccidioidomycosis, petriediosis, torulopsis, mycetoma, and chromomycosis, and dermatophytosis. Rickettsia infections include typhoid fever, Rocky Mountain spotted fever, Q fever, and rickettsialpox. Examples of chlamydia mycoplasma and chlamydial infections include mycoplasmal pneumonia, lymphogranuloma venereum, psittacosis, and perinatal chlamydial infections. Pathogenic eukaryotes include pathogenic protozoa and helminths and the infections caused thereby, including amebiasis, malaria, leishmaniasis, trypanosomiasis, toxoplasmosis, Pneumocystis carinii, trichinosis, Toxoplasma gondii, babesiosis, babesiosis, giardiasis, trichinosis, filariasis, schistosomiasis, nematode, fluke or flukey, and cestode (tapeworm) infections.

[0109] Many of these organisms and / or the toxins produced by them have been identified by the Centers for Disease Control [(CDC), Department of Health and Human Services, USA] as pathogens that could be used in biological attacks. For example, some of these biological agent pathogens include: Bacillus anthracis (anthrax), Clostridium botulinum and its toxins (botulism), Yersinia pestis (plague), Variola major (smallpox), Francisella tularensis (tularemia), and viral hemorrhagic fevers, all of which are currently classified as Category A pathogens; Coxiella burnetti (Q fever), Brucella species (brucellosis), Burkholderia mallei (glanders), Ricinus communis and its toxins (ricin toxin), Clostridium perfringens and its toxins (epsilon toxin), Staphylococcus species and its toxins (enterotoxin B), all of which are currently classified as Category B pathogens; and Nipan virus and Hantavirus, which are classified as Category C pathogens. Additionally, other organisms classified in this manner or of different classifications may be identified and / or used for such purposes in the future. It will be readily understood that the viral vectors and other constructs described herein are useful for delivering antigens derived from these organisms, viruses, their toxins, or other by-products to prevent and / or treat infections or other adverse reactions caused by these biological pathogens.

[0110] Administration of the vectors of the present invention to deliver immunogens to the variable regions of T cells elicits an immune response, including CTLs, to eliminate those T cells. In rheumatoid arthritis (RA), several specific variable regions of T cell receptors (TCRs) have been characterized that are involved in the disease. These TCRs include V-3, V-14, V-17, and Vα-17. Thus, delivery of a nucleic acid sequence encoding at least one of these polypeptides will elicit an immune response that targets T cells involved in RA. In multiple sclerosis (MS), several specific variable regions of TCRs have been characterized that are involved in the disease. These TCRs include V-7 and Vα-10. Thus, delivery of a nucleic acid sequence encoding at least one of these polypeptides will elicit an immune response that targets T cells involved in RA. Delivery of a nucleic acid sequence encoding at least one of these polypeptides will elicit an immune response targeting T cells involved in MS. In scleroderma, several specific variable regions of TCRs have been characterized that are involved in the disease. These TCRs include V-6, V-8, V-14, and Vα-16, Vα-3C, Vα-7, Vα-14, Vα-15, Vα-16, Vα-28, and Vα-12. Therefore, delivery of a nucleic acid molecule encoding at least one of these polypeptides will elicit an immune response targeting T cells involved in scleroderma.

[0111] In one embodiment, the transgene is selected to provide optogenetic therapy. In optogenetic therapy, artificial photoreceptors are constructed by gene delivery of light-activated channels or pumps to surviving cell types in the remaining retinal circuit. This is particularly useful for patients who have lost a significant amount of photoreceptor function but whose ganglion cells and bipolar cell circuits to the optic nerve remain intact. In one embodiment, the heterologous nucleic acid sequence (transgene) is an opsin. The opsin sequence can be derived from any suitable unicellular or multicellular organism, including humans, algae, and bacteria. In one embodiment, the opsin is rhodopsin, photopsin, L / M wavelength (red / green)-opsin, or short wavelength (S) opsin (blue). In another embodiment, the opsin is a channelrhodopsin or halorhodopsin.

[0112] In another embodiment, the transgene is selected for use in gene augmentation therapy, i.e., to provide a replacement copy of a missing or defective gene. In this embodiment, the transgene can be readily selected by one of skill in the art to provide the necessary replacement gene. In one embodiment, the missing / defective gene is associated with an eye disorder. In another embodiment, the transgene is NYX, GRM6, TRPM1L, or GPR179, and the eye disorder is congenital stationary night blindness. See, e.g., Zeitz et al., Am J Hum Genet. 2013 Jan 10;92(1):67-75. Epub 2012 Dec 13, which is incorporated herein by reference. In another embodiment, the transgene is RPGR. In another embodiment, the gene is Rab escort protein 1 (REP-1), encoded by CHM, associated with choroideremia.

[0113] In another embodiment, the transgene is selected for use in gene silencing therapy, i.e., the expression of one or more native genes is disrupted or suppressed at the transcriptional or translational level. This can be achieved using short hairpin RNA (shRNA) or other techniques known in the art. See, for example, Sun et al., Int J Cancer. 2010 Feb 1; 126(3): 764-74, and O'Reilly M, et al. Am J Hum Genet. 2007 Jul; 81(1): 127-35 (incorporated herein by reference). In this embodiment, the transgene can be easily selected by one skilled in the art based on the gene(s) desired to be silenced.

[0114] In another embodiment, the transgene comprises two or more transgenes. This can be achieved using a single vector carrying two or more heterologous sequences, or using two or more rAAVs, each carrying one or more heterologous sequences. In one embodiment, rAAVs are used in gene suppression (or knockdown) combination therapy and gene enhancement combination therapy. In knockdown / enhancement combination therapy, a defective copy of the gene of interest is silenced and a non-mutated copy is provided. In one embodiment, this is achieved using two or more co-administered vectors. See Millington-Ward et al., Molecular Therapy, April 2011, 19(4):642-649 (incorporated herein by reference). The transgene can be easily selected by one skilled in the art based on the desired outcome.

[0115] In another embodiment, the transgene is selected for use in gene correction therapy. This can be achieved, for example, by using zinc finger nuclease (ZFN)-induced DNA double-strand breaks in conjunction with an exogenous DNA donor substrate. See, for example, Ellis et al., Gene Therapy (epub January 2012) 20:35-42 (incorporated herein by reference). In one embodiment, the transgene encodes a nuclease selected from meganucleases, zinc finger nucleases, transcription activator-like (TAL) effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR) / endonucleases (such as Cas9 and Cpf1). Examples of suitable meganucleases are described, for example, in U.S. Patent Nos. 8,445,251, 9,340,777, 9,434,931, 9,683,257, and WO 2018 / 195449. Other suitable enzymes include nuclease-inactive S. pyogenes CRISPR / Cas9 (Nelles et al., Programmable Arrays of Nucleic Acids), which can bind to RNA in a nucleic acid programmable manner. RNA Tracking in Live Cells with CRISPR / Cas9, Cell, 165(2):P488-96 (April 2016)), and base editors (e.g., Levy et al. Cytosine and adenine base editing of the brain, liver, retina, heart, and skeletal muscle of mice via adeno-associated viruses, Nature Biomedical Engineering, 4, 97-110 (Jan 2020)). In certain embodiments, the nuclease is not a zinc finger nuclease. In certain embodiments, the nuclease is not a CRISPR-associated nuclease. In certain embodiments, the nuclease is not a TALEN. In one embodiment, the nuclease is not a meganuclease. In certain embodiments, the nuclease is a member of the LAGLIDADG (SEQ ID NO: 45) family of homing endonucleases. In certain embodiments, the nuclease is a member of the I-CreI family of homing endonucleases, which recognizes and cleaves the 22-base pair recognition sequence SEQ ID NO: 46-CAAAACGTCGTGAGACAGTTTG. See, e.g., International Publication No. WO 2009 / 059195. A method for the rational design of mono-LAGLIDADG homing endonucleases has been described (WO2007 / 047859) that comprehensively redesigns ICreI and other homing endonucleases to target widely dispersed DNA sites, including sites in mammalian, yeast, plant, bacterial, and viral genomes.

[0116] In certain embodiments, provided herein is an rAAV-based gene editing nuclease system, in which the gene editing nuclease targets a site in a disease-associated gene, i.e., a gene of interest.

[0117] In certain embodiments, the AAV-based gene editing nuclease system comprises an rAAV comprising an AAV capsid and a vector genome enclosed therein, wherein the vector genome comprises an AAV 5' inverted terminal repeat (ITR), and the expression cassette comprises a nucleic acid sequence encoding a gene editing nuclease that recognizes and cleaves a recognition site in a gene of interest, the gene editing nuclease coding sequence being operably linked to an expression control sequence that directs its expression in a cell containing the gene of interest, and comprising an AAV 3' ITR. In certain embodiments, the rAAV-based gene editing nuclease system is an rAAVhu71 / 74-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is an rAAVhu79-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is an rAAVhu80-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is , rAAVhu83-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is an rAAVhu74 / 71-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is an rAAVhu77-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is an rAAVhu78 / 88-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is an rAAVhu70-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is an rAAVhu72-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is an rAAVhu75-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVhu76-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVhu81-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVhu82-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVhu84-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVhu86-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVhu87-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVhu88 / 78-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVhu69-based gene editing nuclease system.In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVrh75-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVrh76-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVrh77-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVrh78-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVrh79-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVrh81-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVrh89-based gene editing nuclease system. In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVrh82-based gene editing nuclease system.In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVrh83-based gene editing nuclease system.In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVrh84-based gene editing nuclease system.In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVrh85-based gene editing nuclease system.In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVrh87-based gene editing nuclease system.In certain embodiments, the rAAV-based gene editing nuclease system is a rAAVhu73-based gene editing nuclease system.

[0118] Also provided herein are therapeutic methods using the rAAV-based gene editing nuclease system.

[0119] In some embodiments, the rAAV-based gene editing meganuclease system is used to treat a disease, disorder, syndrome, and / or condition. In some embodiments, the gene editing nuclease targets a gene of interest, where the gene of interest has one or more genetic mutations, deletions, insertions, and / or defects associated with and / or involved in the disease, disorder, syndrome, and / or condition. In some embodiments, the disorder is selected from, but not limited to, a cardiovascular disorder, a liver disorder, an endocrine or metabolic disorder, a musculoskeletal disorder, a neurological disorder, and / or a renal disorder.

[0120] In certain embodiments, the indicated cardiovascular diseases, disorders, syndromes, and / or conditions include, but are not limited to, cardiovascular disease (associated with lysophosphatidic acid, lipoprotein(a), or angiopoietin-like 3 (ANGPTL3), or apolipoprotein C-III (APOC3) encoding genes), blocked clotting, thrombus formation, end-stage renal disease, coagulation disorders (associated with factor XI (F11) encoding genes), hypertension (angiotensinogen (AGT) encoding genes), and heart failure (angiotensinogen (AGT) encoding genes).

[0121] In certain embodiments, the liver diseases, disorders, syndromes and / or conditions represented include, but are not limited to, idiopathic pulmonary fibrosis (associated with the SERPINH1 / Hsp47 gene), liver disease (associated with the gene encoding hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13)), non-alcoholic steatohepatitis (NASH) (associated with the genes encoding diacylglycerol O-acyltransferase-2 (DGAT2), hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13), or patatin-like phospholipase domain-containing 3 (PNPLA3)), and alcohol use disorder (associated with the gene encoding aldehydehydrogenase 2 (ALDH2)).

[0122] In certain embodiments, the musculoskeletal diseases, disorders, syndromes and / or conditions represented include, but are not limited to, muscular dystrophy (associated with the gene encoding dystrophin, or integrin alpha(4) (VLA-4) (CD49D)), Duchen muscular dystrophy (DMD) (associated with the gene encoding dystrophin (DMD)), centronuclear myopathy (associated with the gene encoding dynamin 2 (DNM2)), and myotonic dystrophy (DM1) (associated with the gene encoding myotonic dystrophy protein kinase (DMPK)).

[0123] In certain embodiments, the endocrine or metabolic diseases, disorders, syndromes and / or conditions represented include, but are not limited to, hypertriglyceridemia (associated with the apolipoprotein C-III (APOC3) or angiogenesis ethyl-like 3 (ANGPTL3) encoding genes), lipodystrophy, hyperlipidemia (associated with the apolipoprotein C-III (APOC3) encoding genes), hypercholesterolemia (associated with apolipoprotein B-100 (APOB-100), proprotein convertase subtilisin kexin type 9 (PCSK9)), amyloidosis (associated with the transthyretin (TTR) encoding gene), polyuria (associated with the aminourebinate synthase-1 (ALAS-1) encoding gene) , neuropathy (associated with the transthyretin (TTR) encoding gene), primary hyperoxaluria type 1 (associated with the glycolate oxidase encoding gene), diabetes (associated with the glucagon receptor (GCGR) encoding gene), acromegaly (associated with the growth hormone receptor (GHR) encoding gene), alpha-1 antitrypsin deficiency (AATD) (associated with the alpha-1 antitrypsin (AAT) encoding gene), propionic acidemia (associated with the propionyl-CoA carboxylase (PCCA / PCCB) encoding gene), glycogen storage disease III (GDSIII) (associated with the glycogen debranching enzyme (GSDIII) encoding gene), cardiometabolic diseases (associated with the aspartate glycoprotein (ASGPR), hydroxyacid oxidase 1 (HAO1), or alpha-1 antitrypsin (SERPINA1) encoding gene), methylmalmonoic acid (MMA) (related to methylmalonyl-CoA mutase (MMUT), cobalamin adenosyltransferase (MMAA or MMAB)), methylmalonyl-CoA epimerase (MCEE), LMBR1 domain containing 1 (LMBRD1), or ATP-binding cassette subfamily D member 4 (ABCD4) encoding gene), glycogen storage disease type 1a (related to glucose-6-phosphatase catalytic subunit-related protein (G6PC) encoding gene), and phenylketonuria (PKU) (related to phenylalanine hydroxylase (PAH) encoding gene).

[0124] In certain embodiments, the neurological diseases, disorders, syndromes and / or conditions represented include, but are not limited to, spinal muscular atrophy (SMA) (associated with the survival motor neuron protein (SMN2) gene), amyotrophic lateral sclerosis (ALS) (associated with superoxide dismutase 1 (SOD1), FUS RNA-binding protein (FUS), microRNA-155, chromosome 9 open reading frame 72 (C9orf72), or ataxin-2 (ATXN2) gene), Huntington's disease (associated with the huntingtin (HTT) gene), hATTR polyneuropathy (associated with the transthyretin (TTR) gene), Alzheimer's disease (associated with the MAP-tau (MAPT) gene), multiple system atrophy (associated with α-synuclein (SNCA)), Parkinson's disease (associated with the α-synuclein (SNCA) and leucine-rich repeat kinase 2 (LRRK2) genes), centronuclear myopathy (associated with the dynamin 2 (DNM2) gene), Angelman syndrome (ubiquitin protein ligase These include E3A (UBE3A) gene), epilepsy (associated with the glycogen synthase 1 (GYS1) gene), Dravet syndrome (associated with the sodium voltage-gated channel alpha subunit 1 (SNC1A) gene), leukodystrophy (associated with the glial fibrillary acidic protein (GFAP) gene), prion disease (associated with the prion protein (PRNP) gene), and hereditary cerebral hemorrhage with amyloidosis - Dutch type (HCHWA-D) (associated with the amyloid beta precursor protein (APP) gene).

[0125] In certain embodiments, the renal diseases, disorders, syndromes, and / or conditions indicated include, but are not limited to, glomerulonephritis (IgA nephropathy) (associated with the gene encoding complement factor B), Alport syndrome (associated with a protein in the PPARα signaling pathway), and neuropathy (associated with the gene encoding apolipoprotein L1 (APOL1)), or APOL1-associated chronic kidney disease.

[0126] In certain embodiments, the gene editing nuclease targets a gene of interest, including, but not limited to, a gene encoding lysophosphatidic acid, a lipoprotein(a) encoding gene, ANGPTL3, APOC3, F11, AGT, SERPINH1 / Hsp47, HSD17B13, DGAT2, PNPLA3, ALDH2, DMD, VLA-4, DNM2DM1, DMPK, APOC3, ANGPTL3, APOB-100, PCSK9, TTR, ALAS-1, glycolate oxidase These include the GCGR, GHR, AATD, AAT, PCCA, PCCB, GDSIII, ASGPR, HAO1, SERPINA1, MMA, MMUT, MMAA, MMAB, MCEE, LMBRD1, ABCD4, G6PC, PAH, SMN2, SOD1, FUS, C9orf72, ATXN2, HTT, MAPT, SNCA, LRRK2, UBE3A, GYS1, SNC1A, GFAP, PRNP, APP, complement factor B-encoding gene, APOL1, AAS1, and SLC25A13 genes.

[0127] Suitable gene editing targets include, but are not limited to, liver-expressed genes, such as proprotein convertase subtilisin / kexin type 9 (PCSK9) (cholesterol-related disorders), transthyretin (TTR) (transthyretin amyloidosis), H AO, apolipoprotein C-III (APOC3), factor VIII, factor IX, low-density lipoprotein receptor (LDLr), lipoprotein lipase (LPL) (lipoprotein lipase deficiency), lecithin-cholesterol acyltransferase (LCAT), ornithine transcarbamylase (OTC), carnosinase (CN1), sphingomyelin phosphodiesterase (SMPD1) (Niemann-Pick disease), hypochlorite These include anthracycline phosphate dehydrogenase (HGPRT), branched-chain alpha-keto acid dehydrogenase (BCKDC) complex (maplesin disease), erythropoietin (EPO), carbamyl phosphate synthetase (CPS1), N-acetylglutamate synthetase (NAGS), argininosuccinate synthetase (citrullinemia), argininosuccinate lyase (ASL) (argininosuccinic aciduria), and arginase (AG).

[0128] Other gene editing targets include, for example, hydroxymethylbilane synthase (HMBS), carbamoyl synthetase I, ornithine transcarbamylase (OTC), argininosuccinate synthetase, alpha 1 antitrypsin (A1AT), aporginosuccinate lyase (ASL) for the treatment of argininosuccinate lyase deficiency, arginase, fumarate hydrolase, phenylalanine hydroxylase, alpha-1 antitrypsin, rhesus alpha-fetoprotein (AFP), rhesus chorionic gonadotropin (CG), glucose-6-phosphatase, and porphobilinogen. Examples of useful gene products include enzymes that may be useful in enzyme replacement therapy, which is useful in various conditions resulting from insufficient enzyme activity. For example, enzymes containing mannose-6-phosphate may be used in therapy for lysosomal storage diseases (e.g., suitable genes include those encoding β-glucuronidase (GUSB)).In another example, the gene product may be ubiquitin protein ligase, glucose-6-phosphatase (associated with glycogen storage disease or glycogen storage disease type 1A deficiency (GSD1)), phosphoenolpyruvate carboxykinase (PEPCK, associated with PEPCK deficiency), cyclin-dependent kinase-like 5 (CDKL5, also known as serine / threonine kinase 9 (STK9), associated with seizures and severe neurodevelopmental disorders), galactose-1-phosphate uridyltransferase (associated with galactosemia), phenylalanine hydroxylase (PAH) (associated with phenylketonuria (PKU)), gene products associated with primary hyperoxaluria type 1, including hydroxyacid oxidase 1 (GO / HAO1) ​​and AGXT, branched-chain alpha-ketoacid dehydrogenases, including BCKDH, BCKDH-E2, BAKDH-E1a, and BAKDH-E1b (associated with maple syrup urine disease), fumarylacetoacetate hydrolase (associated with tyrosinemia type 1). ), methylmalonyl-CoA mutase (associated with methylmalonic acidemia), medium-chain acyl-CoA dehydrogenase (associated with medium-chain acyl-CoA dehydrogenase deficiency), ornithine transcarbamylase (OTC, associated with ornithine transcarbamylase deficiency), argininosuccinate synthetase (ASS1, associated with citrullinemia), lecithin-cholesterol acyltransferase (LCAT, deficiency), methylmalonic acidemia (MMA), NPC1 (associated with Niemann-Pick disease, type C1), propionic acidemia (PA), TTR (associated with transthyretin (TTR)-related hereditary amyloidosis), low-density lipoprotein receptor (LDLR) protein (associated with familial hypercholesterolemia (FH)), LDLR variants (e.g., as described in WO2015 / 164778), PCSK9, ApoE and ApoC proteins (associated with dementia), UDP-glucuronosyltransferase. galactosidase (associated with Crigler-Najjar disease), adenosine deaminase (associated with severe combined immunodeficiency), hypoxanthine guanine phosphoribosyltransferase (associated with gout and Lesch-Nyhan syndrome), biotimidase (associated with biotimidase deficiency), alpha-galactosidase A (α-GalA, associated with Fabry disease), beta-galactosidase (GLB1) (associated with GM1 gangliosidosis), ATP7B (associated with Wilson disease), beta-glucocerebrosidase (associated with Gaucher disease types 2 and 3), peroxidase B (associated with Wilson disease), and β-glucocerebrosidase (associated with Gaucher disease types 2 and 3). Xysome membrane protein 70 kDa (associated with Zellweger syndrome), arylsulfatase A (ARSA, associated with metachromatic leukodystrophy), galactocerebrosidase (GALC, an enzyme associated with Krabbe disease), alpha-glucosidase (GAA, associated with Pompe disease), sphingomyelinase (SMPD1, a gene associated with Niemann-Pick disease type A), argininosuccinate synthase (associated with adult-onset type II citrullinemia (CTLN2)), carbamoyl phosphate synthase 1 (CPS1, associated with urea cycle disorders), and biosynthesis. SMN protein (associated with spinal muscular atrophy), ceramidase (associated with Farber lipogranulomatosis), β-hexosaminidase (associated with GM2 gangliosidosis, Tay-Sachs disease, and Sandhoff disease), aspartylglucosaminidase (associated with aspartylglucosaminuria), α-fucosidase (associated with fucosidosis), α-mannosidase (associated with α-mannosidosis), porphobilinogen deaminase (associated with acute intermittent porphyria (AIP)), α-antitrypsin (associated with α-antimycosis), trypsin deficiency (for the treatment of emphysema), erythropoietin (for the treatment of anemia due to thalassemia or renal failure), vascular endothelial growth factor, angiopoietin-1, and fibroblast growth factor (for the treatment of ischemic disease), thrombomodulin and tissue factor pathway inhibitor (for the treatment of blocked blood vessels, e.g., seen in atherosclerosis, thrombosis, or embolism), aromatic amino acid decarboxylase (AADC) and tyrosine hydroxylase (TH) (for the treatment of Parkinson's disease), beta-adrenergic receptors, antisense to phospholamban or its variants,operably linked to a gene selected from sarco(endo)plasmic reticulum adenosine triphosphatase-2 (SERCA2) and cardiac adenylate cyclase (for the treatment of congestive heart failure), tumor suppressor genes (such as p53, for the treatment of various cancers), cytokines (such as various interleukins for the treatment of inflammatory and immune disorders and cancer), dystrophin or mini-dystrophin and utrophin or mini-utrophin (for the treatment of muscular dystrophy), and insulin or GLP-1 (for the treatment of diabetes).

[0129] In one embodiment, the capsids described herein are useful in the CRISPR-Cas dual vector system described in U.S. Published Patent Application No. 2018 / 0110877, filed April 26, 2018, each of which is incorporated herein by reference. The capsids are also useful for delivery of homing endonucleases or other meganucleases.

[0130] In another embodiment, a transgene useful herein comprises a reporter sequence that generates a detectable signal upon expression. Such reporter sequences include, but are not limited to, DNA sequences encoding β-lactamase, β-galactosidase (LacZ), alkaline phosphatase, thymidine kinase, green fluorescent protein (GFP), red fluorescent protein (RFP), chloramphenicol acetyltransferase (CAT), luciferase, membrane-bound proteins (e.g., influenza hemagglutinin protein, including CD2, CD4, CD8, and others known in the art (for which high-affinity antibodies exist or can be produced by conventional means)), and fusion proteins (including membrane-bound proteins appropriately fused to antigen tag domains from hemagglutinin or Myc, among others).

[0131] In certain embodiments, in addition to the transgene coding sequence, another non-AAV coding sequence, For example, they may include peptides, polypeptides, proteins, functional RNA molecules (e.g., miRNAs, miRNA inhibitors), or other gene products of interest. Useful gene products may include miRNAs. miRNAs and other small interfering nucleic acids regulate gene expression through cleavage / degradation of target RNA transcripts or translational repression of target messenger RNAs (mRNAs). miRNAs are typically naturally expressed as final 19-25 untranslated RNA products. miRNAs exert their activity through sequence-specific interactions with the 3' untranslated region (UTR) of target mRNAs. These endogenously expressed miRNAs form hairpin precursors, which are then processed into miRNA duplexes and further into "mature" single-stranded miRNA molecules. This mature miRNA guides the multiprotein complex miRISC, which identifies target sites (e.g., in the 3' UTR region) of target mRNAs based on complementarity to the mature miRNA.

[0132] These above-mentioned coding sequences, when associated with regulatory elements that drive their expression, provide signals that are detectable by conventional means, including enzymatic, radioactive, colorimetric, fluorescent, or other spectroscopic assays, fluorescence-activated cell sorting assays, and immunological assays (including enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and immunohistochemistry). For example, if the marker sequence is the LacZ gene, the presence of a vector bearing a signal is detected by assaying for β-galactosidase activity. If the transgene is green fluorescent protein or luciferase, the presence of a vector bearing a signal can be measured visually by color or light production in a luminometer.

[0133] The transgene preferably encodes a product useful in biology and medicine, such as a protein, peptide, RNA, enzyme, or catalytic RNA. Desirable RNA molecules include shRNA, tRNA, dsRNA, ribosomal RNA, catalytic RNA, and antisense RNA. An example of a useful RNA sequence is one that silences the expression of a target nucleic acid sequence in a target cell.

[0134] Regulatory sequences include conventional control elements operably linked to a transgene in a manner that allows for its transcription, translation, and / or expression in cells transfected with the vector or infected with the virus produced as described herein. As used herein, "operably linked" sequences include both expression control sequences that are contiguous with a gene of interest and expression control sequences that act in trans or at a distance to regulate the gene of interest.

[0135] Expression control sequences may include appropriate transcription initiation, termination, promoter, and enhancer sequences, efficient RNA processing signals such as splicing and polyadenylation (polyA) signals, sequences that stabilize cytoplasmic mRNA, sequences that increase translation efficiency (i.e., Kozak consensus sequences), sequences that enhance protein stability, and, if necessary, sequences that enhance secretion of the encoded product. Numerous expression control sequences, including promoters, are known in the art and are available.

[0136] Regulatory sequences useful in the constructs provided herein may also desirably include an intron located between the promoter / enhancer sequence and the gene. One desirable intron sequence is the 100-bp mini-intron splice donor / splice acceptor sequence derived from SV-40, designated SD-SA. Another suitable sequence includes the woodchuck hepatitis virus posttranscriptional element. (See, e.g., L. Wang and I. Verma, 1999 Proc. Natl. Acad. Sci., USA, 96:3906-3910.) PolyA signals may be derived from many suitable species, including, but not limited to, SV-40, human, and bovine.

[0137] Another regulatory component of rAAV useful in the methods described herein is an internal ribosome entry site (IRES). An IRES sequence, or other suitable system, can be used to generate two or more polypeptides from a single gene transcript. An IRES (or other suitable sequence) is used to produce a protein containing two or more polypeptide chains or to express two different proteins from or within the same cell. An exemplary IRES is the poliovirus internal ribosome entry sequence, which supports transgene expression in photoreceptors, RPE, and ganglion cells. Preferably, the IRES is located 3' of the transgene in the rAAV vector.

[0138] In certain embodiments, the vector genome includes a promoter (or a functional fragment of a promoter). The promoter for use in the rAAV can be selected from among a number of constitutive or inducible promoters capable of directing expression of a selected transgene in the desired target cell. In one embodiment, the target cell is a visual cell. The promoter can be derived from any species, including humans. Desirably, in one embodiment, the promoter is "cell-specific." The term "cell-specific" means that the particular promoter selected for the recombinant vector is capable of directing expression of the selected transgene in a particular cell tissue. In one embodiment, the promoter is specific for expression of the transgene in muscle cells. In another embodiment, the promoter is specific for expression in the lung. In another embodiment, the promoter is specific for expression of the transgene in liver cells. In another embodiment, the promoter is specific for expression of the transgene in airway epithelia. In another embodiment, the promoter is specific for expression of the transgene in neurons. In another embodiment, the promoter is specific for expression of the transgene in the heart.

[0139] The vector genome typically includes, as part of the expression control sequence, a promoter sequence located, for example, between the selected 5'ITR sequence and the coding sequence of the immunoglobulin construct. In one embodiment, expression in the liver is desired. Thus, in one embodiment, a liver-specific promoter is used. Examples of tissue-specific promoters include, for example, thyroid hormone-binding globulin (TBG), albumin (Miyatake et al., (1997) J. Virol., 71:5124-32), and hepatitis B virus core promoter (Sandig et al., (1996) Gene Ther., 3:1002). 9, or human alpha 1-antitrypsin, phosphoenolpyruvate carboxykinase (PECK), or alpha fetoprotein (AFP; Arbuthnot et al., (1996) Hum. Gene Ther., 7:1503 14). Tissue-specific promoters, constitutive promoters, regulatable promoters (see, e.g., WO 2011 / 126808 and WO 2013 / 04943), or promoters that respond to physiological cues can be used in the vectors described herein. In another embodiment, expression in muscle is desired. Thus, in one embodiment, a muscle-specific promoter is used. In one embodiment, the promoter is an MCK-based promoter, such as the dMCK (509-bp) or tMCK (720-bp) promoter (see, e.g., Wang et al., Gene Ther. 2008 Nov;15(22):1489-99. doi:10.1038 / gt.2008.104. Epub 2008 Jun 19, which is incorporated herein by reference). Another useful promoter is the SPc5-12 promoter (see, Rasowo et al., European Scientific Journal June 2014 edition vol.10, No.18, which is incorporated herein by reference). In certain embodiments, a promoter specific to the eye or a portion thereof (e.g., the retina) may be selected.

[0140] In one embodiment, the promoter is a CMV promoter. The promoter is the TBG promoter. In another embodiment, the CB7 promoter is used. CB7 is a chicken β-actin promoter with a cytomegalovirus enhancer element. Alternatively, other liver-specific promoters can be used (see, e.g., the Liver-Specific Promoter Database, Cold Spring Harbor: rulai.schl.edu / LSPD, α1 antitrypsin (A1AT), human albumin: Miyatake et al., J. Virol., 71:5124-32 (1997), humAlb, and hepatitis B virus core promoter: Sandig et al., Gene Ther., 3:1002-9 (1996)). TTR minimal enhancer / promoter, α-antitrypsin promoter, LSP(845nt)25 (requires intronless scAAV).

[0141] The promoter may be selected from different sources, for example, the human cytomegalovirus (CMV) immediate early enhancer / promoter, the SV40 immediate early enhancer / promoter, the JC polymomavirus promoter, the myelin basic protein (MBP) or glial fibrillary acidic protein (GFAP) promoter, the herpes simplex virus (HSV-1) latency-associated promoter (LAP), the Rous sarcoma virus (RSV) long terminal repeat (LTR) promoter, the neuron-specific promoter (NSE), the platelet-derived growth factor (PDGF) promoter, hSYN, the melanin-concentrating hormone (MCH) promoter, CBA, the matrix metalloprotein promoter (MPP), and the chicken β-actin promoter.

[0142] The vector genome may include at least one enhancer, i.e., a CMV enhancer. Still other enhancer elements may include, for example, apolipoprotein enhancers, zebrafish enhancers, GFAP enhancer elements, and brain-specific enhancers such as those described in WO2013 / 1555222, woodchuck hepatitis posttranscriptional regulatory elements. Additionally or alternatively, other promoter-enhancer elements may be selected, such as the hybrid human cytomegalovirus (HCMV)-immediate-early (IE)-PDGR promoter or other promoter-enhancer elements. Other enhancer sequences useful herein include the IRBP enhancer (Nicoud 2007, J Gene Med. 2007 Dec;9(12):1015-23), the immediate-early cytomegalovirus enhancer, those derived from immunoglobulin genes or the SV40 enhancer, and cis-acting elements identified in mouse proximal promoters.

[0143] In addition to a promoter, the vector genome may include suitable transcription initiation, termination, and enhancer sequences, efficient RNA processing signals such as splicing and polyadenylation (polyA) signals, sequences that stabilize cytoplasmic mRNA, sequences that increase translation efficiency (i.e., Kozak consensus sequences), sequences that enhance protein stability, and, optionally, sequences that enhance secretion of the encoded product. A variety of suitable polyA sequences are known. In one example, the polyA is rabbit β-globin, such as the 127-bp rabbit β-globin polyadenylation signal (GenBank #V00882.1). In other embodiments, an SV40 polyA signal is selected. Still other suitable polyA sequences may be selected. In certain embodiments, an intron is included. One suitable intron is the chicken β-actin intron. In one embodiment, the intron is 875 bp (GenBank, #X00182.1). In another embodiment, a chimeric intron available from Promega is used. However, other suitable introns may be selected. In one embodiment, a spacer is included so that the vector genome is approximately the same size as the native AAV vector genome (e.g., 4.1-5.2 kb). In one embodiment, a spacer is included so that the vector genome is approximately 4.7 kb. Wu et al., Effect of Genome Size on AAV Vector P See, Mol Ther. 2010 Jan;18(1):80-86, incorporated herein by reference.

[0144] In certain embodiments, the vector genome further comprises a dorsal root ganglion (drg)-specific miRNA detargeting sequence operably linked to the transgene coding sequence. In certain embodiments, the tandem miRNA target sequences are contiguous or separated by a spacer of 1 to 10 nucleic acids, which is not a miRNA target sequence. In certain embodiments, there are at least two drg-specific miRNA sequences and they are located 3' of the functional transgene coding sequence. In certain embodiments, the start of the first of the at least two drg-specific miRNA tandem repeats is within 20 nucleotides of the 3' end of the transgene coding sequence. In certain embodiments, the start of the first of the at least two drg-specific miRNA tandem repeats is at least 100 nucleotides from the 3' end of the functional transgene coding sequence. In certain embodiments, the miRNA tandem repeat comprises a length of 200 to 1200 nucleotides. In certain embodiments, there are at least two drg-specific miRNA target sequences and they are located 5' of the functional transgene coding sequence. In certain embodiments, at least two drg-specific miRNA target sequences are located both 5' and 3' of the functional transgene coding sequence. In certain embodiments, the miRNA target sequence of at least the first and / or at least the second miRNA target sequence of the expression cassette mRNA or DNA positive strand is selected from (i) AGTGAATTCTAGTGCCATA (SEQ ID NO: 78), (ii) AGCAAAATGTGCTAGTGCCAAA (SEQ ID NO: 79), (iii) AGTGTGAGTCTACCATTGCCAAA (SEQ ID NO: 80), or (iv) AGGGAATTCCTGGGAAAACTGGAC (SEQ ID NO: 81). In certain embodiments, the miRNA target sequence of at least the first and / or at least the second miRNA target sequence of the expression cassette mRNA or DNA positive strand is AGTGAATTCTAGTGCCATA (SEQ ID NO: 78). In certain embodiments, the miRNA target sequence of at least the first and / or at least the second miRNA target sequence of the expression cassette mRNA or DNA positive strand is AGTGAATTCTACAGTGCCATA (SEQ ID NO: 78).In certain embodiments, two or more consecutive miRNA target sequences are contiguous and not separated by a spacer. In certain embodiments, two or more miRNA target sequences are separated by a spacer, each spacer being independently selected from one or more of: (A) GGAT, (B) CACGTG, or (C) GCATGC. In certain embodiments, the spacer located between the miRNA target sequences may be located 3' of the first miRNA target sequence and / or 5' of the last miRNA target sequence. In certain embodiments, the spacers between the miRNA target sequences are the same. See International Patent Application No. PCT / US19 / 67872, filed December 20, 2019, U.S. Provisional Patent Application No. 63 / 023,594, filed May 12, 2020, U.S. Provisional Patent Application No. 63 / 038,488, filed June 12, 2020, U.S. Provisional Patent Application No. 63 / 043,562, filed June 24, 2020, and U.S. Provisional Patent Application No. 63 / 079,299, filed September 16, 2020 (all of which are incorporated by reference in their entirety).

[0145] Selection of these and other common vectors and regulatory elements is conventional, and many such sequences are available. See, e.g., Sambrook et al. and the references cited therein, e.g., pages 3.18-3.26 and 16.17-16.27, and Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989. Of course, not all vectors and expression control sequences function equally well or sufficiently to express all transgenes as described herein. However, one of skill in the art can make a selection from among these and other expression control sequences without departing from the scope of the present invention.

[0146] In another embodiment, a method for producing a recombinant adeno-associated virus is provided. Suitable recombinant adeno-associated viruses (AAV) are produced by culturing host cells containing a minigene consisting of a nucleic acid sequence encoding the AAV capsid proteins described herein, or a fragment thereof, a functional rep gene, minimally AAV inverted terminal repeats (ITRs), and a heterologous nucleic acid sequence encoding a desired transgene, and sufficient helper functions to allow packaging of the minigene into AAV capsid proteins. Components required for culturing within the host cell to package the AAV minigene into an AAV capsid can be provided in trans to the host cell. Alternatively, any one or more of the required components (e.g., minigene, rep sequence, cap sequence, and / or helper functions) can be provided by a stable host cell engineered to contain one or more of the required components using methods known to those skilled in the art.

[0147] Also provided herein are host cells transfected with the AAVs described herein. Most preferably, such stable host cells will contain the required components under the control of an inducible promoter. However, the required components may be under the control of a constitutive promoter. Examples of suitable inducible and constitutive promoters are provided herein below in the discussion of regulatory elements suitable for use with transgenes. As yet another alternative, the selected stable host cell may contain selected components under the control of a constitutive promoter and other selected components under the control of one or more inducible promoters. For example, stable host cells derived from 293 cells (containing E1 helper functions under the control of a constitutive promoter) but containing rep and / or cap proteins under the control of an inducible promoter can be generated. Still other stable host cells can be generated by one of skill in the art. In another embodiment, the host cell contains a nucleic acid molecule (e.g., a plasmid) described herein.

[0148] The minigene, rep sequences, cap sequences, and helper functions required for the production of rAAV described herein can be delivered to packaging host cells in the form of any genetic elements that incorporate the sequences they carry. The selected genetic elements can be delivered by any suitable method, including those described herein. The methods used to construct any embodiment of the present invention are known to those skilled in nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthetic techniques. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY. Similarly, methods for producing rAAV virions are well known, and the selection of a suitable method is not a limitation of the present invention. See, e.g., K. Fisher et al., 1993 J. Virol., 70:520-532, and U.S. Pat. No. 5,478,745, among others. These publications are incorporated herein by reference.

[0149] Also provided herein are plasmids for use in producing the vectors described herein, including AAVhu71 / 74 (SEQ ID NO: 4), AAVhu79 (SEQ ID NO: 6), AAVhu80 (SEQ ID NO: 8), AAVhu83 (SEQ ID NO: 10), AAVhu74 / 71 (SEQ ID NO: 12), AAVhu77 (SEQ ID NO: 14), AAVhu78 / 88 (SEQ ID NO: 16), AAVhu70 (SEQ ID NO: 18), AAVhu72 (SEQ ID NO: 20), AAVhu75 (SEQ ID NO: 22), AAVhu76 (SEQ ID NO: 24), AAVhu81 (SEQ ID NO: 26), AAVhu82 (SEQ ID NO: 28), AAVhu84 (SEQ ID NO: 30), AAVhu86 (SEQ ID NO: 32), AAVhu87 (SEQ ID NO: 34), AAVhu88 / 78 (SEQ ID NO: 36), AAVhu69 (SEQ ID NO: 38), AAVrh75 (SEQ ID NO: 40), AAVrh76 (SEQ ID NO: 42), AAVrh77 (SEQ ID NO: 44), AAVrh78 (SEQ ID NO: 46), AAVrh79 (SEQ ID NO: 48), AAV Examples of nucleic acid sequences include those encoding at least one of AAV vp1, vp2, and vp3 of AAVhu71 / 74 (SEQ ID NO: 3), AAVhu79 (SEQ ID NO: 5), AAVhu80 (SEQ ID NO: 7), AAVhu83 (SEQ ID NO: 9), AAVhu74 / 71 (SEQ ID NO: 11), AAVhu77 (SEQ ID NO: 13), AAVhu78 / 88 (SEQ ID NO: 15), AAVhu70 (SEQ ID NO: 17), AAVhu72 (SEQ ID NO: 19), AAVhu75 (SEQ ID NO: 21), ... hu76 (SEQ ID NO: 23), AAVhu81 (SEQ ID NO: 25), AAVhu82 (SEQ ID NO: 27), AAVhu84 (SEQ ID NO: 29), AAVhu86 (SEQ ID NO: 31), AAVhu87 (SEQ ID NO: 33), AAVhu88 / 78 (SEQ ID NO: 35), AAVhu69 (SEQ ID NO: 37), AAVrh75 (SEQ ID NO: 39), AAVrh76 (SEQ ID NO: 41), AAVrh77 (SEQ ID NO: 43), AAVrh the vp1, vp2, and / or vp3 sequences of AAVrh78 (SEQ ID NO:45), AAVrh79 (SEQ ID NO:47), AAVrh81 (SEQ ID NO:49), AAVrh89 (SEQ ID NO:51), AAVrh82 (SEQ ID NO:53), AAVrh83 (SEQ ID NO:55), AAVrh84 (SEQ ID NO:57), AAVrh85 (SEQ ID NO:59), AAVrh87 (SEQ ID NO:61), or AAVhu73 (SEQ ID NO:73);

[0013] Provided are plasmids having a sequence that shares at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with any of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, or 61. In further embodiments, the plasmid comprises a non-AAV sequence. Also provided are cultured host cells comprising the plasmids described herein.

[0150] In certain embodiments, the plasmids produced are an AAV cis-plasmid encoding the AAV genome and gene of interest, an AAV trans-plasmid containing the AAVrep and novel hu68cap genes, and a helper plasmid. These plasmids may be used in any suitable ratio, e.g., about 1 to about 1, based on the total weight of the genetic elements. In other embodiments, the pRepCap to AAV cis-plasmid ratio is about 1:1 weight percent of each coding sequence and pHelper, which is about 2 times the weight of the other coding sequences. In other embodiments, the ratio may be about 3:1 helper:10:1 pRepCap:1 to 0.10 rAAV plasmid (weight percent). Other suitable ratios may be selected. In certain embodiments, host cells may be stably transformed with one or more of these elements. For example, the host cell may contain a stable nucleic acid molecule comprising the AAVhu68M191 vp1 coding sequence operably linked to regulatory sequences, a nucleic acid molecule encoding a rep coding sequence, and / or one or more nucleic acid molecules encoding helper functions (e.g., adenovirus E1a, etc.). In such embodiments, the various genetic elements may be used in any suitable ratio, e.g., about 1 to about 1 to about 1, based on the total weight of the genetic elements. In certain embodiments, the ratio of pRep DNA to Cap DNA to AAV molecule (e.g., a plasmid carrying the vector genome to be packaged) is about 1 to about 1 to about 1 (1:1:1) weight percent. In certain embodiments, certain host cells contain some helper elements provided in trans (e.g., Ad E2a and / or Ad E2b) and others in cis (e.g., Ad E1a and / or E1b). Helper sequences may be present in about twice the amount of other genetic elements. Other ratios may be determined.

[0151] The vector production process may include method steps such as initiating cell culture, passaging the cells, seeding the cells, transfecting the cells with plasmid DNA, changing the medium to serum-free medium after transfection, and harvesting the vector-containing cells and culture medium. The harvested vector-containing cells and culture medium are referred to herein as crude cell harvest. In this system, gene therapy vectors are introduced into insect cells by infection with baculovirus-based vectors. For a review of these production systems generally, see, e.g., Clement and Grieger, Mol Ther Methods Clin Dev, 2016:3:16002 (published online March 16, 2016). Methods of making and using these and other AAV production systems are also described in the following U.S. patents, the contents of each of which are incorporated herein by reference in their entirety: 5,139,941; 5,741,683; 6,057,152; 6,204,059; 6,268,213; 6,491,907; 6,660,514; 6,951,753; 7,094,604; 7,172,893; 7,201,898; 7,229,823; and 7,439,065.

[0152] The crude cell harvest is then subjected to process steps such as concentration of the vector harvest, diafiltration of the vector harvest, microfluidization of the vector harvest, nuclease digestion of the vector harvest, filtration of the microfluidized intermediate, crude purification by chromatography, crude purification by ultracentrifugation, buffer exchange by tangential flow filtration, and / or formulation and filtration to prepare bulk vector.

[0153] Various AAV purification methods are known in the art. See, for example, WO2017 / 160360, entitled "Scalable Purification Method for AAV9," which is incorporated herein by reference and describes a method generally useful for CladeF capsids. A two-step affinity chromatography purification, followed by anion exchange resin chromatography, is used to purify the vector drug product and remove empty capsids. Crude cell harvests are subjected to steps such as vector harvest concentration, vector harvest diafiltration, vector harvest microfluidization, vector harvest nuclease digestion, filtration of the microfluidized intermediate, crude purification by chromatography, crude purification by ultracentrifugation, buffer exchange by tangential flow filtration, and / or formulation and filtration to prepare bulk vector. Affinity chromatography purification, followed by anion exchange resin chromatography, is used to purify the vector drug product and remove empty capsids. In one example, for an affinity chromatography step, the diafiltered product may be applied to Capture Select™ Poros-AAV2 / 9 affinity resin (Life Technologies), which efficiently captures the AAV2 / 9 serotype. Under these ionic conditions, a significant percentage of residual cellular DNA and proteins flows through the column, and AAV particles are efficiently captured. See also WO2021 / 158915, WO2019 / 241535, and WO2021 / 165537. Alternatively, other purification methods may be selected.

[0154] Methods for characterizing or quantifying rAAV are available to those skilled in the art. For example, to calculate empty and filled particle content, the VP3 band volume for a selected sample (e.g., in the examples herein, a preparation purified on an iodixanol gradient, where the number of GC = the number of particles) is plotted against the number of loaded GC particles. The resulting linear equation (y = mx + c) is used to calculate the number of particles in the band volume of the test article peak. The number of particles (pt) per 20 μL loaded is then multiplied by 50 to obtain particles (pt) / mL. Pt / mL is divided by GC / mL to obtain the ratio of particles to genome copies (pt / GC). Pt / mL - GC / mL gives empty pt / mL. Dividing empty pt / mL by pt / mL and multiplying by 100 gives the percentage of empty particles.

[0155] In certain embodiments, the yield of packaged AAV vector genome copies (VG or GC) can be assessed by use of a biological activity assay of the encoded transgene. For example, after production, the culture supernatant can be collected and spun to remove cellular debris. The yield can be determined by: Equal volumes of supernatant from the test sample compared to a control (reference standard) can be used to transduce selected target cells and assess the biological activity of the encoded protein as measured by a biological activity assay. Other suitable methods for assessing yield may be selected, including, for example, nanoparticle tracking [Povlich, S.F., et al. (2016) Particle Titer Determination and Characterization of rAAV Molecules Using Nanoparticle Tracking Analysis. Molecular Therapy: AAV Vectors II, 24(S1), S122], enzyme-linked immunosorbent assay (ELISA) [Grimm, D., et al. (1999). Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene therapy, 6(7), 1322-1330. doi.org / 10.1038 / sj.gt.3300946], and digital droplet (dd) polymerase chain reaction (PCR). Methods for determining single-stranded and self-complementary AAV vector genome titers have been described. For example, M. Lock et al., Hum Gene Ther Methods. 2014 Apr;25(2):115-25. doi:10.1089 / hgtb.2013.131. Epub 2014 Feb 14]. Another suitable method is qPCR. Optimized PCR methods utilizing broad-spectrum serine proteases, such as proteinase K (such as those commercially available from Qiagen), can be used. More specifically, the optimized qPCR genomic titer assay is similar to the standard assay, except that after DNase I digestion, the sample is diluted with proteinase K buffer and treated with proteinase K, followed by heat inactivation. Preferably, the sample is diluted with a volume of proteinase K buffer equal to the sample size. The proteinase K buffer may be concentrated two-fold or more. Typically, the proteinase K treatment is about 0.2 mg / mL, but can vary from 0.1 mg / mL to about 1 mg / mL. The treatment step is typically performed at about 55°C for about 15 minutes, but may be performed at lower temperatures (e.g., about 37°C to about 50°C) for longer periods (e.g., about 20 to about 30 minutes) or at higher temperatures (e.g., up to about 60°C) for shorter periods (e.g., about 5 to 10 minutes). Similarly, heat inactivation is typically performed at about 95°C for about 15 minutes, but may be performed at lower temperatures (e.g., about 70 to about 90°C) and for longer periods (e.g., about 20 to about 30 minutes). The sample is then diluted (e.g., 1000-fold) and subjected to TaqMan analysis as described for standard assays. Yet another method is quantitative DNA dot blot [Wu, Z., et al. (2008). Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Molecular therapy: the journal of the American Society of Gene Therapy, 16(2), 280-289. doi.org / 10.1038 / sj.mt.6300355). Still other methods may be selected.

[0156] Methods for assaying AAV vector particles containing empty capsids and packaged genomes are well known in the art. See, e.g., Grimm et al., Gene Therapy (1999) 6:1322-1330; Sommer et al., Molec. Ther. (2003) 7:122-128. To test for denatured capsids, the method involves subjecting the processed AAV stock to SDS-polyacrylamide gel electrophoresis (e.g., a gradient gel containing 3-8% Tris-acetate in buffer) consisting of any gel capable of separating the three capsid proteins, then running the gel until the sample material is separated, and then immersing the sample in a nylon or nitrocellulose gel. and blotting the gel onto a cellulose membrane, preferably nylon. An anti-AAV capsid antibody is then used as a primary antibody that binds to the denatured capsid protein, preferably an anti-AAV capsid monoclonal antibody, most preferably a B1 anti-AAV-2 monoclonal antibody (Wobus et al., J. Virol. (2000) 74:9281-9293). A secondary antibody is then used that binds to the primary antibody and includes a means for detecting binding with the primary antibody, more preferably an anti-IgG antibody containing a detection molecule covalently bound to the antibody, most preferably a sheep anti-mouse IgG antibody covalently bound to horseradish peroxidase. To semi-quantitatively determine binding between the primary and secondary antibodies, a method for detecting binding is used, preferably a detection method capable of detecting radioisotope radiation, electromagnetic radiation, or colorimetric changes, most preferably a chemiluminescence detection kit. For example, in SDS-PAGE, samples from column fractions can be taken and heated in SDS-PAGE loading buffer containing a reducing agent (e.g., DTT), and capsid proteins resolved in precast gradient polyacrylamide gels (e.g., Novex). Silver staining can be performed using SilverXpress (Invitrogen, CA) according to the manufacturer's instructions, or other suitable staining methods, i.e., SYPRO Ruby or Coomassie staining. In one embodiment, the concentration of AAV vector genome (vg) in column fractions can be measured by quantitative real-time PCR (Q-PCR). The sample is diluted and digested with DNase I (or another suitable nuclease) to remove exogenous DNA. After inactivation of the nuclease, the sample is further diluted and amplified using a TaqMan™ fluorogenic probe specific for primers and the DNA sequence between the primers. The number of cycles required to reach a defined level of fluorescence (threshold cycle, Ct) is measured for each sample on an Applied Biosystems Prism 7700 sequence detection system. Plasmid DNA containing the same sequence as that contained in the AAV vector is used to generate a standard curve in the Q-PCR reaction.The cycle threshold (Ct) value obtained from the sample is used to determine the vector genome titer by normalizing it to the Ct value of a plasmid standard curve. Digital PCR-based endpoint assays can also be used. As used herein, the terms genome copies (GC) and vector genomes (vg) in the context of dose or administration (e.g., GC / kg and vg / kg) are meant to be interchangeable.

[0157] Methods for determining the ratio of capsid proteins vp1, vp2, and vp3 are also available. See, for example, Vamseedhar Rayaprolu et al., Comparative Analysis of Adeno-Associated Virus Capsid Stability and Dynamics, J Virol. 2013 Dec;87(24):13150-13160, Buller RM, Rose JA. 1978. Characterization of adenovirus-associated virus-induced polypeptides. See in KB cells. J. Virol. 25:331-338, and Rose JA, Maizel JV, Inman JK, Shatkin AJ. 1971. Structural proteins of adenovirus-associated viruses. J. Virol. 8:766-770.

[0158] As used herein, a "stock" of rAAV refers to a population of rAAV. Despite heterogeneity in capsid proteins due to deamidation, rAAV within a stock are expected to share the same vector genome. A stock may, for example, contain rAAVs with capsids that have a selected AAV capsid protein and a heterogeneous deamidation pattern characteristic of a selected production system. A stock may be produced from a single production system or may be pooled from multiple runs of a production system (e.g., different runs of a production system that use the same genetic elements for production). The stocks described herein may be used to generate rAAVs with capsids that have a heterogeneous deamidation pattern characteristic of a selected AAV capsid protein and a selected production system. A variety of production systems can be selected, including, but not limited to:

[0159] C. Pharmaceutical Compositions and Administration In one embodiment, a recombinant AAV containing a desired transgene and promoter for use in a target cell, as detailed above, is optionally evaluated for contamination by conventional methods and then formulated into a pharmaceutical composition intended for administration to a subject in need thereof. Such a formulation includes a pharmaceutically and / or physiologically acceptable vehicle or carrier (such as buffered saline or other buffers (e.g., HEPES) to maintain pH at an appropriate physiological level), and optionally other medicinal agents, pharmaceutical agents, stabilizers, buffers, carriers, adjuvants, diluents, etc. For injection, the carrier is typically a liquid. Exemplary physiologically acceptable carriers include sterile, pyrogen-free water and sterile, pyrogen-free phosphate-buffered saline. A variety of such known carriers are provided in U.S. Patent Publication No. 7,629,322 (incorporated herein by reference). In one embodiment, the carrier is an isotonic sodium chloride solution. In another embodiment, the carrier is a balanced salt solution. In one embodiment, the carrier comprises tween. For long-term storage of the virus, it can be frozen in the presence of glycerol or Tween 20. In another embodiment, the pharmaceutically acceptable carrier comprises a surfactant such as perfluorooctane (Perfluoron liquid). The vector is formulated in a buffer / carrier suitable for infusion in human subjects. The buffer / carrier should contain components that prevent rAAV from adhering to the infusion tubing but do not interfere with rAAV binding activity in vivo.

[0160] In certain embodiments of the methods described herein, the pharmaceutical composition described above is administered to a subject intramuscularly (IM). In other embodiments, the pharmaceutical composition is administered intravenously (IV). In other embodiments, the pharmaceutical composition is administered by intracerebroventricular (ICV) injection. In other embodiments, the pharmaceutical composition is administered by intracisternal (ICM) injection. Other forms of administration that may be useful in the methods described herein include, but are not limited to, direct delivery to the desired organ (e.g., the eye), including subretinal or intravitreal delivery, oral, inhalation, intranasal, intratracheal, intravenous, intramuscular, subcutaneous, intradermal, and other parent routes of administration. Routes of administration may be combined, if desired.

[0161] As used herein, the terms "intrathecal delivery" or "intrathecal administration" refer to a route of administration via injection into the spinal canal, and more particularly into the subarachnoid space to reach the cerebrospinal fluid (CSF). Intrathecal delivery may include lumbar puncture, intraventricular (including intraventricular (ICV)), suboccipital / intracisternal, and / or C1-2 puncture. For example, a material may be introduced by means of a lumbar puncture for diffusion throughout the subarachnoid space. Another example may be injection into the cisterna magna.

[0162] As used herein, the term "intracisternal delivery" or "intracisternal administration" refers to a route of administration directly into the cisternal cerebellar-medullary cerebrospinal fluid, more particularly via suboccipital puncture or by direct injection into the cisterna magna, or via a permanently placed tube.

[0163] The composition may be delivered in a volume of about 0.1 μL to about 10 mL, inclusive of all values ​​within the range, depending on the size of the area to be treated, the viral titer used, the route of administration, and the desired effect of the method. In one embodiment, the volume is about 50 μL. In another embodiment, the volume is about 70 μL. In another embodiment, the volume is about 100 μL. In another embodiment, the volume is about 125 μL. In another embodiment, the volume is about 150 μL. In another embodiment, the volume is about 175 μL. In yet another embodiment, the volume is about 200 μL. In another embodiment, the volume is about 250 μL. In another embodiment, The volume is about 300 μL. In another embodiment, the volume is about 450 μL. In another embodiment, the volume is about 500 μL. In another embodiment, the volume is about 600 μL. In another embodiment, the volume is about 750 μL. In another embodiment, the volume is about 850 μL. In another embodiment, the volume is about 1000 μL. In another embodiment, the volume is about 1.5 mL. In another embodiment, the volume is about 2 mL. In another embodiment, the volume is about 2.5 mL. In another embodiment, the volume is about 3 mL. In another embodiment, the volume is about 3.5 mL. In another embodiment, the volume is about 4 mL. In another embodiment, the volume is about 5 mL. In another embodiment, the volume is about 5.5 mL. In another embodiment, the volume is about 6 mL. In another embodiment, the volume is about 6.5 mL. In another embodiment, the volume is about 7 mL. In another embodiment, the volume is about 8 mL. In another embodiment, the volume is about 8.5 mL. In another embodiment, the volume is about 9 mL. In another embodiment, the volume is about 9.5 mL. In another embodiment, the volume is about 10 mL.

[0164] The effective concentration of recombinant adeno-associated virus carrying a nucleic acid sequence encoding a desired transgene under the control of a regulatory sequence is desirably about 10 per milliliter. 7 ~10 14The range of vector genomes (vg / mL) (also referred to as genome copies / mL (GC / mL)) is 100%. In one embodiment, the rAAV vector genome is measured by real-time PCR. In another embodiment, the rAAV vector genome is measured by digital PCR. Lock et al., Absolute determination of single-stranded and self-complementary See adeno-associated viral vector genome titers by droplet digital PCR, Hum Gene Ther Methods. 2014 Apr;25(2):115-25. doi:10.1089 / hgtb.2013.131. Epub 2014 Feb 14, incorporated herein by reference. In another embodiment, rAAV infectious units are measured as described in S.K. McLaughlin et al., 1988 J. Virol., 62:1963, incorporated herein by reference.

[0165] Preferably, the concentration is about 1.5 x 10 9 vg / mL ~ approx. 1.5×10 13 vg / mL, more preferably about 1.5×10 9 vg / mL ~ approx. 1.5×10 11 In one embodiment, the effective concentration is about 1.4 x 10 8 In one embodiment, the effective concentration is about 3.5 x 10 10 In another embodiment, the effective concentration is about 5.6 x 10 11 In another embodiment, the effective concentration is about 5.3 x 10 12 In yet another embodiment, the effective concentration is about 1.5 x 10 12 In another embodiment, the effective concentration is about 1.5 x 10 13 vg / mL. All ranges stated herein are inclusive of the endpoints.

[0166] In one embodiment, the dose is about 1.5×109 vg / kg body weight ~ approx. 1.5 x 10 13 vg / kg, more preferably about 1.5×10 9 vg / kg ~ approx. 1.5×10 11 In one embodiment, the dosage is about 1.4×10 8 In one embodiment, the dosage is about 3.5×10 10 In another embodiment, the dosage is about 5.6×10 11 In another embodiment, the dosage is about 5.3×10 12 In yet another embodiment, the dosage is about 1.5×10 12 In another embodiment, the dosage is about 1.5×10 13 In another embodiment, the dosage is about 3.0×10 13 In another embodiment, the dosage is about 1.0×10 14 vg / kg. All ranges stated herein are inclusive of the endpoints.

[0167] In one embodiment, the effective dose (total genome copies delivered) is about 10 7 ~10 13 Be In one embodiment, the total dose is about 10 8 In one embodiment, the total administered dose is about 10 9 In one embodiment, the total administered dose is about 10 10 In one embodiment, the total administered dose is about 10 11 In one embodiment, the total administered dose is about 10 12 In one embodiment, the total administered dose is about 10 13 In one embodiment, the total administered dose is about 10 14 In one embodiment, the total administered dose is about 10 15 It is a genome copy.

[0168] It is desirable to utilize the lowest effective concentration of the virus to reduce the risk of undesirable effects such as toxicity. Furthermore, other dosages and administration volumes within these ranges can be selected by the attending physician, taking into consideration the physical condition of the subject (preferably a human) being treated, the subject's age, the specific disorder, and, if progressive, the severity of the disorder. For example, intravenous delivery can be performed at 1.5 x 10 13 Doses on the order of vg / kg may be required.

[0169] D. Method In another aspect, a method of transducing a target tissue or cell is provided. In one embodiment, the method comprises administering an rAAV described herein.

[0170] In one embodiment, the dosage of rAAV is about 1 x 10 per dose (to treat an average subject weighing 70 kg). 9 GC~approx. 1×10 15 genome copies (GC), preferably 1.0 x 10 for human patients 12 GC~2.0×10 15 In another embodiment, the dose is about 1 x 10 of the subject. 14 In certain embodiments, the dose of vector administered to a patient is at least about 1.0 x 10 9 GC / kg, approx. 1.5×10 9 GC / kg, approx. 2.0×10 9 GC / g, approximately 2.5 x 10 9 GC / kg, approx. 3.0×10 9 GC / kg, approx. 3.5×10 9 GC / kg, approx. 4.0×10 9 GC / kg, approx. 4.5×10 9 GC / kg, approx. 5.0×10 9 GC / kg, approx. 5.5×10 9 GC / kg, approx. 6.0×10 9 GC / kg, approx. 6.5×10 9 GC / kg, approx. 7.0×10 9 GC / kg, approx. 7.5×10 9 GC / kg, approx. 8.0×10 9 GC / kg, approx. 8.5×109 GC / kg, approximately 9.0 × 10 9 GC / kg, approximately 9.5 × 10 9 GC / kg, approximately 1.0 × 10 10 GC / kg, approximately 1.5 × 10 10 GC / kg, approximately 2.0 × 10 10 GC / kg, approximately 2.5 × 10 10 GC / kg, approximately 3.0 × 10 10 GC / kg, approximately 3.5 × 10 10 GC / kg, approximately 4.0 × 10 10 GC / kg, approximately 4.5 × 10 10 GC / kg, approximately 5.0 × 10 10 GC / kg, approximately 5.5 × 10 10 GC / kg, approximately 6.0 × 10 10 GC / kg, approximately 6.5 × 10 10 GC / kg, approximately 7.0 × 10 10 GC / kg, approximately 7.5 × 10 10 GC / kg, approximately 8.0 × 10 10 GC / kg, approximately 8.5 × 10 10 GC / kg, approximately 9.0 × 10 10 GC / kg, approximately 9.5 × 10 10 GC / kg, approximately 1.0 × 10 11 GC / kg, approximately 1.5 × 10 11 GC / kg, approximately 2.0 × 10 11 GC / kg, approximately 2.5 × 10 11 GC / kg, approximately 3.0 × 10 11 GC / kg, approximately 3.5 × 10 11 GC / kg, approximately 4.0 × 10 11 GC / kg, approximately 4.5 × 10 11 GC / kg, approximately 5.0 × 10 11 GC / kg, approximately 5.5 × 10 11 GC / kg, approximately 6.0 × 10 11 GC / kg, approximately 6.5 × 10 11 GC / kg, approximately 7.0 × 10 11 GC / kg, approximately 7.5 × 10 11 GC / kg, approximately 8.0 × 10 11 GC / kg, approximately 8.5 × 10 11 GC / kg, approximately 9.0 × 10 11 GC / kg, approximately 9.5 × 10 11GC / kg, approximately 1.0×10 12 GC / kg, approx. 1.5×10 12 GC / kg, approx. 2.0×10 12 GC / kg, approx. 2.5×10 12 GC / kg, approx. 3.0×10 12 GC / kg, approx. 3.5×10 12 GC / kg, approx. 4.0×10 12 GC / kg, approx. 4.5×10 12 GC / kg, approx. 5.0×10 12 GC / kg, approx. 5.5×10 12 GC / kg, approx. 6.0×10 12 GC / kg, approx. 6.5×10 12 GC / kg, approx. 7.0×10 12 GC / kg, approx. 7.5×10 12 GC / kg, approx. 8.0×10 12 GC / kg, approx. 8.5×10 12 GC / kg, approx. 9.0×10 12 GC / kg, approx. 9.5×10 12 GC / kg, approximately 1.0×10 13 GC / kg, approx. 1.5×10 13 GC / kg, approx. 2.0×10 13 GC / kg, approx. 2.5×10 13 GC / kg, approx. 3.0×10 13 G C / kg, approximately 3.5×10 13 GC / kg, approx. 4.0×10 13 GC / kg, approx. 4.5×10 13 GC / kg, approx. 5.0×10 13 GC / kg, approx. 5.5×10 13 GC / kg, approx. 6.0×10 13 GC / kg, approx. 6.5×10 13 GC / kg, approx. 7.0×10 13 GC / kg, approx. 7.5×10 13 GC / kg, approx. 8.0×10 13 GC / kg, approx. 8.5×10 13 GC / kg, approx. 9.0×10 13 GC / kg, approx. 9.5×10 13 GC / kg, or approximately 1.0 x 10 14 GC / kg body weight or subject.

[0171] In one embodiment, the method further includes administering an immunosuppressive combination therapy to the subject. Such immunosuppressive combination therapy may be initiated prior to delivery of the rAAV or the disclosed composition, for example, if an undesirably high level of neutralizing antibodies against the AAV capsid is detected. In certain embodiments, the combination therapy may be initiated prior to delivery of the rAAV as a preventative measure. In certain embodiments, the immunosuppressive combination therapy is initiated after delivery of the rAAV, for example, if an undesirable immune response is observed after treatment.

[0172] Immunosuppressants for such combination therapy include, but are not limited to, glucocorticoids, steroids, antimetabolites, T-cell inhibitors, macrolides (e.g., rapamycin or rapalogs), and cytostatic agents (including alkylating agents, antimetabolites, cytotoxic antibiotics, antibodies, or agents active against immunophilins). Immunosuppressants may include prednelisone, nitrogen mustards, nitrosoureas, platinum compounds, methotrexate, azathioprine, mercaptopurine, fluorouracil, dactinomycin, anthracyclines, mitomycin C, bleomycin, mithramycin, IL-2 receptor (CD25)-specific antibodies or CD3-specific antibodies, anti-IL-2 antibodies, cyclosporine, tacrolimus, sirolimus, IFN-β, IFN-γ, opioids, or TNF-α (tumor necrosis factor-α) binding agents. In certain embodiments, immunosuppressive therapy can be initiated 0, 1, 2, 7 or more days before rAAV administration, or 0, 1, 2, 3, 7 or more days after rAAV administration. Such therapy can involve the simultaneous administration of a single drug (e.g., prednisone) or two or more drugs (e.g., prednisolone, mycophenolate mofetil (MMF), and / or sirolimus (i.e., rapamycin)) on the same day. One or more of these drugs can be continued at the same dose or at an adjusted dose after gene therapy administration. Such therapy can be for about 1 week (7 days), 2 weeks, 3 weeks, about 60 days, or longer, as needed. In certain embodiments, a tacrolimus-free regimen is selected.

[0173] Further embodiments are listed below as 1-12. 1. A recombinant adeno-associated virus (rAAV) comprising a capsid and a vector genome, the vector genome comprising an AAV 5' inverted terminal repeat (ITR), an expression cassette comprising a nucleic acid sequence encoding a gene product operably linked to an expression control sequence, and an AAV 3' ITR, wherein the capsid (a) AAVrh75 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:40, or a sequence at least 99% identical thereto, having an Asn (N) amino acid residue at position 24 based on the numbering of SEQ ID NO:40, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:39, or a sequence at least 95% identical thereto, encoding SEQ ID NO:40, or (iii) a capsid that is a heterogeneous mixture of AAVrh75 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least positions N57, N262, N384, and / or N512 of SEQ ID NO:40, and optionally deamidated at other positions; (b) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 3, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 3 that encodes SEQ ID NO: 4 or a sequence at least 95% identical thereto, or (iii) an AAVrh7 that is 95% to 100% deamidated at at least four positions of SEQ ID NO: 4 and optionally deamidated at other positions. AAVhu71 / 74 capsid, consisting of a capsid that is a heterogeneous mixture of 1 / 74 vp1, vp2, and vp3 proteins; (c) AAVhu79 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:6, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:5, a sequence encoding SEQ ID NO:6 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu79 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:6 and optionally deamidated at other positions; (d) AAVhu80 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:8, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:7 that encodes SEQ ID NO:8 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu80 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:8 and optionally deamidated at other positions; (e) AAVhu83 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:10, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:9, a sequence encoding SEQ ID NO:10 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu83 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:10 and optionally deamidated at other positions; (f) AAVhu74 / 71 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:12, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:11, a sequence encoding SEQ ID NO:12 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu74 / 71 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:12 and optionally deamidated at other positions; (g) AAVhu77 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 14, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 13, a sequence encoding SEQ ID NO: 14 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu77 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 14 and optionally deamidated at other positions; (h) AAVhu78 / 88 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 16, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 15, a sequence encoding SEQ ID NO: 16 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu78 / 88 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 16 and optionally deamidated at other positions; (i) an AAVhu70 capsid consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 18, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 17, a sequence encoding SEQ ID NO: 18 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu70 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 18 and optionally deamidated at other positions; (j) AAVhu72 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:20, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:19, a sequence encoding SEQ ID NO:20 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu72 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:20 and optionally deamidated at other positions; (k) AAVhu75 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:22, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:21, a sequence encoding SEQ ID NO:22 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu75 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:22 and optionally deamidated at other positions; (l) AAVhu76 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:24, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:23, a sequence encoding SEQ ID NO:24 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu76 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:24 and optionally deamidated at other positions; (m) AAVhu81 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:26, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:25, a sequence encoding SEQ ID NO:26 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu81 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:26 and optionally deamidated at other positions; (n) AAVhu82 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:28, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:27, a sequence encoding SEQ ID NO:28 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu82 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:28 and optionally deamidated at other positions; (o) AAVhu84 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:30, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:29, a sequence encoding SEQ ID NO:30 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu84 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:30 and optionally deamidated at other positions; (p) an AAVhu86 capsid consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 32, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 31, a sequence encoding SEQ ID NO: 32 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu86 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 32 and optionally deamidated at other positions; (q) AAVhu87 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 34, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 33, a sequence encoding SEQ ID NO: 34 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu87 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 34 and optionally deamidated at other positions; (r) AAVhu88 / 78 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 36, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 35, a sequence encoding SEQ ID NO: 36 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu88 / 78 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 36 and optionally deamidated at other positions; (s) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 38, (ii) a sequence encoding SEQ ID NO: 38 or a sequence at least 95% identical thereto 7, or (iii) an AAVhu69 capsid consisting of a capsid that is a heterogeneous mixture of AAVhu69 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 38, and optionally deamidated at other positions; (t) AAVhu76 capsids, consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:42, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:41, a sequence encoding SEQ ID NO:42 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu69 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:42 and optionally deamidated at other positions; (u) AAVrh77 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 44, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 43, a sequence encoding SEQ ID NO: 44 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVrh77 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 44 and optionally deamidated at other positions; (v) AAVrh78 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 46, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 45, a sequence encoding SEQ ID NO: 46 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVrh78 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 46 and optionally deamidated at other positions; (w) AAVrh81 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 50, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 49, a sequence encoding SEQ ID NO: 50 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVrh81 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 50 and optionally deamidated at other positions; (x) AAVrh89 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 52, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 51, a sequence encoding SEQ ID NO: 52 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVrh89 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 52 and optionally deamidated at other positions; (y) AAVrh82 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 54, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 53, a sequence encoding SEQ ID NO: 54 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVrh82 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 54 and optionally deamidated at other positions; (z) AAVrh83 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 56, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 55, a sequence encoding SEQ ID NO: 56 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVrh83 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 56 and optionally deamidated at other positions; (aa) (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 58, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 57, a sequence encoding SEQ ID NO: 58 or a sequence at least 95% identical thereto, or (iii) an A that is 95% to 100% deamidated at at least four positions of SEQ ID NO: 58 and optionally deamidated at other positions. AAVrh84 capsid, consisting of a capsid that is a heterogeneous mixture of AVrh84 vp1, vp2, and vp3 proteins; (bb) AAVrh85 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 60, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 59, a sequence encoding SEQ ID NO: 60 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVrh85 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 60 and optionally deamidated at other positions; (cc) an AAVrh87 capsid consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 62, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 61, a sequence encoding SEQ ID NO: 62 or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVrh87 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 62 and optionally deamidated at other positions; or (dd) An rAAV that is an AAVhu73 capsid, consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO: 74, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO: 73, a sequence that encodes SEQ ID NO: 74 or a sequence that is at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu73 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO: 74 and optionally deamidated at other positions. 2. The rAAV of embodiment 1, wherein the gene product is useful for treating a liver disorder or disease and the capsid is an AAVrh75, AAVrh79, AAVrh83, or AAVrh84 capsid. 3. The rAAV of embodiment 1, wherein the gene product is a gene-editing nuclease. 4. The rAAV of claim 1, wherein the gene encodes a gene-editing nuclease for. 5. The rAAV of any one of embodiments 1 to 4, wherein the expression cassette comprises a tissue-specific promoter. 6. A host cell containing an rAAV according to any one of embodiments 1 to 5. 7. A pharmaceutical composition comprising an rAAV according to any one of embodiments 1 to 5 and a physiologically compatible carrier, buffer, adjuvant, and / or diluent. 8. A method for delivering a transgene to a cell, comprising contacting the cell with an rAAV of any one of embodiments 1 to 5, wherein the rAAV comprises a transgene. 9. A method of generating a recombinant adeno-associated virus (rAAV) comprising an AAV capsid, comprising: (a) producing a recombinant adeno-associated virus (rAAV) comprising AAV capsids selected from the group consisting of AAVrh75 (SEQ ID NO: 40), AAVhu71 / 74 (SEQ ID NO: 4), AAVhu79 (SEQ ID NO: 6), AAVhu80 (SEQ ID NO: 8), AAVhu83 (SEQ ID NO: 10), AAVhu74 / 71 (SEQ ID NO: 12), AAVhu77 (SEQ ID NO: 14), AAVhu78 / 88 (SEQ ID NO: 16), AAVhu70 (SEQ ID NO: 18), AAVhu72 (SEQ ID NO: 20), AAVhu75 (SEQ ID NO: 22), AAVhu76 (SEQ ID NO: 24), AAVhu81 (SEQ ID NO: 26), AAVhu82 (SEQ ID NO: 27), AAVhu83 (SEQ ID NO: 28), AAVhu83 (SEQ ID NO: 29), AAVhu84 (SEQ ID NO: 30), AAVhu85 (SEQ ID NO: 31), AAVhu86 (SEQ ID NO: 32), AAVhu87 (SEQ ID NO: 33), AAVhu88 (SEQ ID NO: 34), AAVhu89 (SEQ ID NO: 35), AAVhu90 (SEQ ID NO: 36), AAVhu91 (SEQ ID NO: 37), AAVhu92 (SEQ ID NO: 38), AAVhu93 (SEQ ID NO: 39), AAVhu94 (SEQ ID NO: 40), AAVhu95 (SEQ ID NO: 41), AAVhu96 (SEQ ID NO: 42), AAVhu97 (SEQ No. 28), AAVhu84 (SEQ ID NO: 30), AAVhu86 (SEQ ID NO: 32), AAVhu87 (SEQ ID NO: 34), AAVhu88 / 78 (SEQ ID NO: 36), AAVhu69 (SEQ ID NO: 38), AAVrh76 (SEQ ID NO: 42), AAVrh77 (SEQ ID NO: 44), AAVrh78 (SEQ ID NO: 46), AAVrh81 (SEQ ID NO: 50), AAVrh89 (SEQ ID NO: 52), AAVrh82 (SEQ ID NO: 54), AAVrh83 (SEQ ID NO: 56), AAVrh84 (SEQ ID NO: 58), AAVrh85 (SEQ ID NO: 60), AAVrh87 (SEQ ID NO: 62), or AAVhu73 (SEQ ID NO: 74). vp1, vp2, and / or vp3 capsid proteins or SEQ ID NOs: 40, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 42, 44, 46, 5 10. A method for producing a vector genome comprising: culturing a host cell containing: (a) a molecule encoding AAV vp1, vp2, and / or vp3 capsid proteins that share at least 99% identity with any of 0, 52, 54, 56, 58, 60, 62, or 74; (b) functional genes; (c) a vector genome comprising AAV inverted terminal repeats (ITRs) and a transgene; and (d) helper functions sufficient to allow packaging of the vector genome into the AAV capsid proteins. 10. AAVrh75 (SEQ ID NO: 39), AAVhu71 / 74 (SEQ ID NO: 3), AAVhu79 (SEQ ID NO: 5), AAVhu80 (SEQ ID NO: 7), AAVhu83 (SEQ ID NO: 9), AAVhu74 / 71 (SEQ ID NO: 11), AAVhu77 (SEQ ID NO: 13), AAVhu78 / 88 (SEQ ID NO: 15), AAVhu70 (SEQ ID NO: 17), AAVhu72 (SEQ ID NO: 19), AAVhu75 (SEQ ID NO: 21), AAVhu76 (SEQ ID NO: 23), AAVhu81 (SEQ ID NO: 25), AAVhu82 (SEQ ID NO: 27), AAVhu84 (SEQ ID NO: 29), AAVhu86 (SEQ ID NO: 31), AAVhu87 (SEQ ID NO: 33), AAVhu88 / 78 (SEQ ID NO: 35), AAVhu69 (SEQ ID NO: 37), AAVrh76 (SEQ ID NO: 41), AA A plasmid comprising the vp1, vp2, and / or vp3 sequences of Vrh77 (SEQ ID NO:43), AAVrh78 (SEQ ID NO:45), AAVrh81 (SEQ ID NO:49), AAVrh89 (SEQ ID NO:51), AAVrh82 (SEQ ID NO:53), AAVrh83 (SEQ ID NO:55), AAVrh84 (SEQ ID NO:57), AAVrh85 (SEQ ID NO:59), AAVrh87 (SEQ ID NO:61), or AAVhu73 (SEQ ID NO:73), or vp1, vp2, and / or vp3 sequences that share at least 95% identity with any of SEQ ID NOs: 39, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 41, 43, 45, 49, 51, 53, 55, 57, 59, 61, or 73. 11. A cultured host cell containing the plasmid of embodiment 10.

[0174] The following examples illustrate certain embodiments of the present invention, but do not limit them. [Example]

[0175] Adeno-associated virus (AAV) is advantageous as a gene transfer vector due to its favorable biological and safety properties, and discovering novel AAV variants is key to improving this treatment platform. To date, researchers have isolated over 200 AAVs from natural sources using polymerase chain reaction (PCR)-based methods. We compared two modern DNA polymerases and their utility for isolating and amplifying AAV genomes. Compared with HotStar polymerase, the higher-fidelity Q5 HotStar high-fidelity DNA polymerase provided more accurate and precise amplification of input AAV sequences. The low-fidelity HotStar DNA polymerase introduced mutations during the isolation and amplification process, thus generating multiple mutant capsids with variable biological activity compared to the input AAV gene. Using Q5 polymerase, we successfully discovered novel AAV capsid sequences from human and non-human primate tissue sources. Novel AAV sequences from these sources showed evidence of positive selection. This study highlights the importance of using the highest fidelity DNA polymerase available to accurately isolate and characterize AAV genomes from natural sources in order to ultimately develop more effective gene therapy vectors.

[0176] Adeno-associated virus (AAV) is a safe and effective vehicle used for gene transfer for several clinical indications. AAV-mediated gene therapy drugs have been approved by the FDA for the treatment of spinal muscular atrophy and Leber congenital amaurosis. These approved gene therapy products, as well as many others currently in development, use AAV capsids isolated from natural sources as delivery vehicles. 4 The AAV genome is a set of multiple protein products. It consists of two major open reading frames (ORFs), Rep and Cap, which encode sequences for translation. Translation of the Cap ORF occurs from multiple initiation sites to produce three AAV structural proteins, VP1, VP2, and VP3. These structural protein subunits are integrated into the icosahedral virion that carries the gene payload to its target. 5 The sequence and structural diversity of AAV capsid genes contributes to the observed variations in viral tropism, antigenicity, and packaging efficiency among viral clades. Advances in the efficacy and utility of gene therapy require the discovery of novel capsids with a range of tissue tropisms.

[0177] AAV Cap sequences have been isolated from natural sources using a variety of techniques that have emerged and evolved over time, but the most common approach involves PCR amplification. First, extracted viral DNA can be sequenced directly; this method was used to identify AAV2, which was found to grow with helper adenovirus in cell culture. Second, extracted viral DNA can be extracted, cloned into a plasmid backbone, and sequenced (AAV1, AAV3, AAV3B, AAV6, and AAV5). Third, viral genomes can be extracted via PCR, and amplicons can be cloned into plasmids prior to Sanger sequencing. Using this method, many AAVs from primates, cattle, pigs, rodents, and other species have been isolated. Next-generation sequencing (NGS) analysis of mammalian genomic DNA has detected fragments of endogenous AAV genomic elements. More recently, metagenomic virome sequencing studies, which use shotgun-NGS to simultaneously sequence thousands of DNA molecules in complex samples, have identified many novel AAV sequences.

[0178] The use of PCR for AAV amplification provides a simple and effective means for discovering novel AAV capsid sequences. However, it is important to utilize PCR enzymes with high-fidelity replication capabilities to amplify viral sequences as accurately as possible. Enzymes with high misincorporation and template switching rates can significantly confound sequencing data and hinder the discovery of novel AAV capsids. Indeed, artificial variability introduced by low-fidelity polymerases while amplifying capsid sequences can undermine research into AAV biology and diversity due to amplification errors that distort the "true" genetic variation in samples.

[0179] We compared multiple AAV PCR methods to screen tissue samples for AAV naturally isolated genomes, aiming to expand the range of capsid sequences available for characterization as potential gene delivery vectors. Discovering more capsids increases the likelihood of successfully identifying capsids that can deliver therapeutic transgenes to a range of tissues with high efficiency, reduce immunogenicity at high doses, and have a lower prevalence of neutralizing antibody profiles in the human population than existing AAV capsids. Given that DNA polymerase technology has undergone significant development since the last wave of AAV discovery approximately 20 years ago, we compared two modern DNA polymerases and amplification methods to isolate AAV sequences. We found that the Q5 Hot Star high-fidelity DNA polymerase produced PCR products from input templates with higher accuracy compared to the low-fidelity Hot Star DNA polymerase. Using the Q5 DNA polymerase, we also studied the genetic diversity of newly isolated AAV capsid sequences by conducting phylogenetic analyses. Furthermore, novel AAV natural isolates were found to show evidence of evolution by positive selection.

[0180] Example 1: Materials and Methods DNA extraction from non-human primate and human tissues Non-human primate (Macaca mulatta) tissue samples were collected post-mortem from the Gene Therapy Program at the Perelman School of Medicine at the University of Pennsylvania. Human tissue samples (including aortic valve, bone marrow, brain, breast, cervix, colon, heart, intestine, kidney, liver, lung, lymph node, ovary, pancreas, pericardium, skeletal muscle, and spleen) were obtained. Genomic DNA was isolated using the QIAamp DNA Mini Kit. Extraction was performed using a QIAGEN (QIAGEN Inc., Germantown, MD) kit.

[0181] Conventional AAV isolation We utilized Q5 HotStar high-fidelity DNA polymerase to amplify a 3.1 kb AAV genome sequence from host genomic DNA, using working conditions determined by the manufacturer (New England Biolabs, Ipswich, MA). We isolated the AAV genome using the previously described AV1NS forward primer and AV2CAS reverse primer; we replaced the degenerate base Y in AV1NS with a T (AV1NS The primers were replaced with AV2CAS (5'-GCTGCGTCAACTGGACCAATGAGAAC-3', SEQ ID NO: 63) and AV2CAS (5'-CGCAGAGACCAAAGTTCAACTGAAACGA-3', SEQ ID NO: 64) (Gao GP et al. PNAS USA. 2002;99:11854-59) because T is the primary nucleotide represented in the AAV sequence phylogeny across many clades of AAV. Each primer was used at a final concentration of 0.5 μM as described in the Q5 protocol (New England Biolabs, Ipswich, MA). The following thermocycling conditions were applied: 98°C for 30 seconds; 50 cycles of 98°C for 10 seconds, 59°C for 10 seconds, 72°C for 93 seconds, and extension at 72°C for 120 seconds. PCR products were TOPO cloned (Thermo Fisher Scientific, Waltham, MA) and Sanger sequenced (GENEWIZ, South Plainfield, NJ). For most PCR products, we sequenced at least three clones.

[0182] AAV isolation by single genome amplification Genomic DNA from a human cardiac tissue sample previously found to be AAV-positive by conventional AAV isolation PCR was subjected to AAV-SGA. AAV-containing genomic DNA was diluted end-point in 20 ng / μL sheared salmon sperm DNA (Ambion, Inc., Austin, TX) by serial dilution. Material from each serial dilution was probed with AV1NS and AV2CAS primers (Mueller C et al. Curr Protocol). Microbiol 2012; Chapter 14: Unit 14D11). AAV DNA was amplified using Q5 Hot Star high-fidelity DNA polymerase (New England Biolabs, Ipswich, MA) using the following cycling conditions: 98°C for 30 seconds; 50 cycles of 98°C for 10 seconds, 59°C for 10 seconds, 72°C for 93 seconds, and extension at 72°C for 120 seconds. For a Poisson distribution, a DNA dilution that yields PCR products in 30% or fewer wells contains one amplifiable AAV DNA template per positive PCR in more than 80% of cases (Salazar-Gonzalez JF et al. Journal of Virology 2008;82:3952-70). AAV DNA amplicons from positive PCR reactions were purified using Agencourt Ampure XP beads (Beckman Coulter, Brea, CA), libraries were constructed using the NEBNext® Ultra™ II DNA Library Prep Kit Illumina® (NEB, Ipswich, MA), sequenced using an Illumina MiSeq2x250 (Illumina, San Diego, CA) paired-end sequencing platform, and the resulting reads were de novo assembled using the SPAdes assembler (cab.spbu.ru / software / spades / ).

[0183] Sequence analysis AAV sequences were aligned using the AlignX component of Vector NTI Advance® 11.5.4 (Thermo Fisher Scientific, Waltham, MA) or Geneious Prime version 2019.2 (geneious.com). GenBank sequence comparisons were performed using the NCBI This was performed on the BLAST server (blast.ncbi.nlm.nih.gov / Blast.cgi).

[0184] Polymerase fidelity comparison The pAAV2 / 9 trans-plasmid was used as a template. To confirm the purity of the template, we first retransformed the plasmid into stable, competent E. coli cells (Thermo Fisher, Waltham, MA) and sequenced two single-colony clones via next-generation sequencing (Illumina, San Diego, CA) as previously described (Saveliev A et al. Human Gene Therapy Methods 2018;29:201-11). To ensure complete sequence identity to the input pAAV2 / 9 trans-plasmid, we used one of the two sequenced plasmids as a template for subsequent experiments. In this comparative study, HotStar High-Fidelity Polymerase ("HiFi") (QIAGEN Inc., Germantown, MD) was the low-fidelity polymerase, while Q5 HotStar High-Fidelity DNA Polymerase (Q5) (New England Biolabs, Ipswich, MA) was the high-fidelity polymerase. For "HiFi circular," the pAAV2 / 9 trans plasmid was diluted and used as a PCR template. For "HiFi linear" and "Q5 linear," the pAAV2 / 9 trans plasmid was linearized with the restriction enzyme PvuII (New England Biolabs, Ipswich, MA) and then diluted for use as a template. For all first-round PCRs, we used five copies of the template in a 25-μL reaction. For the second round, 1 μL of the first-round PCR product was used as a template in a 50-μL reaction. PCR conditions were based on the manufacturer's guidelines.

[0185] All "HiFi" experiments used HotStar high-fidelity polymerase (QIAGEN Inc., Germantown, MD). AV1NS and AV2CAS primers were used according to the manufacturer's protocol. The following thermal cycling conditions were applied to the first-round PCR: 95°C for 300 seconds; 94°C for 15 seconds, 63°C for 60 seconds, and 68°C for 371 seconds for 40 cycles; and 72°C for 600 seconds of extension. For the second round of PCR, a nested reaction was performed using primers McapF3SpeI (5'-ATCGATACTAGTCCATCGACGTCAGACGCGGAAG-3'; SEQ ID NO: 65) and McapR1NotI (5'-ATCGATGCGGCCGCAGTTCAACTGAAACGAATTAAACGGT-3'; SEQ ID NO: 66). McapF3SpeI and McapR1NotI' were previously described in a publication on AAV PCR technology (Smith LJ et al. Molecular Therapy 2014;22:1625-1634). McapR1NotI' is a modified version of the primer McapR1NotI from the aforementioned publication; we modified McapR1NotI to correct two base pairs near its 3' end that do not align with any reported AAV sequences, including those of the isolates reported in the previous publication. One μL of the first-round PCR product was used as a template for a second, nested round of PCR. The following thermal cycling conditions were used for the second round of PCR: 95°C for 300 seconds; 94°C for 15 seconds, 63°C for 60 seconds, and 68°C for 315 seconds for 40 cycles; and 72°C for 600 seconds of extension.

[0186] For the first round of "Q5" reactions, we used Q5 Hot Start High-Fidelity DNA Polymerase Master Mix (New England Biolabs, Ipswich, MA). AV1NS' and AV2CAS primers were used in each reaction according to the manufacturer's protocol. Thermal cycling conditions were as follows: 98°C for 30 seconds; 40 cycles of 98°C for 10 seconds, 59°C for 30 seconds, and 72°C for 186 seconds; and extension at 72°C for 120 seconds. For the second round of "Q5" reactions, primers Mca pF3SpeI and McapR1NotI' were utilized. 1 μL of the first-round "Q5" PCR product was used as template for a second, nested round of PCR in each 50 μL reaction. Thermal cycling conditions were as follows: 98°C for 30 seconds; 40 cycles of 98°C for 10 seconds, 66°C for 30 seconds, and 72°C for 164 seconds; and an extension of 72°C for 120 seconds. PCR products were then TOPO cloned and sequenced.

[0187] Vector production, quantitative PCR (qPCR) titration, and Huh7 transduction assays For AAV vector production in 6-well plates, we adapted a previously described single-cell stack-scale HEK293 triple transfection protocol with several modifications based on the reduced culture area: 1) the plasmid ratio used was 2:1:0.1 at the time of harvest (helper plasmid containing the necessary adenovirus helper genes: trans-plasmid containing the AAV2Rep and AAV capsid genes: cis-plasmid containing the CB7 promoter, firefly luciferase gene, and rabbit β-globin polyadenylation sequence transgene (i.e., CB7.ffluciferase.rBG)), and 2) no other treatments other than freeze / thaw were performed (Lock M). (Human Gene Therapy 2010;21:1259-1271). We measured vector production titers by qPCR using primers and a probe against the vector poly(A) sequence.

[0188] AAV VP1 sequence evolution analysis Geneious version 2019.2 (geneious.com) was applied to construct DNA sequence alignments, using the Geneious alignment algorithm. Positive selection hypothesis testing statistical analysis for AAV VP1 DNA sequences was performed using the branch-site unrestricted statistical test for episodic diversification (BUSTED) and the mixed-effects model of evolution (MEME) programs. Negative selection hypothesis testing was performed using the fixed-effect likelihood (FEL) test. These programs were run on the HyPhy server at datamonkey.org. For human and rhesus macaque AAV natural isolates, BUSTED and FEL were used to compare the phylogenetic branch of each new isolate with the branch ending in the closest BLASTn hit. For AAV HSC and AAV HiFi PCR mutant variants, all branches of the phylogeny were examined as a whole to determine whether positive selection had occurred at any possible site throughout the tree due to the inherent sequence similarity of these populations (Smith LJ et al. Molecular Therapy 2014;22:1625-34). BUSTED and FEL utilize a likelihood ratio test to determine significance, i.e., whether there is evidence of gene-wide positive or negative selection. In the MEME analysis, each phylogeny (human, rhesus, HSC, and HiFi) was evaluated for the presence of positive episodic or global selection. MEME uses a likelihood ratio test to determine significance. Results producing p<0.05 were considered significant. AAVrh81 was removed from the rhesus phylogeny for analysis due to significant sequence divergence from the remaining groups.

[0189] All phylogenetic trees were constructed using the MAFFT version 7 server (mafft.cbrc.jp / alignment / server / ) using the neighbor-joining method. Trees were bootstrapped 100 times and formatted using FigTree (tree.bio.ed.ac.uk / software / figtree / ).

[0190] statistics For Figure 2A, pairwise comparisons were performed between groups using the Wilcoxon rank sum test with the "wilcox.test" function in the R program (version 3.5.0; cran.r-project.org). For Figures 2B and 2C, pairwise comparisons were performed using the Student t-test with the R program (version 4.0.0; cran.r-project.org). Each mutant was compared to AAV9 using the "t.test" function within t.org. Statistical significance was assessed at the 0.05 level.

[0191] Example 2: Low-fidelity DNA polymerases generated more random mismatch errors First, we evaluated the effect of polymerase fidelity on AAV isolation to verify the assertion that low-fidelity DNA polymerases produce amplicons with a higher frequency of PCR errors. We used a pure, NGS-validated AAV9 transfection plasmid (i.e., pAAV2 / 9) containing the AAV2 Rep gene and the AAV9 Cap gene as a PCR template in reactions containing DNA polymerases with varying levels of replication fidelity. A high-fidelity polymerase, Q5 Hot Start High-Fidelity DNA Polymerase (Q5), and a relatively low-fidelity polymerase, Hot Star High-Fidelity (HiFi) Polymerase, were applied for various levels of known polymerase fidelity. Using the same protocol used to isolate the AAV natural isolate AAVHSC1-17 with HiFi polymerase (Smith LJ et al. Molecular Therapy 2014;22:16-1634), we found that plasmids cloned and sequenced from HiFi polymerase PCR products contained 30-60% more random errors throughout the VP1 region than those generated using the high-fidelity Q5 DNA polymerase. A total of 11 of 19 and 6 of 20 sequenced PCR product clones in the HiFi circular and linear groups contained at least one mismatch, respectively. In contrast, only 1 of 20 and 1 of 24 sequenced PCR product clones had a mismatch in the Q5 linear and circular groups, respectively (Figure 2A, Figure 2D, and Table 1).

[0192] Next, we aimed to determine whether the AAV9 PCR-isolated capsid sequences generated from the HiFi polymerase experiments were functional. We cloned the isolates into pAAV2 / 9 transplasmids containing the AAV2Rep gene, such that each plasmid contained a mutant AAV9 VP1 cap gene. These mutant transplasmids then produced AAV vectors containing the firefly luciferase transgene (i.e., CB7.ffluciferase.rBG). Two of the mutant capsids produced vector titers at levels similar to those of wild-type AAV9 (D87G and G174D). The remaining mutants exhibited reduced vector production capacity compared to AAV9 (Figure 2B). P32S had a 17% lower titer than AAV9, while G177S, Q299H, and Q678R showed 80%–90% reductions in production titers. S632F, K33T L648I, and S348P M436T showed a 60%–65% reduction in Huh7 infectivity compared to AAV9. The Huh7 infectivity titers of the mutants (Figure 2C) show a pattern similar to their vector production titers, with some exceptions—for example, the mutant P32S has a production titer of approximately 83% of that of AAV9, but its Huh7 infectivity titer is only approximately 6% of that of AAV9. This suggests that the mutant P32S may impair Huh7 capsid transduction, which warrants further investigation. Together, these results indicate that low-fidelity HiFi DNA polymerases produce mutants with variable functional properties in unpredictable ways that may impair the discovery and characterization of novel isolates. [Table 2]

[0193] Example 3: Novel AAV sequences from multiple clades were isolated from non-human primate and human tissues using high-fidelity PCR polymerases Advances in gene therapy require the identification of novel AAV capsids. The majority of currently used AAV natural variants are derived from primate tissues. Using a validated, high-fidelity Q5 PCR-based technique, we investigated whether novel capsid sequences could be isolated from a panel of primate tissue samples. We used primers that bind to conserved regions of the capsid sequence to amplify a 3.1-kb AAV amplicon to detect and amplify the AAV genome present in 50 non-human primate intestinal tissue samples. In this manner, we discovered 12 AAV natural isolate sequences. Most of these isolates belonged to clades D or E, or to the exobasal clade of primates, including AAVrh32.33 (Table 2). [Table 3]

[0194] We also used Q5 polymerase to screen genomic DNA from 271 human tissue samples and obtained 22 novel AAV natural isolate capsid sequences, including the clade F member AAVhu68 (SEQ ID NO: 1). These novel AAV sequences were isolated from the heart, intestine, kidney, liver, lung, and spleen. Overall, 8% of human samples were AAV-positive. Most of the novel human isolates could be classified as clade B and C viruses or resembled AAV2 and AAV2-AAV3 hybrids (Table 3). Three human-derived natural isolates displayed novel DNA sequences despite having the same protein sequences as previously reported GenBank entries (i.e., AAVhu32, AAV9, and CHC367_AAV). [Table 4]

[0195] Example 4: AAV single genome amplification (AAV-SGA) identifies natural isolate AAVhu68 capsid sequences with high accuracy and precision Single genome amplification (SGA) can accurately amplify individual viral sequences from mixed samples. Salazar et al., 2014, for amplification and study of HIV dynamics in infected patients. Based on previous reports by Salazar-Gonzalez et al. and others ( JF et al.Journal of Virology 2008;82:39 52-70; Simmonds P et al. Journal of Virology 1990;64:5840-50), we adapted SGA (Figure 1) to accurately isolate AAV sequences from mammalian tissue samples using the previously described high-fidelity Q5 polymerase (data not shown). In this technique, end-point diluted genomic DNA serves as the PCR template, and each amplicon-positive PCR contains only one amplifiable AAV genome. This method prevents sequence ambiguity caused by DNA polymerase-induced mutations due to the replicative nature of the method. This technique also mitigates the problem of DNA polymerase template exchange, which can occur in DNA mixtures, because only one AAV genome is amplified in each reaction (thus leading to the recovery of artificially recombined amplicons).

[0196] We attempted to validate the sequence of a previously isolated AAVhu68 by performing AAV-SGA on the same tissue sample from which it was derived, as described in Table 2. This technique, combined with the use of the high-fidelity Q5 polymerase, allowed us to accurately and precisely confirm the identity of this sequence. Our results show that all single AAV genomes recovered from this sample had 99.94%–100% capsid sequence identity with the previous, conventional Q5 PCR-isolated AAVhu68 sequence. Of the 61 single AAV genome-derived amplicons recovered from this sample, only seven had one to two nucleotide mismatches from the original sequence. The majority (54 / 61) of amplicons had 100% DNA sequence identity to the previously isolated AAVhu68 capsid sequence, indicating that sequence data generated using Q5 polymerase can be interpreted with a high degree of confidence.

[0197] Example 5: AAV natural isolate capsid protein sequences show evidence of positive selection Using the Q5 polymerase AAV isolation strategy, we were able to investigate the evolutionary characteristics of the AAV genome with minimal influence from PCR-mediated errors. We observed that several recovered AAV natural isolate capsid sequences had a greater number of DNA differences than corresponding protein sequence changes compared to their closest previously reported AAV sequences according to the GenBank sequence database.

[0198] If a virus is subject to selective pressure favoring a particular genetic mutation, the nonsynonymous mutation rate (dN) is expected to be higher than the synonymous mutation rate (dS) in that region. The converse is true for deleterious mutations within the sequence. To assess the evolutionary stability of AAV sequences isolated from primate tissues, we performed statistical analyses to determine whether there was evidence of positive diversifying selection across the entire VP1 gene of our novel AAVs compared to their closest natural isolate sequences. We used the branch-site unrestricted statistical test for episodic diversification (BUSTED) because it is easy to use for evolutionary analysis of small numbers of similar sequences (Murrell B (Molecular Biology and Evolution 2015;32:1365-71). BUSTED determines whether the dN / dS ratio across the entire gene of interest (different groups of branches within the phylogenetic tree) indicates positive selection. We detected statistical significance (p<0.05) at several branch points, indicating that at least one site in the VP1 gene experienced diversifying selection across the tested branches in the phylogeny (Figures 3A-C, 4, and Table 4). [Table 5]

[0199] In 3 / 20 cases, our human-derived AAV natural isolates were positive for diversifying selection from their closest natural isolate clade members (Figure 3A, Table 4). In 3 / 9 cases of rhesus macaque isolates, diversifying selection was evident in at least one region across the capsid sequence (Figure 3B, Table 4). In contrast, when comparing test branches across the phylogeny of sequences from a group of previously published AAV natural isolates derived from human hematopoietic stem cells (HSCs), BUSTED analysis showed no evidence of positive diversifying selection (Figure 3C, Table 4). Similarly, HiFi PCR mutant AAV VP1 genes showed no evidence of positive selection (Tables 1, 4, and Figure 4).

[0200] In addition to conducting a gene-wide test for positive selection, we assessed whether individual sites within the VP1 gene for each phylogeny showed evidence of positive or negative selection. To analyze each group of AAV sequences for the presence of positively selected evolutionary hotspots, we used the Mixed Effects Model of Evolution (MEME) program due to its ability to detect episodic and global selection.

[0201] MEME detected 13 sites in the VP1 gene of AAV isolated from human samples that showed evidence of positive diversifying selection (Table 5). Four of these sites are located in the hypervariable regions (HVRs) of the capsid gene (i.e., surface-exposed capsid regions that show significant sequence diversity). Six sites are located in the internal VP1 unique region (VP1u). Additionally, 19 significant sites were found in the capsid sequence dataset from samples from rhesus macaques (Table 5). Of these 19 sites, 10 were in the HVR regions and 1 was located in VP1u. Both sequence sets also showed evidence of positive selection in the region between the HVRs, including non-surface-exposed regions of the capsid structure (Table 5). MEME was performed using either the AAV HSC sequence or HiFi No sites for positive selection could be detected in any of the PCR mutant-capsid sequences.

[0202] We also used the fixed effects likelihood (FEL) program (Kosakovsky Pond SL et al. Molecular Biological Evolution 2005;22:1208-22) to detect branch-pair-spanning sites in the novel human and nonhuman primate AAV phylogeny that had undergone negative selection (Table 6). Sites within 15 of 29 novel AAV natural isolate sequences showed evidence of negative purifying selection compared with their closest known AAV relatives. In contrast, neither the AAV HSC variants nor the HiFi PCR mutants contained any phylogenetically spanning sites that showed evidence of evolution by negative selection. [Table 6] [Table 7]

[0203] AAV sequence isolation techniques have evolved significantly since the discovery of AAV in 1965. In this study, we compared the DNA replication fidelity of two DNA polymerases for AAV isolation: HotStar High-Fidelity Polymerase and Q5 HotStar High-Fidelity Polymerase. We found that using HiFi Polymerase and a protocol with a high number of PCR cycles (a method previously used to discover novel AAVs) resulted in a significantly higher rate of random mutations in amplicons generated from template DNA compared to methods utilizing Q5 Polymerase. Mutant PCR produced vectors that transduced Huh7 cells in vitro at variable levels. These experiments highlight the variable and unpredictable effects that low DNA polymerase fidelity can have on AAV function during capsid-genome isolation. Tune.

[0204] Tindall et al. were one of the first to demonstrate that DNA polymerases can generate mutations in amplified DNA (Tindall (KR et al. Biochemistry 1988;27:6008-6013). Since then, researchers have reported a 5.3x10 polymerase yield, which corresponds to approximately 280-fold higher fidelity compared to Taq polymerase. -7 A variety of new polymerases have been isolated and engineered to address this issue, including Q5, one of the most accurate polymerases with a base substitution rate of 10 bp (Potapov V et al. PloS one 2017;12:e016977). In contrast, the fidelity of HotStar HiFi polymerase is reported to be only 10-fold higher than that of Taq. We have demonstrated that optimal AAV isolation requires the use of the highest fidelity DNA polymerase available, in this case, Q5.

[0205] To verify the sequence identity of AAVhu68, one of the human-derived AAVs isolated in this study, we also performed AAV-SGA using Q5 polymerase. The replicative nature of this technique, coupled with the high fidelity of Q5 polymerase, enabled precise and accurate identification of the capsid sequence of this isolate. Furthermore, the sequencing data of the amplicons obtained using Q5 polymerase-based technology were consistent with those obtained by NGS, thereby verifying the identity of the capsid gene of this AAV natural isolate. AAV-SGA recovered a small number of amplicon sequences that were mismatched by one or two nucleotides from the AAVhu68 genome, as characterized by Potapov et al. (PloS One 2017;12:e0169774). This may be due to NGS errors, the low error rate of Q5, or DNA damage induced by thermal cycling. These data demonstrate that AAV-SGA is a robust tool for analyzing viral populations with very high precision and accuracy.

[0206] By utilizing the high-fidelity Q5-based AAV isolation method, we found that while natural AAV variant capsid protein sequences remain relatively stable, their DNA sequences can exhibit considerable variation compared to their closest relatives in GenBank. This finding is in stark contrast to our HiFi PCR variant sequences and a subset of AAV sequences identified from human HSCs (AAVHSCs), in which many more amino acid changes correlate with DNA sequence changes. In any viral population, one would expect host-mediated evolutionary pressures from the immune system or factors mediating tissue tropism to promote positive and divergent selection related to processes involving host-capsid interactions, such as cell attachment, entry, and viral transport. However, these selection pressures are not present in an in vitro replication environment, such as the one used when generating PCR variants.

[0207] We used the BUSTED program to determine whether the overall AAV capsid sequence has undergone positive selection in recent evolutionary lineages. Our results showed evidence of diversifying selection even in cases where two isolates exhibited high DNA sequence variation but high amino acid sequence similarity. Conversely, BUSTED analysis did not provide evidence of diversifying selection for the few cases in which DNA sequence variation between multiple AAVs resulted in amino acid changes (i.e., AAVHSC and AAV HiFi PCR mutants). An unexpected finding was that populations of AAVs recovered from natural sources, such as human HSCs, showed no evidence of evolutionary pressure-mediated change despite having high nonsynonymous mutation rates.

[0208] We used MEME to elucidate patterns of site-specific evolution in novel AAV natural variants (Murrell B et al. PLoS Genetics 2012;8:e1002764). The majority of sites showing evidence of evolution are located within the AAV H Surface-exposed HVRs mapped to VRs mediate interactions with host factors such as antibodies and cell surface receptors. Additionally, several sites were located before the start of VP3 within the VP1u region, which interacts with the host intracellular transport machinery. The evolutionary pressure exhibited by these sites can provide a good indication of which capsid regions are suitable for modification from the perspective of vector engineering. In contrast, neither the AAV HSC isolates nor the HiFi PCR mutants contained sites exhibiting significant selective pressure, further confirming that polymerase-induced errors can significantly impact AAV sequence analysis, discovery, and function. While high-fidelity DNA polymerases are necessary for optimal PCR-based AAV isolation and characterization from natural sources, error-prone polymerases can expand and diversify libraries of candidate AAVs by introducing random mutations into a given AAV capsid backbone.

[0209] These results highlight the need for accurate AAV isolation methods to reach valid conclusions about AAV evolution, genetics, and biological function arising from genomic variation. Our findings indicate that not all "high-fidelity" DNA polymerases are created equal, and caution must be exercised when analyzing AAV sequences generated with low-fidelity polymerases. Utilizing methods such as SGA in combination with high-fidelity polymerases allows for the accurate isolation of natural AAV populations that may contain the next candidate gene therapy vector.

[0210] Tables 7 and 8 below summarize the novel AAV natural isolates and their sequences recovered from human and non-human primate tissue samples. [Table 8] [Table 9]

[0211] Example 6: Evaluation of production yields and transduction levels of recombinant AAV vectors with novel capsids For CellSTACK® scale production, rAAV was produced and purified using the protocol described by Lock et al. (Human Gene Therapy 21:1259-1271, October 2010). The titer of the purified product was determined using the protocol described by Lock et al. (Human Gene Therapy 25:115-25, April 2014). The three plasmids used in the triple transfection portion of the protocol were the adenovirus helper plasmid pAdΔF6, a trans-plasmid carrying the AAV2 rep gene and the capsid gene of a new AAV isolate, and a cis-plasmid carrying a transgene cassette flanked by the AAV2 5' and 3' ITRs. The cis-plasmid contained an expression cassette carrying the TBG promoter and an eGFP transgene. The yields of recombinant vectors carrying AAVrh75, AAVrh76, AAVrh77, AAVrh78, AAVrh79, AAVrh81, AAVrh82, AAVrh83, AAVrh84, AAVrh87, and AAVrh89 capsids are shown in Figure 15 .

[0212] For 12-well plate-scale production, the protocol was adapted from the CellSTACK® protocol described above, primarily by reducing the materials used proportionally to the cell culture area, without any purification steps. The trans-plasmid used here contains the AAVrh75 and AAVrh81 capsid genes. The cis-plasmid used herein contains the CB7 promoter and firefly luciferase gene. After production, the culture supernatant was collected and spun to remove cellular debris. The same volume of supernatant was then used to transduce Huh7 and MC57G cells, and the yield was determined by a bioactivity assay in which luciferase activity was measured using a photometer (BioTek). Figure 16 shows the infectious titers for comparable AAV8 vectors. The AAVrh81 vector was used to transduce human cell lines. It had a higher level of infectivity in Huh7 than the AAVrh75 vector, but showed a lower level of infectivity in the mouse cell line MC57G.

[0213] Additionally, transgene delivery was evaluated in vivo. Mice were intravenously injected with rAAV harboring an AAV8 or AAVrh81 capsid and a vector genome containing the liver-specific promoter (LSP) promoter and a human factor IX transgene. On day 28, plasma was collected and factor IX levels were measured. Human factor IX expression after AAVrh81 vector delivery was much lower than that of AAV8 (Figure 17). In further studies, rAAV vectors harboring AAVrh78, AAVrh83, AAVrh84, AAVrh85, AAVrh87, AAVrh89, or AAV8 capsid and a vector genome harboring the TBG promoter and eGFP transgene were injected intravenously at 1 × 10 11 AAVrh78, AAVrh85, AAVrh87, and AAVrh89 were administered intravenously in GC / mice. Livers were harvested on day 14 to assess GFP expression. Transduction was comparable to that of AAV8 for AAVrh83, but GFP levels were significantly lower after delivery of the AAVrh84 vector (Figure 18). Genomic DNA was extracted from the liver and vector genome copies were measured by qPCR. Liver transduction levels for AAVrh78, AAVrh85, AAVrh87, and AAVrh89 were approximately 49%, 72%, 16%, and 22% of the levels detected with AAV8, respectively (Figure 19).

[0214] (Sequence listing free text) The following information is a numeric identifier <223> Below provides an array containing free text. [Table 10-1] [Table 10-2] [Table 10-3] [Table 10-4] [Table 10-5] [Table 10-6] [Table 10-7] [Table 10-8] [Table 10-9] [Table 10-10] [Table 10-11] [Table 10-12] [Table 10-13] [Table 10-14]

[0215] All patents, patent publications, and other publications cited herein are incorporated by reference. U.S. Provisional Patent Application No. 63 / 107,030, filed October 29, 2020, and U.S. Provisional Patent Application No. 63 / 214,530, filed June 24, 2021, are incorporated by reference herein. The attached Sequence Listing, labeled "21-9492.PCT_ST25," is incorporated by reference herein. While the present invention has been described with reference to particularly preferred embodiments, it will be understood that modifications can be made without departing from the spirit of the invention. Such modifications are intended to be within the scope of the appended claims.

Claims

1. A recombinant adeno-associated virus (rAAV) comprising a capsid and a vector genome, the vector genome comprising an AAV 5′ inverted terminal repeat (ITR), an expression cassette comprising a nucleic acid sequence encoding a gene product operably linked to an expression control sequence, and an AAV 3′ ITR, wherein the capsid comprises (a) an AAVrh75 capsid consisting of (i) a nucleic acid sequence encoding SEQ ID NO:40, or a sequence at least 99% identical thereto having an Asn (N) amino acid residue at position 24 based on the numbering of SEQ ID NO:40, (ii) a nucleic acid sequence of SEQ ID NO:39, or a sequence at least 95% identical thereto encoding SEQ ID NO:40, or (iii) a capsid that is a heterogeneous mixture of AAVrh75 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least positions N57, N262, N384, and / or N512 of SEQ ID NO:40, and optionally deamidated at other positions; (b) AAVhu71 / 74 capsids, consisting of (i) capsids produced from a nucleic acid sequence encoding SEQ ID NO:4, (ii) capsids produced from a nucleic acid sequence encoding SEQ ID NO:3, or a sequence at least 95% identical thereto, or (iii) capsids that are a heterogeneous mixture of AAVrh71 / 74 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:4, and optionally deamidated at other positions; (c) an AAVhu79 capsid consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:6, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:5 that encodes SEQ ID NO:6 or is at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu79 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:6 and optionally deamidated at other positions; (d) AAVhu80 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:8, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:7 that encodes SEQ ID NO:8 or is at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu80 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:8 and optionally deamidated at other positions; (e) AAVhu83 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:10, (ii) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:9, or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu83 vp1, vp2, and vp3 proteins that are 95%-100% deamidated at at least four positions of SEQ ID NO:10, and optionally deamidated at other positions; (f) AAVhu74 / 71 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:12, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:11 that encodes SEQ ID NO:12 or is at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu74 / 71 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:12 and optionally deamidated at other positions; (g) AAVhu77 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:14, (ii) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:14 or at least 95% identical thereto, SEQ ID NO:13, or (iii) a capsid that is a heterogeneous mixture of AAVhu77 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:14 and optionally deamidated at other positions; (h) AAVhu78 / 88 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:16, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:15 that encodes SEQ ID NO:16 or is at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu78 / 88 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:16 and optionally deamidated at other positions; (i) an AAVhu70 capsid consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:18, (ii) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:18 or at least 95% identical thereto, SEQ ID NO:17, or (iii) a capsid that is a heterogeneous mixture of AAVhu70 vp1, vp2, and vp3 proteins that are 95%-100% deamidated at at least four positions of SEQ ID NO:18 and optionally deamidated at other positions; (j) AAVhu72 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:20, (ii) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:19, which is at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu72 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:20, and optionally deamidated at other positions; (k) AAVhu75 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:22, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:21 that encodes SEQ ID NO:22 or is at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu75 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:22 and optionally deamidated at other positions; (l) AAVhu76 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:24, (ii) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:24 or at least 95% identical thereto, SEQ ID NO:23, or (iii) a capsid that is a heterogeneous mixture of AAVhu76 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:24 and optionally deamidated at other positions; (m) AAVhu81 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:26, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:25 that encodes SEQ ID NO:26 or is at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu81 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:26 and optionally deamidated at other positions; (n) an AAVhu82 capsid consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:28, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:27 that encodes SEQ ID NO:28 or is at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu82 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:28 and optionally deamidated at other positions; (o) AAVhu84 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:30, (ii) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:29, which is at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu84 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:30, and optionally deamidated at other positions; (p) AAVhu86 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:32, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:31 that encodes SEQ ID NO:32 or is at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu86 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:32 and optionally deamidated at other positions; (q) AAVhu87 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:34, (ii) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:34 or at least 95% identical thereto, SEQ ID NO:33, or (iii) a capsid that is a heterogeneous mixture of AAVhu87 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:34 and optionally deamidated at other positions; (r) AAVhu88 / 78 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:36, (ii) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:36 or at least 95% identical thereto, SEQ ID NO:35, or (iii) a capsid that is a heterogeneous mixture of AAVhu88 / 78 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:36 and optionally deamidated at other positions; (s) an AAVhu69 capsid consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:38, (ii) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:38 or at least 95% identical thereto, SEQ ID NO:37, or (iii) a capsid that is a heterogeneous mixture of AAVhu69 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:38 and optionally deamidated at other positions; (t) AAVhu76 capsids, consisting of (i) capsids produced from a nucleic acid sequence encoding SEQ ID NO:42, (ii) capsids produced from a nucleic acid sequence of SEQ ID NO:41 that encodes SEQ ID NO:42 or is at least 95% identical thereto, or (iii) capsids that are a heterogeneous mixture of AAVhu69 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:42 and optionally deamidated at other positions; (u) AAVrh77 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:44, (ii) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:44 or at least 95% identical thereto, SEQ ID NO:43, or (iii) a capsid that is a heterogeneous mixture of AAVrh77 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:44 and optionally deamidated at other positions; (v) AAVrh78 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:46, (ii) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:46 or at least 95% identical thereto, SEQ ID NO:45, or (iii) a capsid that is a heterogeneous mixture of AAVrh78 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:46 and optionally deamidated at other positions; (w) an AAVrh81 capsid consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:50, (ii) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:49, or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVrh81 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:50, and optionally deamidated at other positions; (x) an AAVrh89 capsid consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:52, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:51 that encodes SEQ ID NO:52 or is at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVrh89 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:52 and optionally deamidated at other positions; (y) an AAVrh82 capsid consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:54, (ii) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:54 or at least 95% identical thereto, SEQ ID NO:53, or (iii) a capsid that is a heterogeneous mixture of AAVrh82 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:54 and optionally deamidated at other positions; (z) an AAVrh83 capsid consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:56, (ii) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:56 or at least 95% identical thereto, SEQ ID NO:55, or (iii) a capsid that is a heterogeneous mixture of AAVrh83 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:56 and optionally deamidated at other positions; (aa) an AAVrh84 capsid consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:58, (ii) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:58 or at least 95% identical thereto, SEQ ID NO:57, or (iii) a capsid that is a heterogeneous mixture of AAVrh84 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:58, and optionally deamidated at other positions; (bb) AAVrh85 capsids consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:60, (ii) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:59, or a sequence at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVrh85 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:60, and optionally deamidated at other positions; (cc) an AAVrh87 capsid consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:62, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:61 that encodes SEQ ID NO:62 or is at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVrh87 vp1, vp2, and vp3 proteins that are 95% to 100% deamidated at at least four positions of SEQ ID NO:62 and optionally deamidated at other positions; or (dd) an rAAV that is an AAVhu73 capsid, consisting of (i) a capsid produced from a nucleic acid sequence encoding SEQ ID NO:74, (ii) a capsid produced from a nucleic acid sequence of SEQ ID NO:73 that encodes SEQ ID NO:74 or is at least 95% identical thereto, or (iii) a capsid that is a heterogeneous mixture of AAVhu73 vp1, vp2, and vp3 proteins that are 95%-100% deamidated at at least four positions of SEQ ID NO:74, and optionally deamidated at other positions.

2. The rAAV of claim 1, wherein the gene product is useful for treating a liver disorder or disease and the capsid is an AAVrh75, AAVrh79, AAVrh83, or AAVrh84 capsid.

3. The rAAV of claim 1 , wherein the gene product is a gene-editing nuclease.

4. The rAAV of claim 1 , wherein the gene encodes a gene-editing nuclease.

5. The rAAV of any one of claims 1 to 4, wherein the expression cassette comprises a tissue-specific promoter.

6. A host cell containing an rAAV according to any one of claims 1 to 5.

7. A pharmaceutical composition comprising an rAAV according to any one of claims 1 to 5, and a physiologically compatible carrier, buffer, adjuvant and / or diluent.

8. 6. Use of the rAAV of any one of claims 1 to 5 in a method for delivering a transgene to a cell, the method comprising contacting the cell with the rAAV, the rAAV comprising the transgene.

9. 1. A method of producing a recombinant adeno-associated virus (rAAV) comprising an AAV capsid, comprising: (a) administering to the patient a recombinant adeno-associated virus (rAAV) comprising an AAV capsid, the method comprising: (i) administering to the patient a recombinant adeno-associated virus (rAAV) comprising administering to the patient a recombinant adeno-associated virus (rAAV) comprising administering to the patient a recombinant adeno-associated virus (rAAV) comprising administering to the patient a recombinant adeno-associated virus (rAAV) comprising administering to the patient a recombinant adeno-associated virus (rAAV) comprising administering to the patient a recombinant adeno-associated virus (rAAV) comprising administering to the patient a recombinant adeno-associated virus (rAAV) 28), AAVhu84 (SEQ ID NO:30), AAVhu86 (SEQ ID NO:32), AAVhu87 (SEQ ID NO:34), AAVhu88 / 78 (SEQ ID NO:36), AAVhu69 (SEQ ID NO:38), AAVrh76 (SEQ ID NO:42), AAVrh77 (SEQ ID NO:44), AAVrh78 (SEQ ID NO:46), AAVrh81 (SEQ ID NO:50), AAVrh89 (SEQ ID NO:52), AAVrh82 (SEQ ID NO:54), AAVrh83 (SEQ ID NO:56), AAVrh84 (SEQ ID NO:58), AAVrh85 (SEQ ID NO:60), AAVrh87 (SEQ ID NO:62), or AAVhu73 (SEQ ID NO:74) 50, 52, 54, 56, 58, 60, 62, or 74; (b) a functional gene; (c) a vector genome comprising AAV inverted terminal repeats (ITRs) and a transgene; and (d) sufficient helper functions to permit packaging of the vector genome into the AAV capsid proteins.

10. AAVrh75 (SEQ ID NO: 39), AAVhu71 / 74 (SEQ ID NO: 3), AAVhu79 (SEQ ID NO: 5), AAVhu80 (SEQ ID NO: 7), AAVhu83 (SEQ ID NO: 9), AAVhu74 / 71 (SEQ ID NO: 11), AAVhu77 (SEQ ID NO: 13), AAVhu78 / 88 (SEQ ID NO: 15), AAVhu70 (SEQ ID NO: 17), AAVhu72 (SEQ ID NO: 19), A AVhu75 (SEQ ID NO:21), AAVhu76 (SEQ ID NO:23), AAVhu81 (SEQ ID NO:25), AAVhu82 (SEQ ID NO:27), AAVhu84 (SEQ ID NO:29), AAVhu86 (SEQ ID NO:31), AAVhu87 (SEQ ID NO:33), AAVhu88 / 78 (SEQ ID NO:35), AAVhu69 (SEQ ID NO:37), AAVrh76 (SEQ ID NO:41), AAVr vp1, vp2, vp3, vp4, vp5, vp6, vp7, vp8, vp9, vp10, vp11, vp22, vp23, vp24, vp25, vp36, vp37, vp38, vp41, vp42, vp43, vp44, vp45, vp46, vp47, vp48, vp49, vp50, vp51, vp52, vp53, vp54, vp55, vp56, vp57, vp59, vp60, vp61, vp62, vp63, vp64, vp65, vp66, vp67, vp68, vp69, vp70, vp71, vp72, vp73, vp74, vp75, vp76, vp77, vp78, vp79, vp81, vp82, vp83, vp84, vp85, vp86, vp87, vp88, vp90, vp91, vp92, vp93, vp94, vp95, vp96, vp97, vp98, vp99, vp100, vp111, vp120, vp130, vp140, vp150, vp161, vp170, vp180, vp190, vp191, vp1120, vp133, vp141, vp151, vp152, vp163, vp174, vp185, vp195, vp196, vp197, vp198, vp199, vp199 2, and / or vp3 sequences, or vp1, vp2, and / or vp3 sequences that share at least 95% identity with any of SEQ ID NOs: 39, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 41, 43, 45, 49, 51, 53, 55, 57, 59, 61, or 73.

11. A cultured host cell containing the plasmid of claim 10.